US  	US  	 PRP	O
20070003560  	20070003560  	 CD	O
A1  	A1  	 CD	O
20070104  	20070104  	 CD	O
US  	US  	 NNP	O
11471369  	11471369  	 CD	O
20060620  	20060620  	 CD	O
11  	11  	 CD	O
20060101  	20060101  	 CD	O
A  	A  	 DT	O
A  	A  	 NNP	O
61  	61  	 CD	O
K  	K  	 NNP	O
39  	39  	 CD	O
40  	40  	 CD	O
F  	F  	 NN	O
I  	I  	 PRP	O
20070104  	20070104  	 CD	O
US  	US  	 NNP	O
B  	B  	 NNP	B-NP
H  	H  	 NNP	I-NP
20060101  	20060101  	 CD	O
A  	A  	 DT	O
C  	C  	 $	O
07  	07  	 CD	O
H  	H  	 NNP	O
21  	21  	 CD	O
04  	04  	 CD	O
L  	L  	 NNP	O
I  	I  	 NNP	O
20070104  	20070104  	 CD	O
US  	US  	 NNP	O
B  	B  	 NNP	B-NP
H  	H  	 NNP	I-NP
20060101  	20060101  	 CD	O
A  	A  	 DT	O
C  	C  	 $	O
12  	12  	 CD	O
P  	P  	 NN	O
21  	21  	 CD	O
06  	06  	 CD	O
L  	L  	 NNP	O
I  	I  	 NNP	O
20070104  	20070104  	 CD	O
US  	US  	 NNP	O
B  	B  	 NNP	B-NP
H  	H  	 NNP	I-NP
20060101  	20060101  	 CD	O
A  	A  	 DT	O
C  	C  	 $	O
12  	12  	 CD	O
N  	N  	 NNP	O
5  	5  	 CD	O
06  	06  	 CD	O
L  	L  	 NNP	O
I  	I  	 NNP	O
20070104  	20070104  	 CD	O
US  	US  	 NNP	O
B  	B  	 NNP	B-NP
H  	H  	 NNP	I-NP
20060101  	20060101  	 CD	O
A  	A  	 DT	O
C  	C  	 $	O
07  	07  	 CD	O
K  	K  	 NNP	O
16  	16  	 CD	O
12  	12  	 CD	O
L  	L  	 NNP	O
I  	I  	 NNP	O
20070104  	20070104  	 CD	O
US  	US  	 NNP	O
B  	B  	 NNP	B-NP
H  	H  	 NNP	I-NP
US  	US  	 NNP	O
424164100  	424164100  	 CD	O
435069100  	435069100  	 CD	O
435320100  	435320100  	 CD	O
435326000  	435326000  	 CD	O
530388400  	530388400  	 CD	O
536023530  	536023530  	 CD	O
Humanized  	Humanized  	 JJ	B-NP
monoclonal  	monoclonal  	 JJ	I-NP
antibodies  	antibodies  	 NNS	I-NP
that  	that  	 WDT	O
protect  	protect  	 VBP	O
against  	against  	 IN	O
shiga  	shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
induced  	induced  	 NN	I-NP
disease  	disease  	 NN	I-NP
US  	US  	 NNP	O
09215163  	09215163  	 CD	O
19981218  	19981218  	 CD	O
PENDING  	PENDING  	 NNP	O
US  	US  	 NNP	O
11471369  	11471369  	 CD	O
A1  	A1  	 CD	O
20060620  	20060620  	 CD	O
US  	US  	 NNP	O
60068635  	60068635  	 CD	O
19971223  	19971223  	 CD	O
Stinson  	Stinson  	 NNP	B-NP
Jeffrey  	Jeffrey  	 NNP	I-NP
R 	R 	 NNP	I-NP
.  	.  	 .	I-NP
Davie  	Davie  	 NNP	O
FL  	FL  	 NNP	O
US  	US  	 NNP	O
Weston  	Weston  	 NNP	B-NP
FL  	FL  	 NNP	I-NP
US  	US  	 NNP	O
Bethesda  	Bethesda  	 NNP	B-NP
MD  	MD  	 NNP	I-NP
US  	US  	 NNP	O
Rockville  	Rockville  	 NNP	B-NP
MD  	MD  	 NNP	I-NP
US  	US  	 NNP	O
Sterling  	Sterling  	 NNP	B-NP
VA  	VA  	 NNP	I-NP
US  	US  	 NNP	O
101  	101  	 CD	O
FEDERAL  	FEDERAL  	 NNP	B-NP
STREET  	STREET  	 NNP	I-NP
BOSTON  	BOSTON  	 NNP	I-NP
MA  	MA  	 NNP	I-NP
02110  	02110  	 CD	O
US  	US  	 NNP	O
The  	The  	 DT	O
present  	present  	 JJ	O
invention  	invention  	 NN	O
describes  	describes  	 VBZ	O
the  	the  	 DT	O
preparation  	preparation  	 NN	B-NP
and  	and  	 CC	O
use  	use  	 NN	O
of  	of  	 IN	O
biologically  	biologically  	 NN	O
and  	and  	 CC	O
immunologically  	immunologically  	 JJ	O
active  	active  	 JJ	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxin 	toxin 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
toxin  	toxin  	 NN	B-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
HC  	HC  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
potentially  	potentially  	 RB	O
life-threatening  	life-threatening  	 JJ	B-NP
sequela  	sequela  	 JJ	I-NP
HUS  	HUS  	 NNP	I-NP
transmitted  	transmitted  	 VBD	O
by  	by  	 IN	O
strains  	strains  	 NNS	O
of  	of  	 IN	O
pathogenic  	pathogenic  	 JJ	B-NP
bacteria 	bacteria 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 JJ	O
invention  	invention  	 NN	O
describes  	describes  	 VBZ	O
how  	how  	 WRB	O
these  	these  	 DT	O
humanized  	humanized  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
may  	may  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
or  	or  	 CC	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
induced  	induced  	 NN	I-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
One  	One  	 CD	O
aspect  	aspect  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
is  	is  	 VBZ	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
which  	which  	 WDT	O
binds  	binds  	 VBZ	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
where  	where  	 WRB	O
the  	the  	 DT	O
constant  	constant  	 JJ	O
regions  	regions  	 NNS	O
are  	are  	 VBP	O
IgG1-kappa  	IgG1-kappa  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
are  	are  	 VBP	O
murine  	murine  	 VBN	O
in  	in  	 IN	O
origin 	origin 	 NN	O
.  	.  	 .	O
Yet  	Yet  	 RB	O
another  	another  	 DT	O
aspect  	aspect  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
is  	is  	 VBZ	O
expression  	expression  	 JJ	B-NP
vectors  	vectors  	 NN	I-NP
and  	and  	 CC	O
host  	host  	 NN	B-NP
cells  	cells  	 NNS	I-NP
transformed  	transformed  	 VBN	O
with  	with  	 IN	O
such  	such  	 JJ	O
vectors  	vectors  	 NN	O
which  	which  	 WDT	O
express  	express  	 VBP	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
present  	present  	 JJ	O
invention 	invention 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
application  	application  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
continuation  	continuation  	 NN	B-NP
of  	of  	 IN	O
U.S.  	U.S.  	 NNP	O
patent  	patent  	 NN	O
application  	application  	 NN	O
Ser 	Ser 	 NNP	O
.  	.  	 .	O
No.  	No.  	 NNP	O
09 	09 	 CD	O
/ 	/ 	 CD	O
215,163 	215,163 	 CD	O
,  	,  	 ,	O
filed  	filed  	 VBD	O
Dec.  	Dec.  	 NNP	O
18 	18 	 CD	O
,  	,  	 ,	O
1998 	1998 	 CD	O
,  	,  	 ,	O
which  	which  	 WDT	O
claims  	claims  	 VBZ	O
the  	the  	 DT	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
U.S.  	U.S.  	 NNP	O
Provisional  	Provisional  	 NNP	O
Application  	Application  	 NNP	O
No.  	No.  	 NNP	O
60 	60 	 CD	O
/ 	/ 	 CD	O
068,635 	068,635 	 CD	O
,  	,  	 ,	O
filed  	filed  	 VBD	O
Dec.  	Dec.  	 NNP	O
23 	23 	 CD	O
,  	,  	 ,	O
1997 	1997 	 CD	O
,  	,  	 ,	O
each  	each  	 DT	O
of  	of  	 IN	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
hereby  	hereby  	 VBN	O
incorporated  	incorporated  	 VBN	O
by  	by  	 IN	O
reference 	reference 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
invention  	invention  	 NN	O
relates  	relates  	 VBZ	O
to  	to  	 TO	O
a  	a  	 DT	O
family  	family  	 NN	O
of  	of  	 IN	O
multi-unit  	multi-unit  	 JJ	B-NP
bacterial  	bacterial  	 JJ	I-NP
proteins  	proteins  	 NNS	I-NP
that  	that  	 WDT	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
hemorrhagic  	hemorrhagic  	 JJ	B-NP
colitis  	colitis  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
life-threatening  	life-threatening  	 JJ	B-NP
sequela 	sequela 	 NN	I-NP
,  	,  	 ,	O
hemolytic  	hemolytic  	 JJ	B-NP
uremic  	uremic  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
proteins 	proteins 	 NNS	O
,  	,  	 ,	O
defined  	defined  	 VBN	O
as  	as  	 IN	O
members  	members  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
family 	family 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
; 	; 	 :	O
,  	,  	 ,	O
have  	have  	 VBP	O
been  	been  	 VBN	O
utilized  	utilized  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
isolation  	isolation  	 NN	O
and  	and  	 CC	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	I-NP
murine  	murine  	 JJ	I-NP
monoclonal  	monoclonal  	 JJ	I-NP
antibodies 	antibodies 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
invention  	invention  	 NN	O
further  	further  	 RBR	O
relates  	relates  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
which  	which  	 WDT	O
incorporate  	incorporate  	 VBZ	O
the  	the  	 DT	O
mouse  	mouse  	 NN	O
variable  	variable  	 NN	O
regions 	regions 	 NNS	O
.  	.  	 .	O
It  	It  	 PRP	O
also  	also  	 RB	O
relates  	relates  	 VBZ	O
to  	to  	 TO	O
antibodies  	antibodies  	 VB	O
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxins  	toxins  	 NN	I-NP
or  	or  	 CC	O
toxoids 	toxoids 	 NN	B-NP
,  	,  	 ,	O
both  	both  	 DT	O
monoclonal  	monoclonal  	 NN	B-NP
and  	and  	 CC	O
polyclonal 	polyclonal 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
their  	their  	 PRP$	O
use  	use  	 NN	O
in  	in  	 IN	O
treating 	treating 	 VBG	O
,  	,  	 ,	O
diagnosing 	diagnosing 	 VBG	O
,  	,  	 ,	O
and  	and  	 CC	O
preventing  	preventing  	 VBG	O
of  	of  	 IN	O
disease  	disease  	 NN	O
and  	and  	 CC	O
infections  	infections  	 NNS	O
caused  	caused  	 VBN	O
by  	by  	 IN	O
pathogenic  	pathogenic  	 JJ	B-NP
E.  	E.  	 NNP	I-NP
coli 	coli 	 NNS	I-NP
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
relates  	relates  	 VBZ	O
to  	to  	 TO	O
preparing  	preparing  	 VBG	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
proteins  	proteins  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
family 	family 	 NN	I-NP
.  	.  	 .	O
Enterohemorrhagic  	Enterohemorrhagic  	 NNP	B-NP
Escherichia  	Escherichia  	 NNP	I-NP
coli  	coli  	 NNS	I-NP
( 	( 	 -LRB-	O
EHEC 	EHEC 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
food-borne  	food-borne  	 JJ	B-NP
outbreaks  	outbreaks  	 NNS	I-NP
of  	of  	 IN	O
bloody  	bloody  	 JJ	O
diarrhea  	diarrhea  	 NN	O
or  	or  	 CC	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
hemorrhagic  	hemorrhagic  	 JJ	B-NP
colitis 	colitis 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
( 	( 	 -LRB-	O
HC 	HC 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
hemolytic  	hemolytic  	 JJ	B-NP
uremic  	uremic  	 JJ	I-NP
syndrome  	syndrome  	 NN	I-NP
( 	( 	 -LRB-	O
HUS 	HUS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
( 	( 	 -LRB-	O
Spika 	Spika 	 NNP	O
,  	,  	 ,	O
J.  	J.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
J.  	J.  	 NNP	B-NP
Pediatr. 	Pediatr. 	 NNP	I-NP
,  	,  	 ,	O
109 	109 	 CD	O
:  	:  	 :	O
287-291  	287-291  	 CD	O
( 	( 	 -LRB-	O
1986 	1986 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
Remis 	Remis 	 NNP	O
,  	,  	 ,	O
R. 	R. 	 NNP	O
,  	,  	 ,	O
Ann 	Ann 	 NNP	O
.  	.  	 .	O
Intern 	Intern 	 NNP	O
.  	.  	 .	O
Med. 	Med. 	 NNP	B-NP
,  	,  	 ,	O
101 	101 	 CD	O
: 	: 	 :	O
624-626  	624-626  	 CD	O
( 	( 	 -LRB-	O
1984 	1984 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
Riley 	Riley 	 NNP	O
,  	,  	 ,	O
L.  	L.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
N.  	N.  	 NNP	O
Engl 	Engl 	 NNP	O
.  	.  	 .	O
J.  	J.  	 NNP	B-NP
Med. 	Med. 	 NNP	I-NP
,  	,  	 ,	O
308 	308 	 CD	O
: 	: 	 :	O
681-685  	681-685  	 CD	O
( 	( 	 -LRB-	O
1983 	1983 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
EHEC  	EHEC  	 NNP	B-NP
infection  	infection  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
deadly  	deadly  	 JJ	O
and  	and  	 CC	O
poses  	poses  	 VBZ	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
threat  	threat  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
young  	young  	 JJ	O
and  	and  	 CC	O
the  	the  	 DT	O
elderly 	elderly 	 JJ	O
,  	,  	 ,	O
who  	who  	 WP	O
are  	are  	 VBP	O
the  	the  	 DT	O
most  	most  	 RBS	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
develop  	develop  	 VB	O
serious  	serious  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
from  	from  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
infections 	infections 	 NNS	I-NP
.  	.  	 .	O
Several  	Several  	 JJ	O
outbreaks  	outbreaks  	 NNS	O
and  	and  	 CC	O
sporadic  	sporadic  	 JJ	B-NP
cases  	cases  	 NNS	I-NP
of  	of  	 IN	I-NP
HC  	HC  	 NNP	I-NP
and  	and  	 CC	O
HUS  	HUS  	 NNP	B-NP
have  	have  	 VBP	O
occurred  	occurred  	 VBN	O
over  	over  	 IN	O
the  	the  	 DT	O
past  	past  	 JJ	O
few  	few  	 JJ	O
years 	years 	 NNS	O
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
largest  	largest  	 JJS	O
U.S.  	U.S.  	 NNP	O
outbreak  	outbreak  	 NN	O
in  	in  	 IN	O
1993 	1993 	 CD	O
.  	.  	 .	O
In  	In  	 IN	O
that  	that  	 DT	O
outbreak 	outbreak 	 NN	O
,  	,  	 ,	O
over  	over  	 IN	O
500  	500  	 CD	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
HC  	HC  	 NNP	B-NP
and  	and  	 CC	O
HUS  	HUS  	 NNP	B-NP
were  	were  	 VBD	O
traced  	traced  	 VBN	O
to  	to  	 TO	O
contaminated  	contaminated  	 VB	O
hamburgers  	hamburgers  	 VBN	O
from  	from  	 IN	O
a  	a  	 DT	O
Jack-in-the  	Jack-in-the  	 JJ	B-NP
Box  	Box  	 NNP	I-NP
fast  	fast  	 JJ	O
food  	food  	 NN	B-NP
restaurant 	restaurant 	 NN	I-NP
.  	.  	 .	O
( 	( 	 -LRB-	O
Centers  	Centers  	 NNS	O
for  	for  	 IN	O
Disease  	Disease  	 NNP	B-NP
Control  	Control  	 NNP	I-NP
and  	and  	 CC	O
Prevention 	Prevention 	 NNP	O
,  	,  	 ,	O
Morbid 	Morbid 	 NNP	O
.  	.  	 .	O
Mortal 	Mortal 	 NNP	O
.  	.  	 .	O
Weekly  	Weekly  	 NNP	O
Rep. 	Rep. 	 NNP	O
,  	,  	 ,	O
42 	42 	 CD	O
: 	: 	 :	O
258  	258  	 CD	O
( 	( 	 -LRB-	O
1993 	1993 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
July  	July  	 NNP	O
1996 	1996 	 CD	O
,  	,  	 ,	O
a  	a  	 DT	O
large  	large  	 JJ	O
outbreak  	outbreak  	 NN	O
of  	of  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
in  	in  	 IN	O
Japan  	Japan  	 NNP	O
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
over  	over  	 IN	O
10,000  	10,000  	 CD	O
infected  	infected  	 JJ	O
individuals  	individuals  	 NNS	O
and  	and  	 CC	O
8  	8  	 CD	O
deaths 	deaths 	 NNS	O
.  	.  	 .	O
Many  	Many  	 JJ	O
Japanese  	Japanese  	 JJ	O
children  	children  	 NNS	O
required  	required  	 VBN	B-NP
hospitalization 	hospitalization 	 NN	I-NP
.  	.  	 .	O
Primarily 	Primarily 	 RB	O
,  	,  	 ,	O
HC  	HC  	 NNP	B-NP
and  	and  	 CC	O
HUS  	HUS  	 NNP	B-NP
are  	are  	 VBP	O
transmitted  	transmitted  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
ingestion  	ingestion  	 NN	B-NP
of  	of  	 IN	O
contaminated  	contaminated  	 JJ	O
food 	food 	 NN	O
,  	,  	 ,	O
particularly  	particularly  	 RB	O
undercooked  	undercooked  	 JJ	B-NP
beef  	beef  	 NN	I-NP
products 	products 	 NNS	I-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
hamburger 	hamburger 	 NN	O
.  	.  	 .	O
( 	( 	 -LRB-	O
Doyle  	Doyle  	 FW	O
et  	et  	 FW	O
al. 	al. 	 FW	O
,  	,  	 ,	O
J.  	J.  	 NNP	O
Appl 	Appl 	 NNP	O
.  	.  	 .	O
Environ 	Environ 	 NNP	B-NP
.  	.  	 .	O
Microbiol.  	Microbiol.  	 CD	B-NP
53 	53 	 CD	O
: 	: 	 :	O
2394  	2394  	 CD	O
( 	( 	 -LRB-	O
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
Samadpour  	Samadpour  	 FW	B-NP
et  	et  	 FW	O
al. 	al. 	 FW	O
, 	, 	 ,	O
J  	J  	 NNP	O
Appl 	Appl 	 NNP	O
.  	.  	 .	O
Environ 	Environ 	 NNP	B-NP
.  	.  	 .	O
Microbiol.  	Microbiol.  	 CD	B-NP
60 	60 	 CD	O
: 	: 	 :	O
1038  	1038  	 CD	O
( 	( 	 -LRB-	O
1994 	1994 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
With  	With  	 IN	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
in  	in  	 IN	O
cattle  	cattle  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
subjective  	subjective  	 JJ	B-NP
nature  	nature  	 NN	I-NP
of  	of  	 IN	O
differentiating  	differentiating  	 VBG	O
between  	between  	 IN	O
cooked  	cooked  	 NN	O
and  	and  	 CC	O
undercooked  	undercooked  	 JJ	B-NP
hamburgers 	hamburgers 	 NNS	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
stop  	stop  	 NN	O
at  	at  	 IN	O
a  	a  	 DT	O
fast  	fast  	 JJ	O
food  	food  	 NN	B-NP
restaurant  	restaurant  	 NN	I-NP
or  	or  	 CC	O
a  	a  	 DT	O
family  	family  	 NN	B-NP
barbecue  	barbecue  	 NN	I-NP
can  	can  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
tragedy 	tragedy 	 NN	O
.  	.  	 .	O
HC  	HC  	 NNP	B-NP
and  	and  	 CC	O
HUS  	HUS  	 NNP	B-NP
appear  	appear  	 VBP	O
to  	to  	 TO	O
be  	be  	 VB	O
mediated  	mediated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
toxin  	toxin  	 NN	B-NP
produced  	produced  	 VBN	O
by  	by  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
and  	and  	 CC	O
Shigella  	Shigella  	 NNP	B-NP
dysenteriae  	dysenteriae  	 NNS	I-NP
( 	( 	 -LRB-	O
for  	for  	 IN	O
a  	a  	 DT	O
review 	review 	 NN	O
,  	,  	 ,	O
see  	see  	 VB	O
O 	O 	 NNP	O
' 	' 	 POS	O
Brien  	Brien  	 NNP	O
and  	and  	 CC	O
Holmes 	Holmes 	 NNP	O
,  	,  	 ,	O
Microbiol 	Microbiol 	 NNP	B-NP
.  	.  	 .	O
Rev. 	Rev. 	 NNP	B-NP
,  	,  	 ,	O
51 	51 	 CD	O
: 	: 	 :	O
206-220  	206-220  	 CD	O
( 	( 	 -LRB-	O
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
bacteria  	bacteria  	 NNS	O
produce  	produce  	 VBP	O
a  	a  	 DT	O
family  	family  	 NN	O
of  	of  	 IN	O
closely  	closely  	 RB	O
related  	related  	 VBN	O
cytotoxins  	cytotoxins  	 NNS	B-NP
that  	that  	 WDT	O
collectively  	collectively  	 RB	O
will  	will  	 MD	O
be  	be  	 VB	O
called  	called  	 VBN	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
Shiga  	Shiga  	 NNP	B-NP
toxins 	toxins 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
for  	for  	 IN	O
the  	the  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
application 	application 	 NN	O
.  	.  	 .	O
Shiga  	Shiga  	 JJ	B-NP
toxins  	toxins  	 NNS	I-NP
( 	( 	 -LRB-	O
alternatively 	alternatively 	 RB	O
,  	,  	 ,	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
verotoxins 	verotoxins 	 NNS	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
; 	; 	 CD	O
)  	)  	 -RRB-	O
have  	have  	 VBP	O
cytotoxic 	cytotoxic 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
enterotoxic  	enterotoxic  	 JJ	B-NP
activity  	activity  	 NN	I-NP
( 	( 	 -LRB-	O
Strockbine 	Strockbine 	 NNP	B-NP
,  	,  	 ,	O
N.  	N.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
Infect 	Infect 	 NNP	B-NP
.  	.  	 .	O
Immun. 	Immun. 	 NNP	B-NP
,  	,  	 ,	O
53 	53 	 CD	O
: 	: 	 :	O
135-140  	135-140  	 CD	O
( 	( 	 -LRB-	O
1986 	1986 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
exhibition  	exhibition  	 NN	O
of  	of  	 IN	O
immunological  	immunological  	 JJ	B-NP
non-cross-reactivity 	non-cross-reactivity 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
Shiga  	Shiga  	 JJ	B-NP
toxins  	toxins  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
divided  	divided  	 VBN	O
into  	into  	 IN	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
( 	( 	 -LRB-	O
Strockbine  	Strockbine  	 FW	B-NP
et  	et  	 FW	O
al. 	al. 	 FW	O
,  	,  	 ,	O
supra 	supra 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
groups  	groups  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
designated  	designated  	 VBN	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
1  	1  	 CD	O
( 	( 	 -LRB-	O
Stx1 	Stx1 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
2  	2  	 CD	O
( 	( 	 -LRB-	O
Stx2 	Stx2 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
Stx1  	Stx1  	 JJ	B-NP
group  	group  	 NN	I-NP
contains  	contains  	 VBZ	O
the  	the  	 DT	O
prototype  	prototype  	 NN	B-NP
Stx1  	Stx1  	 CD	I-NP
toxin  	toxin  	 NN	I-NP
from  	from  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
the  	the  	 DT	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
from  	from  	 IN	O
Shigella  	Shigella  	 NNP	B-NP
dysenteriae  	dysenteriae  	 JJ	I-NP
type  	type  	 NN	I-NP
1 	1 	 CD	O
.  	.  	 .	O
In  	In  	 IN	O
recent  	recent  	 JJ	O
years 	years 	 NNS	O
,  	,  	 ,	O
other  	other  	 JJ	O
types  	types  	 NNS	O
of  	of  	 IN	O
toxins  	toxins  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
discovered  	discovered  	 VBN	O
and  	and  	 CC	O
considered  	considered  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
members  	members  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
Stx2  	Stx2  	 JJ	B-NP
group 	group 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
are  	are  	 VBP	O
Stx2e 	Stx2e 	 RB	O
,  	,  	 ,	O
Stx2c 	Stx2c 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
Stx2d 	Stx2d 	 NNP	O
.  	.  	 .	O
( 	( 	 -LRB-	O
Lindgren  	Lindgren  	 FW	O
et  	et  	 FW	O
al. 	al. 	 FW	O
,  	,  	 ,	O
Infection  	Infection  	 NNP	B-NP
and  	and  	 CC	O
Immunology 	Immunology 	 NNP	B-NP
,  	,  	 ,	O
61 	61 	 CD	O
: 	: 	 :	O
3832  	3832  	 CD	O
( 	( 	 -LRB-	O
1993 	1993 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
Schmitt 	Schmitt 	 NNP	O
,  	,  	 ,	O
C.  	C.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
Infect 	Infect 	 NNP	B-NP
.  	.  	 .	O
Immun. 	Immun. 	 NNP	B-NP
,  	,  	 ,	O
59 	59 	 CD	O
: 	: 	 :	O
1065-1073  	1065-1073  	 CD	O
( 	( 	 -LRB-	O
1991 	1991 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
Marques 	Marques 	 NNP	O
,  	,  	 ,	O
L.  	L.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
FEMS  	FEMS  	 NNP	B-NP
Lett. 	Lett. 	 NNP	O
,  	,  	 ,	O
44 	44 	 CD	O
: 	: 	 :	O
33-38  	33-38  	 CD	O
( 	( 	 -LRB-	O
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
purposes  	purposes  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
application  	application  	 NN	O
the  	the  	 DT	O
term  	term  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
Shiga  	Shiga  	 NNP	B-NP
toxin 	toxin 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
encompasses  	encompasses  	 JJ	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
and  	and  	 CC	O
any  	any  	 DT	O
other  	other  	 JJ	O
toxins  	toxins  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
Stx1  	Stx1  	 NNP	B-NP
or  	or  	 CC	O
Stx2  	Stx2  	 CD	B-NP
group  	group  	 NN	I-NP
or  	or  	 CC	O
their  	their  	 PRP$	O
variants 	variants 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
abbreviation  	abbreviation  	 NN	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
Stx 	Stx 	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
will  	will  	 MD	O
refer  	refer  	 VB	O
to  	to  	 TO	O
the  	the  	 DT	O
toxin  	toxin  	 NN	B-NP
protein  	protein  	 NN	I-NP
itself 	itself 	 PRP	O
.  	.  	 .	O
Despite  	Despite  	 IN	O
this  	this  	 DT	O
knowledge  	knowledge  	 NN	O
about  	about  	 IN	O
the  	the  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
exposure  	exposure  	 NN	O
to  	to  	 TO	O
these  	these  	 DT	O
toxins 	toxins 	 NN	O
,  	,  	 ,	O
currently  	currently  	 RB	O
there  	there  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
known  	known  	 JJ	O
cure  	cure  	 NN	O
or  	or  	 CC	O
vaccine  	vaccine  	 NN	O
for  	for  	 IN	O
HC  	HC  	 NNP	B-NP
or  	or  	 CC	O
HUS 	HUS 	 NNP	B-NP
.  	.  	 .	O
Antibiotics  	Antibiotics  	 NNP	O
may  	may  	 MD	O
even  	even  	 RB	O
make  	make  	 VB	O
the  	the  	 DT	O
severe  	severe  	 JJ	O
complications  	complications  	 NNS	B-NP
worse  	worse  	 JJR	O
by  	by  	 IN	O
increasing  	increasing  	 VBG	B-NP
toxin  	toxin  	 NN	I-NP
release  	release  	 NN	I-NP
from  	from  	 IN	O
bacteria 	bacteria 	 NNS	O
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
a  	a  	 DT	O
compound  	compound  	 NN	B-NP
to  	to  	 TO	O
prevent  	prevent  	 VB	O
or  	or  	 CC	O
to  	to  	 TO	O
treat  	treat  	 VB	O
the  	the  	 DT	O
complications  	complications  	 NNS	B-NP
of  	of  	 IN	I-NP
EHEC  	EHEC  	 NNP	I-NP
produced  	produced  	 VBD	O
by  	by  	 IN	O
Shiga  	Shiga  	 NNP	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
Such  	Such  	 PDT	O
a  	a  	 DT	O
compound  	compound  	 NN	B-NP
could  	could  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
to  	to  	 TO	O
treat  	treat  	 VB	O
infected  	infected  	 JJ	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
decrease  	decrease  	 VB	O
the  	the  	 DT	O
systemic  	systemic  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	I-NP
toxin  	toxin  	 NN	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
CNS 	CNS 	 NNP	B-NP
,  	,  	 ,	O
blood  	blood  	 NN	O
and  	and  	 CC	O
kidneys 	kidneys 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
if  	if  	 IN	O
the  	the  	 DT	O
toxin  	toxin  	 NN	B-NP
could  	could  	 MD	O
be  	be  	 VB	O
neutralized 	neutralized 	 NNS	O
,  	,  	 ,	O
antibiotics  	antibiotics  	 NNS	O
could  	could  	 MD	O
be  	be  	 VB	O
safely  	safely  	 RB	O
given  	given  	 VBN	O
to  	to  	 TO	O
kill  	kill  	 VB	O
the  	the  	 DT	O
bacteria  	bacteria  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
GI  	GI  	 NNP	B-NP
tract 	tract 	 NN	I-NP
.  	.  	 .	O
Such  	Such  	 PDT	O
a  	a  	 DT	O
compound  	compound  	 NN	B-NP
could  	could  	 MD	O
also  	also  	 RB	O
be  	be  	 VB	O
used  	used  	 VBN	O
to  	to  	 TO	O
prevent  	prevent  	 VB	O
infectious  	infectious  	 JJ	B-NP
complications 	complications 	 NNS	I-NP
,  	,  	 ,	O
by  	by  	 IN	O
treating  	treating  	 VBG	O
exposed  	exposed  	 VBN	O
or  	or  	 CC	O
high  	high  	 JJ	O
risk  	risk  	 NN	B-NP
individuals  	individuals  	 NNS	I-NP
before  	before  	 IN	O
they  	they  	 PRP	O
acquire  	acquire  	 VB	O
EHEC  	EHEC  	 JJ	B-NP
infection 	infection 	 NN	I-NP
.  	.  	 .	O
Such  	Such  	 JJ	O
individuals  	individuals  	 NNS	O
would  	would  	 MD	O
include  	include  	 VB	O
children  	children  	 NNS	O
in  	in  	 IN	O
day  	day  	 NN	O
care  	care  	 NN	O
or  	or  	 CC	O
the  	the  	 DT	O
elderly  	elderly  	 JJ	O
in  	in  	 IN	O
nursing  	nursing  	 NN	B-NP
homes 	homes 	 NNS	I-NP
,  	,  	 ,	O
where  	where  	 WRB	O
a  	a  	 DT	O
case  	case  	 NN	O
of  	of  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
diarrhea  	diarrhea  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
detected 	detected 	 VBN	O
.  	.  	 .	O
These  	These  	 DT	O
individuals  	individuals  	 NNS	O
are  	are  	 VBP	O
at  	at  	 IN	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
to  	to  	 TO	O
develop  	develop  	 VB	O
severe  	severe  	 JJ	O
complications  	complications  	 NNS	B-NP
and  	and  	 CC	O
spread  	spread  	 NN	O
of  	of  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
in  	in  	 IN	O
these  	these  	 DT	O
environments  	environments  	 NN	O
is  	is  	 VBZ	O
not  	not  	 RB	O
unusual 	unusual 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
knowledge  	knowledge  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
immunological  	immunological  	 NNS	B-NP
cross  	cross  	 VBP	O
reactivity  	reactivity  	 VBN	O
of  	of  	 IN	O
the  	the  	 DT	O
Shiga  	Shiga  	 JJ	B-NP
toxins  	toxins  	 NN	I-NP
offers  	offers  	 VBZ	O
a  	a  	 DT	O
tantalizing  	tantalizing  	 JJ	O
prospect  	prospect  	 NN	O
for  	for  	 IN	O
pharmacological  	pharmacological  	 JJ	B-NP
approaches  	approaches  	 NNS	I-NP
to  	to  	 TO	O
EHEC  	EHEC  	 NNP	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
Currently 	Currently 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
are  	are  	 VBP	O
no  	no  	 RB	O
known  	known  	 VBN	O
prophylactic  	prophylactic  	 NNS	O
or  	or  	 CC	O
therapeutic  	therapeutic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
available  	available  	 JJ	O
for  	for  	 IN	O
this  	this  	 DT	O
disease 	disease 	 NN	O
.  	.  	 .	O
Accordingly 	Accordingly 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
need  	need  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
to  	to  	 TO	O
provide  	provide  	 VB	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
that  	that  	 WDT	O
can  	can  	 MD	O
bind  	bind  	 VB	O
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxins  	toxins  	 NN	I-NP
which  	which  	 WDT	O
could  	could  	 MD	O
prevent  	prevent  	 VB	O
or  	or  	 CC	O
lessen  	lessen  	 VB	O
the  	the  	 DT	O
devastating  	devastating  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
these  	these  	 DT	O
toxins 	toxins 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
also  	also  	 RB	O
a  	a  	 DT	O
need  	need  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
for  	for  	 IN	O
data  	data  	 NNS	O
concerning  	concerning  	 VBG	O
the  	the  	 DT	O
binding  	binding  	 JJ	O
site  	site  	 NN	O
of  	of  	 IN	O
such  	such  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
so  	so  	 RB	O
that  	that  	 IN	O
other  	other  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
with  	with  	 IN	O
similar  	similar  	 JJ	O
abilities  	abilities  	 NNS	O
can  	can  	 MD	O
be  	be  	 VB	O
identified  	identified  	 VBN	O
and  	and  	 CC	O
isolated 	isolated 	 VBN	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
related  	related  	 JJ	O
need  	need  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
for  	for  	 IN	O
humanized  	humanized  	 NN	O
or  	or  	 CC	O
other  	other  	 JJ	O
chimeric  	chimeric  	 FW	B-NP
human 	human 	 FW	I-NP
/ 	/ 	 FW	I-NP
mouse  	mouse  	 FW	I-NP
monoclonal  	monoclonal  	 FW	I-NP
antibodies 	antibodies 	 FW	I-NP
.  	.  	 .	O
In  	In  	 IN	O
well  	well  	 RB	O
publicized  	publicized  	 VBN	B-NP
studies 	studies 	 NNS	I-NP
,  	,  	 ,	O
patients  	patients  	 FW	O
administered  	administered  	 FW	B-NP
murine  	murine  	 FW	I-NP
anti-TNF  	anti-TNF  	 FW	I-NP
( 	( 	 -LRB-	O
tumor  	tumor  	 NN	B-NP
necrosis  	necrosis  	 NN	I-NP
factor 	factor 	 NN	I-NP
)  	)  	 -RRB-	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
developed  	developed  	 VBD	I-NP
anti-murine  	anti-murine  	 JJ	I-NP
antibody  	antibody  	 NN	I-NP
responses  	responses  	 NNS	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
administered  	administered  	 JJ	O
antibody 	antibody 	 NN	B-NP
.  	.  	 .	O
( 	( 	 -LRB-	O
See 	See 	 VB	O
,  	,  	 ,	O
e.g. 	e.g. 	 NNP	O
,  	,  	 ,	O
Exley  	Exley  	 NNP	O
A.  	A.  	 NNP	O
R. 	R. 	 NNP	O
,  	,  	 ,	O
et  	et  	 FW	O
al. 	al. 	 FW	O
,  	,  	 ,	O
Lancet  	Lancet  	 NNP	O
335 	335 	 CD	O
: 	: 	 :	O
1275-1277  	1275-1277  	 CD	O
( 	( 	 -LRB-	O
1990 	1990 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
immune  	immune  	 JJ	B-NP
response  	response  	 NN	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
treatment  	treatment  	 NN	B-NP
regimen 	regimen 	 NN	I-NP
,  	,  	 ,	O
commonly  	commonly  	 RB	O
referred  	referred  	 VBN	O
to  	to  	 TO	O
as  	as  	 IN	O
the  	the  	 DT	O
HAMA  	HAMA  	 NNP	B-NP
response  	response  	 NN	I-NP
( 	( 	 -LRB-	O
for  	for  	 IN	O
human  	human  	 JJ	O
anti-mouse  	anti-mouse  	 JJ	B-NP
antibodies 	antibodies 	 NNS	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
decreases  	decreases  	 VBZ	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
may  	may  	 MD	O
even  	even  	 RB	O
render  	render  	 VB	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
completely  	completely  	 RB	O
ineffective 	ineffective 	 JJ	O
.  	.  	 .	O
Humanized  	Humanized  	 NNP	O
or  	or  	 CC	O
chimeric  	chimeric  	 JJ	B-NP
human 	human 	 JJ	I-NP
/ 	/ 	 CD	I-NP
mouse  	mouse  	 NN	I-NP
monoclonal  	monoclonal  	 NN	I-NP
antibodies  	antibodies  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
significantly  	significantly  	 RB	O
decrease  	decrease  	 VB	O
the  	the  	 DT	O
HAMA  	HAMA  	 NNP	B-NP
response  	response  	 NN	I-NP
and  	and  	 CC	O
to  	to  	 TO	O
increase  	increase  	 VB	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
effectiveness 	effectiveness 	 NN	I-NP
.  	.  	 .	O
( 	( 	 -LRB-	O
LoBuglio  	LoBuglio  	 FW	B-NP
et  	et  	 FW	O
al. 	al. 	 FW	O
,  	,  	 ,	O
P.N.A.S.  	P.N.A.S.  	 CD	B-NP
86 	86 	 CD	O
: 	: 	 :	O
4220-4224  	4220-4224  	 CD	O
( 	( 	 -LRB-	O
June  	June  	 NNP	O
1989 	1989 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
To  	To  	 TO	O
satisfy  	satisfy  	 VB	O
these  	these  	 DT	O
needs  	needs  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
art 	art 	 NN	O
,  	,  	 ,	O
applicants  	applicants  	 NNS	O
provide  	provide  	 VBP	O
humanized  	humanized  	 JJ	O
mouse  	mouse  	 NN	B-NP
monoclonal  	monoclonal  	 NN	I-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
1  	1  	 CD	O
and  	and  	 CC	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
2 	2 	 CD	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
this  	this  	 DT	O
invention  	invention  	 NN	O
sets  	sets  	 VBZ	O
forth  	forth  	 RB	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
neutralization  	neutralization  	 NN	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
the  	the  	 DT	O
specific  	specific  	 JJ	O
complementarity  	complementarity  	 NNS	B-NP
determining  	determining  	 VBG	I-NP
regions  	regions  	 NNS	I-NP
( 	( 	 -LRB-	O
CDRs 	CDRs 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region 	region 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 JJ	O
invention  	invention  	 NN	O
particularly  	particularly  	 RB	O
provides  	provides  	 VBZ	O
human  	human  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies 	antibodies 	 NNS	I-NP
,  	,  	 ,	O
derived  	derived  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
mouse  	mouse  	 FW	B-NP
monoclonal  	monoclonal  	 FW	I-NP
antibodies  	antibodies  	 FW	I-NP
13C4  	13C4  	 FW	I-NP
and  	and  	 CC	O
11E10 	11E10 	 NNP	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
are  	are  	 VBP	O
specifically  	specifically  	 RB	O
reactive  	reactive  	 VBN	O
with  	with  	 IN	O
Stx1  	Stx1  	 NNP	B-NP
and  	and  	 CC	O
Stx2 	Stx2 	 NNP	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
In  	In  	 IN	O
another  	another  	 DT	O
aspect 	aspect 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
includes  	includes  	 VBZ	O
a  	a  	 DT	O
pharmaceutical  	pharmaceutical  	 JJ	B-NP
composition  	composition  	 NN	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
method  	method  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
such  	such  	 JJ	O
composition  	composition  	 NN	O
which  	which  	 WDT	O
will  	will  	 MD	O
prevent  	prevent  	 VB	O
or  	or  	 CC	O
treat  	treat  	 VB	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
induced  	induced  	 NN	I-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
understood  	understood  	 VBN	O
that  	that  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
foregoing  	foregoing  	 JJ	O
general  	general  	 JJ	O
description  	description  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
following  	following  	 JJ	O
detailed  	detailed  	 JJ	O
description  	description  	 NNS	O
are  	are  	 VBP	O
exemplary  	exemplary  	 JJ	O
and  	and  	 CC	O
explanatory  	explanatory  	 JJ	O
and  	and  	 CC	O
are  	are  	 VBP	O
intended  	intended  	 VBN	O
to  	to  	 TO	O
provide  	provide  	 VB	O
further  	further  	 JJ	O
explanation  	explanation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
as  	as  	 IN	O
claimed 	claimed 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
accompanying  	accompanying  	 JJ	O
drawings  	drawings  	 NNS	O
are  	are  	 VBP	O
included  	included  	 VBN	O
to  	to  	 TO	O
provide  	provide  	 VB	O
a  	a  	 DT	O
further  	further  	 JJ	O
understanding  	understanding  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
and  	and  	 CC	O
are  	are  	 VBP	O
incorporated  	incorporated  	 VBN	O
in  	in  	 IN	O
and  	and  	 CC	O
constitute  	constitute  	 VB	O
a  	a  	 DT	O
part  	part  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
specification 	specification 	 NN	B-NP
.  	.  	 .	O
They  	They  	 PRP	O
illustrate  	illustrate  	 VBP	O
several  	several  	 JJ	O
embodiments  	embodiments  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
and 	and 	 CC	O
,  	,  	 ,	O
together  	together  	 RB	O
with  	with  	 IN	O
the  	the  	 DT	O
description 	description 	 NN	O
,  	,  	 ,	O
serve  	serve  	 VBP	O
to  	to  	 TO	O
explain  	explain  	 VB	O
the  	the  	 DT	O
principles  	principles  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
invention 	invention 	 NN	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
1  	1  	 CD	O
provides  	provides  	 VBZ	O
a  	a  	 DT	O
schematic  	schematic  	 JJ	B-NP
representation  	representation  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
general  	general  	 JJ	O
cloning  	cloning  	 JJ	B-NP
strategy  	strategy  	 NN	I-NP
used  	used  	 VBN	O
for  	for  	 IN	O
cloning  	cloning  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
gene  	gene  	 NN	O
fragments  	fragments  	 NNS	O
of  	of  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
11E10  	11E10  	 NNP	B-NP
and  	and  	 CC	O
13C4  	13C4  	 CD	B-NP
antibodies 	antibodies 	 NNS	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
2  	2  	 CD	O
lists  	lists  	 NNS	O
the  	the  	 DT	O
oligonucleotide  	oligonucleotide  	 JJ	B-NP
sequences  	sequences  	 NNS	I-NP
used  	used  	 VBN	O
for  	for  	 IN	O
PCR  	PCR  	 NNP	B-NP
amplification  	amplification  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
13C4  	13C4  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
3  	3  	 CD	O
recites  	recites  	 CD	O
the  	the  	 DT	O
DNA  	DNA  	 NN	B-NP
and  	and  	 CC	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
consensus  	consensus  	 NN	I-NP
sequences  	sequences  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
light  	light  	 JJ	O
chains  	chains  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
13C4  	13C4  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
DNA  	DNA  	 NN	B-NP
consensus  	consensus  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
was  	was  	 VBD	O
determined  	determined  	 VBN	O
using  	using  	 VBG	O
automated  	automated  	 JJ	O
fluorescent  	fluorescent  	 JJ	O
dye-terminator  	dye-terminator  	 JJ	B-NP
sequence  	sequence  	 NN	I-NP
reactions  	reactions  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
amplified  	amplified  	 JJ	O
cDNAs  	cDNAs  	 JJ	B-NP
analyzed  	analyzed  	 NN	I-NP
with  	with  	 IN	O
an  	an  	 DT	O
ABI  	ABI  	 NNP	B-NP
373  	373  	 CD	O
sequencing  	sequencing  	 JJ	B-NP
instrument 	instrument 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
CDRs  	CDRs  	 NN	B-NP
were  	were  	 VBD	O
identified  	identified  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
nomenclature  	nomenclature  	 NN	O
of  	of  	 IN	O
Kabat  	Kabat  	 NNP	O
and  	and  	 CC	O
Wu  	Wu  	 NNP	O
( 	( 	 -LRB-	O
Kabat 	Kabat 	 NNP	O
,  	,  	 ,	O
et  	et  	 FW	O
al.  	al.  	 FW	O
( 	( 	 -LRB-	O
1991 	1991 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
Sequences  	Sequences  	 NNP	O
of  	of  	 IN	O
Proteins  	Proteins  	 NNPS	O
of  	of  	 IN	O
Immunological  	Immunological  	 NNP	B-NP
Interest 	Interest 	 NNP	I-NP
,  	,  	 ,	O
Vol 	Vol 	 NNP	B-NP
.  	.  	 .	O
I 	I 	 PRP	O
,  	,  	 ,	O
5th  	5th  	 JJ	B-NP
edition 	edition 	 NN	I-NP
,  	,  	 ,	O
U.S.  	U.S.  	 NNP	O
Department  	Department  	 NNP	O
of  	of  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Human  	Human  	 NNP	O
Services 	Services 	 NNPS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
are  	are  	 VBP	O
located  	located  	 VBN	O
as  	as  	 RB	O
follows 	follows 	 VBZ	O
:  	:  	 :	O
Heavy  	Heavy  	 NNP	O
Chain  	Chain  	 NNP	B-NP
CDRs 	CDRs 	 NNP	I-NP
:  	:  	 :	O
CDR1-aa31-35  	CDR1-aa31-35  	 CD	B-NP
( 	( 	 -LRB-	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
:  	:  	 :	O
19 	19 	 CD	O
)  	)  	 -RRB-	O
CDR2-aa50-66  	CDR2-aa50-66  	 NNP	B-NP
CDR3-aa99-111  	CDR3-aa99-111  	 NNP	I-NP
Light  	Light  	 NNP	O
Chain  	Chain  	 NNP	B-NP
CDRs 	CDRs 	 NNP	I-NP
:  	:  	 :	O
CDR1-aa24-34  	CDR1-aa24-34  	 CD	B-NP
( 	( 	 -LRB-	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
:  	:  	 :	O
21 	21 	 CD	O
)  	)  	 -RRB-	O
CDR2-aa50-56  	CDR2-aa50-56  	 FW	B-NP
CDR3-aa89-97  	CDR3-aa89-97  	 FW	I-NP
FIG.  	FIG.  	 CD	O
4  	4  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
mammalian  	mammalian  	 JJ	I-NP
expression  	expression  	 NN	I-NP
vector  	vector  	 NNS	I-NP
tKMC249A  	tKMC249A  	 VBP	O
containing  	containing  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
13C4  	13C4  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
5  	5  	 CD	O
lists  	lists  	 NNS	O
the  	the  	 DT	O
oligonucleotides  	oligonucleotides  	 NN	B-NP
used  	used  	 VBN	O
for  	for  	 IN	O
PCR  	PCR  	 NNP	B-NP
amplification  	amplification  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
11E10  	11E10  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
6  	6  	 CD	O
recites  	recites  	 CD	O
the  	the  	 DT	O
DNA  	DNA  	 NN	B-NP
and  	and  	 CC	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
consensus  	consensus  	 NN	I-NP
sequences  	sequences  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
light  	light  	 JJ	O
chains  	chains  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
11E10  	11E10  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
DNA  	DNA  	 NN	B-NP
consensus  	consensus  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
was  	was  	 VBD	O
determined  	determined  	 VBN	O
using  	using  	 VBG	O
automated  	automated  	 JJ	O
fluorescent  	fluorescent  	 JJ	O
dye-terminator  	dye-terminator  	 JJ	B-NP
sequence  	sequence  	 NN	I-NP
reactions  	reactions  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
amplified  	amplified  	 JJ	O
cDNAs  	cDNAs  	 JJ	B-NP
analyzed  	analyzed  	 NN	I-NP
with  	with  	 IN	O
an  	an  	 DT	O
ABI  	ABI  	 NNP	B-NP
373  	373  	 CD	O
sequencing  	sequencing  	 JJ	B-NP
instrument 	instrument 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
CDRs  	CDRs  	 NN	B-NP
were  	were  	 VBD	O
identified  	identified  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
nomenclature  	nomenclature  	 NN	O
of  	of  	 IN	O
Kabat  	Kabat  	 NNP	O
and  	and  	 CC	O
Wu  	Wu  	 NNP	O
( 	( 	 -LRB-	O
Kabat  	Kabat  	 NNP	O
and  	and  	 CC	O
Wu 	Wu 	 NNP	O
;  	;  	 :	O
supra 	supra 	 LS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
are  	are  	 VBP	O
located  	located  	 VBN	O
as  	as  	 RB	O
follows 	follows 	 VBZ	O
:  	:  	 :	O
Heavy  	Heavy  	 NNP	O
Chain  	Chain  	 NNP	B-NP
CDRs 	CDRs 	 NNP	I-NP
:  	:  	 :	O
CDR1-aa31-35  	CDR1-aa31-35  	 CD	B-NP
( 	( 	 -LRB-	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
:  	:  	 :	O
44 	44 	 CD	O
)  	)  	 -RRB-	O
CDR2-aa50-66  	CDR2-aa50-66  	 NNP	B-NP
CDR3-aa99-108  	CDR3-aa99-108  	 NNP	I-NP
Light  	Light  	 NNP	O
Chain  	Chain  	 NNP	B-NP
CDRs 	CDRs 	 NNP	I-NP
:  	:  	 :	O
CDR1-aa24-40  	CDR1-aa24-40  	 CD	B-NP
( 	( 	 -LRB-	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
:  	:  	 :	O
42 	42 	 CD	O
)  	)  	 -RRB-	O
CDR2-aa56-62  	CDR2-aa56-62  	 FW	B-NP
CDR3-aa95-103  	CDR3-aa95-103  	 FW	I-NP
FIG.  	FIG.  	 CD	O
7  	7  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
mammalian  	mammalian  	 JJ	I-NP
expression  	expression  	 NN	I-NP
vector  	vector  	 NNS	I-NP
pACE4  	pACE4  	 VBP	O
containing  	containing  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
11E10  	11E10  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
8  	8  	 CD	O
shows  	shows  	 NNS	O
the  	the  	 DT	O
anti-Stx1  	anti-Stx1  	 CD	B-NP
13C4  	13C4  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
production  	production  	 NN	I-NP
ELISA  	ELISA  	 NNP	I-NP
and  	and  	 CC	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
H13C4  	H13C4  	 JJ	O
cell  	cell  	 NN	O
line  	line  	 NN	O
produces  	produces  	 VBZ	O
an  	an  	 DT	O
antibody  	antibody  	 NN	B-NP
consisting  	consisting  	 VBG	O
of  	of  	 IN	O
human  	human  	 JJ	O
IgG  	IgG  	 JJ	O
and  	and  	 CC	O
kappa  	kappa  	 JJ	B-NP
constant  	constant  	 JJ	O
domains 	domains 	 NN	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
9  	9  	 CD	O
shows  	shows  	 NNS	O
the  	the  	 DT	O
anti-Stx1  	anti-Stx1  	 CD	B-NP
13C4  	13C4  	 CD	I-NP
toxin  	toxin  	 NN	I-NP
binding  	binding  	 JJ	O
activity  	activity  	 NN	B-NP
ELISA  	ELISA  	 NNP	I-NP
and  	and  	 CC	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
antibody  	antibody  	 NN	B-NP
produced  	produced  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
H13C4  	H13C4  	 JJ	O
cell  	cell  	 NN	O
line  	line  	 NN	O
binds  	binds  	 NN	O
to  	to  	 TO	O
Stx1  	Stx1  	 CD	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
10  	10  	 CD	O
shows  	shows  	 NNS	O
the  	the  	 DT	O
anti-Stx2  	anti-Stx2  	 CD	B-NP
11E10  	11E10  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
production  	production  	 NN	I-NP
ELISA  	ELISA  	 NNP	I-NP
and  	and  	 CC	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
H11E10  	H11E10  	 JJ	O
cell  	cell  	 NN	O
line  	line  	 NN	O
produces  	produces  	 VBZ	O
an  	an  	 DT	O
antibody  	antibody  	 NN	B-NP
consisting  	consisting  	 VBG	O
of  	of  	 IN	O
human  	human  	 JJ	O
IgG  	IgG  	 JJ	O
and  	and  	 CC	O
kappa  	kappa  	 JJ	B-NP
constant  	constant  	 JJ	O
domains 	domains 	 NN	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
11  	11  	 CD	O
shows  	shows  	 NNS	O
the  	the  	 DT	O
anti-Stx2  	anti-Stx2  	 CD	B-NP
11E10  	11E10  	 CD	I-NP
toxin  	toxin  	 NN	I-NP
binding  	binding  	 JJ	O
activity  	activity  	 NN	B-NP
ELISA  	ELISA  	 NNP	I-NP
and  	and  	 CC	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
antibody  	antibody  	 NN	B-NP
produced  	produced  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
H11E10  	H11E10  	 JJ	O
cell  	cell  	 NN	O
line  	line  	 NN	O
binds  	binds  	 NN	O
to  	to  	 TO	O
Stx2  	Stx2  	 CD	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
12  	12  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
pCDNA3mut.LCPL.LCVK 	pCDNA3mut.LCPL.LCVK 	 NN	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
13  	13  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
pCDNA3mut.HCPL.HCV2b 	pCDNA3mut.HCPL.HCV2b 	 NN	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
14  	14  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
plasmids  	plasmids  	 JJ	I-NP
pSUN9  	pSUN9  	 NN	I-NP
and  	and  	 CC	O
pSUN9 	pSUN9 	 NNP	B-NP
: 	: 	 :	O
kappa 	kappa 	 CD	B-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
15  	15  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
plasmids  	plasmids  	 JJ	I-NP
pSUN10  	pSUN10  	 NN	I-NP
and  	and  	 CC	O
pSUN10 	pSUN10 	 NNP	B-NP
: 	: 	 :	O
IgG1 	IgG1 	 CD	B-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
16  	16  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
plasmid  	plasmid  	 JJ	I-NP
pJRS311 	pJRS311 	 NN	I-NP
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
17  	17  	 CD	O
illustrates  	illustrates  	 VBZ	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
construction  	construction  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
plasmid  	plasmid  	 JJ	I-NP
pJRS315 	pJRS315 	 NN	I-NP
.  	.  	 .	O
Additional  	Additional  	 JJ	B-NP
features  	features  	 NNS	I-NP
and  	and  	 CC	O
advantages  	advantages  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
will  	will  	 MD	O
be  	be  	 VB	O
set  	set  	 VBN	O
forth  	forth  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
description  	description  	 NN	O
which  	which  	 WDT	O
follows 	follows 	 VBZ	O
.  	.  	 .	O
The  	The  	 DT	O
objectives  	objectives  	 NNS	O
and  	and  	 CC	O
other  	other  	 JJ	O
advantages  	advantages  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
will  	will  	 MD	O
be  	be  	 VB	O
realized  	realized  	 VBN	O
and  	and  	 CC	O
attained  	attained  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
composition  	composition  	 NN	O
of  	of  	 IN	O
matter  	matter  	 NN	O
and  	and  	 CC	O
process  	process  	 NN	O
particularly  	particularly  	 RB	O
pointed  	pointed  	 VBD	O
out  	out  	 RP	O
in  	in  	 IN	O
the  	the  	 DT	O
written  	written  	 JJ	O
description  	description  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
claims  	claims  	 NNS	O
hereof  	hereof  	 VBP	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
the  	the  	 DT	O
appended  	appended  	 JJ	O
drawings 	drawings 	 NNS	O
.  	.  	 .	O
To  	To  	 TO	O
achieve  	achieve  	 VB	O
these  	these  	 DT	O
and  	and  	 CC	O
other  	other  	 JJ	O
advantages  	advantages  	 NNS	O
and  	and  	 CC	O
in  	in  	 IN	O
accordance  	accordance  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention 	invention 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
embodied  	embodied  	 VBN	O
and  	and  	 CC	O
broadly  	broadly  	 RB	O
described 	described 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
describes  	describes  	 VBZ	O
monoclonal  	monoclonal  	 JJ	B-NP
humanized  	humanized  	 JJ	I-NP
antibodies  	antibodies  	 NNS	I-NP
which  	which  	 WDT	O
bind  	bind  	 VBZ	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
proteins 	proteins 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 JJ	O
invention  	invention  	 NN	O
relates  	relates  	 VBZ	O
to  	to  	 TO	O
humanized  	humanized  	 VB	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
that  	that  	 IN	O
bind  	bind  	 NN	O
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
proteins 	proteins 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
such  	such  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
or  	or  	 CC	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
Shiga  	Shiga  	 NNP	B-NP
toxin-induced  	toxin-induced  	 JJ	I-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
Antibodies  	Antibodies  	 NNS	B-NP
are  	are  	 VBP	O
proteinaceous  	proteinaceous  	 JJ	B-NP
structures  	structures  	 NNS	I-NP
made  	made  	 VBD	O
up  	up  	 RP	O
of  	of  	 IN	O
two  	two  	 CD	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
two  	two  	 CD	O
light  	light  	 JJ	O
chains 	chains 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
five  	five  	 CD	O
different  	different  	 JJ	O
classes  	classes  	 NNS	O
of  	of  	 IN	O
higher  	higher  	 JJR	O
vertebrate  	vertebrate  	 JJ	B-NP
antibodies 	antibodies 	 NNS	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x2014 	x2014 	 CD	O
; 	; 	 :	O
IgM 	IgM 	 NNP	B-NP
,  	,  	 ,	O
IgD 	IgD 	 NNP	B-NP
,  	,  	 ,	O
IgG 	IgG 	 NNP	B-NP
,  	,  	 ,	O
IgA  	IgA  	 JJ	O
and  	and  	 CC	O
IgE 	IgE 	 JJ	O
& 	& 	 CC	O
# 	# 	 #	O
x2014 	x2014 	 CD	O
; 	; 	 :	O
are  	are  	 VBP	O
distinguished  	distinguished  	 VBN	O
by  	by  	 IN	O
their  	their  	 PRP$	O
heavy  	heavy  	 JJ	O
chains  	chains  	 NNS	O
( 	( 	 -LRB-	O
mu 	mu 	 UH	B-NP
,  	,  	 ,	O
delta 	delta 	 NN	O
,  	,  	 ,	O
gamma 	gamma 	 NN	B-NP
,  	,  	 ,	O
alpha  	alpha  	 NN	O
and  	and  	 CC	O
epsilon 	epsilon 	 NN	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Each  	Each  	 DT	O
class  	class  	 NN	O
has  	has  	 VBZ	O
further  	further  	 JJ	O
subclasses 	subclasses 	 NN	B-NP
;  	;  	 :	O
IgG 	IgG 	 NNP	B-NP
,  	,  	 ,	O
for  	for  	 IN	O
example 	example 	 NN	O
,  	,  	 ,	O
may  	may  	 MD	O
be  	be  	 VB	O
IgG1 	IgG1 	 CD	B-NP
,  	,  	 ,	O
IgG2 	IgG2 	 NNP	B-NP
,  	,  	 ,	O
IgG3 	IgG3 	 NNP	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
IgG4 	IgG4 	 NNP	B-NP
,  	,  	 ,	O
where  	where  	 WRB	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
is  	is  	 VBZ	O
gamma  	gamma  	 CD	B-NP
1 	1 	 CD	O
,  	,  	 ,	O
gamma  	gamma  	 CD	B-NP
2 	2 	 CD	O
,  	,  	 ,	O
gamma  	gamma  	 CD	B-NP
3  	3  	 CD	O
or  	or  	 CC	O
gamma  	gamma  	 CD	B-NP
4 	4 	 CD	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
pair  	pair  	 NN	O
of  	of  	 IN	O
light  	light  	 JJ	O
chains  	chains  	 NNS	O
in  	in  	 IN	O
these  	these  	 DT	O
classes  	classes  	 NNS	O
or  	or  	 CC	O
subclasses  	subclasses  	 NNS	B-NP
may  	may  	 MD	O
be  	be  	 VB	O
either  	either  	 DT	O
kappa  	kappa  	 NN	B-NP
or  	or  	 CC	O
lambda 	lambda 	 NN	B-NP
.  	.  	 .	O
Antibodies  	Antibodies  	 NNS	B-NP
are  	are  	 VBP	O
further  	further  	 RB	O
divided  	divided  	 VBN	O
into  	into  	 IN	O
a  	a  	 DT	O
constant  	constant  	 JJ	O
region  	region  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
variable  	variable  	 JJ	O
region 	region 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
light  	light  	 JJ	O
chains 	chains 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
carboxy-terminal  	carboxy-terminal  	 JJ	B-NP
ends  	ends  	 NNS	I-NP
make  	make  	 VBP	O
up  	up  	 RP	O
the  	the  	 DT	O
constant  	constant  	 JJ	O
sequence  	sequence  	 NN	O
region 	region 	 NN	O
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
terminal  	terminal  	 NN	I-NP
ends  	ends  	 NNS	I-NP
contain  	contain  	 VBP	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
sequence  	sequence  	 NN	O
region 	region 	 NN	O
.  	.  	 .	O
Within  	Within  	 IN	O
these  	these  	 DT	O
variable  	variable  	 JJ	O
regions 	regions 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
complementarity  	complementarity  	 NN	B-NP
determining  	determining  	 VBG	I-NP
regions  	regions  	 NNS	I-NP
( 	( 	 -LRB-	O
CDRs 	CDRs 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
located  	located  	 VBN	O
which  	which  	 WDT	O
are  	are  	 VBP	O
primarily  	primarily  	 RB	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
observed  	observed  	 JJ	O
antigen  	antigen  	 NN	B-NP
binding  	binding  	 NNS	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
characteristic  	characteristic  	 VBN	O
of  	of  	 IN	O
antibodies 	antibodies 	 NNS	B-NP
.  	.  	 .	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
Humanized 	Humanized 	 NNP	O
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
mean  	mean  	 VBP	I-NP
monoclonal  	monoclonal  	 JJ	I-NP
antibodies  	antibodies  	 NNS	I-NP
originally  	originally  	 RB	O
from  	from  	 IN	O
a  	a  	 DT	O
non-human  	non-human  	 JJ	B-NP
source  	source  	 NN	I-NP
to  	to  	 TO	O
which  	which  	 WDT	O
human  	human  	 JJ	O
components  	components  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
substituted 	substituted 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
preferred  	preferred  	 JJ	O
embodiment 	embodiment 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
of  	of  	 IN	O
this  	this  	 DT	O
invention  	invention  	 NNS	O
comprise  	comprise  	 VBP	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
which  	which  	 WDT	O
derive  	derive  	 VBZ	O
from  	from  	 IN	O
non-human  	non-human  	 JJ	B-NP
sources  	sources  	 NNS	I-NP
and  	and  	 CC	O
constant  	constant  	 JJ	O
regions  	regions  	 NNS	O
which  	which  	 WDT	O
derive  	derive  	 VBZ	O
from  	from  	 IN	O
human  	human  	 JJ	O
sources 	sources 	 NNS	O
.  	.  	 .	O
As  	As  	 RB	O
set  	set  	 VBN	O
forth  	forth  	 RB	O
above 	above 	 RB	O
,  	,  	 ,	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
proteins  	proteins  	 NNS	I-NP
( 	( 	 -LRB-	O
Stx 	Stx 	 NNP	B-NP
)  	)  	 -RRB-	O
refer  	refer  	 VBP	O
to  	to  	 TO	O
the  	the  	 DT	O
family  	family  	 NN	O
of  	of  	 IN	O
multi-unit  	multi-unit  	 JJ	B-NP
bacterial  	bacterial  	 JJ	I-NP
proteins  	proteins  	 NNS	I-NP
produced  	produced  	 VBN	O
by  	by  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
and  	and  	 CC	O
Shigella  	Shigella  	 NNP	B-NP
dysenteriae  	dysenteriae  	 NN	I-NP
which  	which  	 WDT	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
outbreaks  	outbreaks  	 NNS	O
of  	of  	 IN	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
induced  	induced  	 NN	I-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
proteins  	proteins  	 NNS	I-NP
are  	are  	 VBP	O
meant  	meant  	 VBN	O
to  	to  	 TO	O
encompass  	encompass  	 VB	O
Stx  	Stx  	 NNP	B-NP
of  	of  	 IN	I-NP
Shigella  	Shigella  	 NNP	I-NP
dysenteriae-type  	dysenteriae-type  	 NNP	I-NP
1  	1  	 CD	O
and  	and  	 CC	O
Stx  	Stx  	 NNP	B-NP
type  	type  	 NN	I-NP
1  	1  	 CD	O
and  	and  	 CC	O
type  	type  	 NN	O
2 	2 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
type  	type  	 NN	O
2  	2  	 CD	O
variant  	variant  	 JJ	O
toxins  	toxins  	 NN	O
of  	of  	 IN	O
E.  	E.  	 NNP	B-NP
coli 	coli 	 NNS	I-NP
.  	.  	 .	O
Shiga  	Shiga  	 JJ	B-NP
toxin-induced  	toxin-induced  	 JJ	I-NP
diseases  	diseases  	 NNS	I-NP
of  	of  	 IN	O
humans  	humans  	 NNS	O
include  	include  	 VBP	O
bloody  	bloody  	 JJ	O
diarrhea 	diarrhea 	 NN	O
,  	,  	 ,	O
hemorrhagic  	hemorrhagic  	 JJ	B-NP
colitis 	colitis 	 NN	I-NP
,  	,  	 ,	O
hemolytic  	hemolytic  	 JJ	B-NP
uremic  	uremic  	 JJ	I-NP
syndrome 	syndrome 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
thrombotic  	thrombotic  	 JJ	B-NP
thrombocytopenic  	thrombocytopenic  	 JJ	I-NP
purpura 	purpura 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
more  	more  	 RBR	O
specific  	specific  	 JJ	O
embodiment 	embodiment 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
relates  	relates  	 VBZ	O
to  	to  	 TO	O
humanized  	humanized  	 VB	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
that  	that  	 WDT	O
have  	have  	 VBP	O
the  	the  	 DT	O
same  	same  	 JJ	O
binding  	binding  	 JJ	O
specificity  	specificity  	 NN	O
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
two  	two  	 CD	O
well  	well  	 RB	O
characterized  	characterized  	 VBN	O
murine  	murine  	 JJ	B-NP
monoclonal  	monoclonal  	 JJ	I-NP
antibodies 	antibodies 	 NNS	I-NP
.  	.  	 .	O
These  	These  	 DT	O
two  	two  	 CD	O
monoclonal  	monoclonal  	 CD	B-NP
antibodies  	antibodies  	 NNS	I-NP
were  	were  	 VBD	O
developed  	developed  	 VBN	O
in  	in  	 IN	O
Dr.  	Dr.  	 NNP	B-NP
Alison  	Alison  	 NNP	O
O 	O 	 NNP	O
' 	' 	 POS	O
Brien 	Brien 	 NNP	O
's  	's  	 POS	O
laboratory  	laboratory  	 NN	O
as  	as  	 IN	O
set  	set  	 VBN	O
forth  	forth  	 RB	O
in  	in  	 IN	O
Strockbine 	Strockbine 	 NNP	B-NP
,  	,  	 ,	O
N.  	N.  	 NNP	O
A.  	A.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
Infection  	Infection  	 NNP	B-NP
and  	and  	 CC	O
Immunity 	Immunity 	 NNP	O
,  	,  	 ,	O
1985 	1985 	 CD	O
,  	,  	 ,	O
50 	50 	 CD	O
: 	: 	 :	O
695-700  	695-700  	 CD	O
and  	and  	 CC	O
Perera 	Perera 	 NNP	O
,  	,  	 ,	O
L.  	L.  	 NNP	B-NP
P.  	P.  	 NNP	I-NP
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
J.  	J.  	 NNP	O
Clinical  	Clinical  	 NNP	B-NP
Microbiol. 	Microbiol. 	 NNP	I-NP
,  	,  	 ,	O
1988 	1988 	 CD	O
,  	,  	 ,	O
26 	26 	 CD	O
: 	: 	 :	O
2127-2131 	2127-2131 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
have  	have  	 VBP	O
been  	been  	 VBN	O
deposited  	deposited  	 VBN	O
at  	at  	 IN	O
the  	the  	 DT	O
ATCC  	ATCC  	 NNP	B-NP
as  	as  	 RB	O
set  	set  	 VBN	O
forth  	forth  	 RB	O
below 	below 	 RB	O
.  	.  	 .	O
By  	By  	 IN	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
same  	same  	 JJ	O
binding  	binding  	 JJ	O
specificity 	specificity 	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
is  	is  	 VBZ	O
meant  	meant  	 VBN	O
a  	a  	 DT	O
level  	level  	 NN	O
of  	of  	 IN	O
binding  	binding  	 VBG	O
sufficiently  	sufficiently  	 RB	O
detectable  	detectable  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
standard  	standard  	 JJ	O
binding  	binding  	 JJ	O
assay  	assay  	 NN	B-NP
to  	to  	 TO	O
distinguish  	distinguish  	 VB	O
between  	between  	 IN	O
toxin  	toxin  	 NN	B-NP
binding  	binding  	 NNS	O
and  	and  	 CC	O
non-specific  	non-specific  	 JJ	B-NP
background  	background  	 NN	I-NP
binding  	binding  	 NN	I-NP
as  	as  	 IN	O
exemplified  	exemplified  	 NN	O
by  	by  	 IN	O
appropriate  	appropriate  	 JJ	O
controls  	controls  	 NNS	O
( 	( 	 -LRB-	O
for  	for  	 IN	O
examples 	examples 	 NNS	O
,  	,  	 ,	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
9  	9  	 CD	O
and  	and  	 CC	O
FIG.  	FIG.  	 CD	O
11 	11 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Those  	Those  	 DT	O
of  	of  	 IN	O
ordinary  	ordinary  	 JJ	B-NP
skill  	skill  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
can  	can  	 MD	O
readily  	readily  	 RB	O
test  	test  	 VB	O
for  	for  	 IN	O
binding  	binding  	 JJ	O
levels  	levels  	 NNS	O
using  	using  	 VBG	O
routine  	routine  	 JJ	B-NP
skills  	skills  	 NNS	I-NP
and  	and  	 CC	O
techniques 	techniques 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
another  	another  	 DT	O
preferred  	preferred  	 JJ	O
embodiment 	embodiment 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
are  	are  	 VBP	O
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
their  	their  	 PRP$	O
structural  	structural  	 JJ	B-NP
features 	features 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
one  	one  	 CD	O
aspect  	aspect  	 NN	B-NP
of  	of  	 IN	O
this  	this  	 DT	O
embodiment 	embodiment 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
constant  	constant  	 JJ	O
region  	region  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
human  	human  	 JJ	O
constant  	constant  	 JJ	O
region  	region  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
derives  	derives  	 VBZ	O
from  	from  	 IN	O
a  	a  	 DT	O
rodent 	rodent 	 NN	B-NP
,  	,  	 ,	O
preferably  	preferably  	 RB	O
a  	a  	 DT	O
mouse 	mouse 	 NN	O
.  	.  	 .	O
Although  	Although  	 IN	O
not  	not  	 RB	O
limited  	limited  	 VBN	O
to  	to  	 TO	O
these 	these 	 DT	O
,  	,  	 ,	O
the  	the  	 DT	O
four  	four  	 CD	O
variable  	variable  	 CD	B-NP
regions  	regions  	 NNS	I-NP
set  	set  	 VBD	O
forth  	forth  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
specification 	specification 	 NN	B-NP
,  	,  	 ,	O
particularly  	particularly  	 RB	O
in  	in  	 IN	O
FIG.  	FIG.  	 CD	O
3  	3  	 CD	O
and  	and  	 CC	O
FIG.  	FIG.  	 CD	O
6 	6 	 CD	O
,  	,  	 ,	O
are  	are  	 VBP	O
preferred 	preferred 	 VBN	O
.  	.  	 .	O
Of  	Of  	 IN	O
course 	course 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
includes  	includes  	 VBZ	O
modifications  	modifications  	 NNS	B-NP
( 	( 	 -LRB-	O
i.e. 	i.e. 	 FW	O
,  	,  	 ,	O
deletions 	deletions 	 NNS	O
,  	,  	 ,	O
additions 	additions 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
substitutions 	substitutions 	 CD	B-NP
)  	)  	 -RRB-	O
that  	that  	 WDT	O
do  	do  	 VBP	O
not  	not  	 RB	O
appreciably  	appreciably  	 RB	O
diminish  	diminish  	 VB	O
the  	the  	 DT	O
characteristic  	characteristic  	 JJ	O
binding  	binding  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
exemplified  	exemplified  	 JJ	O
variable  	variable  	 JJ	O
regions 	regions 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
yet  	yet  	 RB	O
another  	another  	 DT	O
embodiment 	embodiment 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
CDRs  	CDRs  	 JJ	O
of  	of  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
are  	are  	 VBP	O
employed  	employed  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
invention 	invention 	 NN	O
.  	.  	 .	O
As  	As  	 RB	O
noted  	noted  	 VBD	O
above 	above 	 RB	O
,  	,  	 ,	O
CDRs  	CDRs  	 NNS	B-NP
are  	are  	 VBP	O
located  	located  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
both  	both  	 PDT	O
the  	the  	 DT	O
light  	light  	 NN	O
and  	and  	 CC	O
heavy  	heavy  	 JJ	O
chains  	chains  	 NNS	O
and  	and  	 CC	O
are  	are  	 VBP	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
antigen  	antigen  	 JJ	B-NP
binding 	binding 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
view  	view  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
ready  	ready  	 JJ	O
ability  	ability  	 NN	B-NP
of  	of  	 IN	O
those  	those  	 DT	O
in  	in  	 IN	O
this  	this  	 DT	O
art  	art  	 NN	O
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
CDR  	CDR  	 NNP	B-NP
regions 	regions 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
present  	present  	 JJ	O
invention  	invention  	 NN	O
is  	is  	 VBZ	O
not  	not  	 RB	O
limited  	limited  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
CDRs  	CDRs  	 JJ	O
specifically  	specifically  	 RB	O
set  	set  	 VBN	O
forth 	forth 	 RB	O
.  	.  	 .	O
Indeed 	Indeed 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
vectors  	vectors  	 NN	O
created  	created  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
applicants  	applicants  	 NNS	O
and  	and  	 CC	O
described  	described  	 VBN	O
in  	in  	 IN	O
great  	great  	 JJ	O
detail  	detail  	 NN	O
below  	below  	 RB	O
are  	are  	 VBP	O
sufficient  	sufficient  	 JJ	O
for  	for  	 IN	O
use  	use  	 NN	O
with  	with  	 IN	O
any  	any  	 DT	O
CDRs  	CDRs  	 JJ	O
of  	of  	 IN	O
non-human  	non-human  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxins 	toxins 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
preferred  	preferred  	 JJ	O
embodiment  	embodiment  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
present  	present  	 JJ	O
invention 	invention 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
derives  	derives  	 VBZ	O
its  	its  	 PRP$	O
constant  	constant  	 JJ	O
regions  	regions  	 NNS	O
from  	from  	 IN	O
IgG1-kappa  	IgG1-kappa  	 NNP	B-NP
and  	and  	 CC	O
its  	its  	 PRP$	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
from  	from  	 IN	O
all  	all  	 DT	O
or  	or  	 CC	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
sequences  	sequences  	 NN	O
as  	as  	 IN	O
set  	set  	 VBN	O
forth  	forth  	 RB	O
in  	in  	 IN	O
FIGS.  	FIGS.  	 CD	O
3  	3  	 CD	O
and  	and  	 CC	O
6 	6 	 CD	O
.  	.  	 .	O
In  	In  	 IN	O
further  	further  	 JJ	O
embodiments 	embodiments 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
also  	also  	 RB	O
relates  	relates  	 VBZ	O
to  	to  	 TO	O
the  	the  	 DT	O
expression  	expression  	 NN	B-NP
vectors  	vectors  	 NNS	I-NP
which  	which  	 WDT	O
code  	code  	 NN	O
for  	for  	 IN	O
these  	these  	 DT	O
monoclonal  	monoclonal  	 JJ	B-NP
humanized  	humanized  	 JJ	I-NP
antibodies 	antibodies 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
to  	to  	 TO	O
host  	host  	 VB	O
cells  	cells  	 NNS	O
which  	which  	 WDT	O
have  	have  	 VBP	O
been  	been  	 VBN	O
transformed  	transformed  	 VBN	O
with  	with  	 IN	O
such  	such  	 JJ	O
expression  	expression  	 NN	B-NP
vectors 	vectors 	 NN	I-NP
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
invention  	invention  	 NN	O
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
pharmaceutical  	pharmaceutical  	 JJ	B-NP
compositions  	compositions  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
methods  	methods  	 NNS	O
of  	of  	 IN	O
use  	use  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
to  	to  	 TO	O
treat  	treat  	 VB	O
or  	or  	 CC	O
prevent  	prevent  	 VB	O
Shiga  	Shiga  	 JJ	B-NP
toxin-producing  	toxin-producing  	 JJ	I-NP
bacterial  	bacterial  	 JJ	I-NP
infections 	infections 	 NNS	I-NP
.  	.  	 .	O
As  	As  	 IN	O
a  	a  	 DT	O
pharmaceutical 	pharmaceutical 	 JJ	O
,  	,  	 ,	O
this  	this  	 DT	O
invention  	invention  	 NN	O
includes  	includes  	 VBZ	O
but  	but  	 CC	O
is  	is  	 VBZ	O
not  	not  	 RB	O
limited  	limited  	 VBN	O
to  	to  	 TO	O
diluents  	diluents  	 VB	O
and  	and  	 CC	O
carriers  	carriers  	 NNS	O
known  	known  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
art 	art 	 NN	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
saline  	saline  	 NN	O
and  	and  	 CC	O
sucrose  	sucrose  	 JJ	B-NP
solutions  	solutions  	 NNS	I-NP
appropriate  	appropriate  	 JJ	O
for  	for  	 IN	O
application  	application  	 NN	O
to  	to  	 TO	O
patients 	patients 	 NNS	O
.  	.  	 .	O
As  	As  	 RB	O
used  	used  	 VBN	O
herein 	herein 	 NN	O
,  	,  	 ,	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
patients 	patients 	 NNS	O
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
refers  	refers  	 VBZ	O
to  	to  	 TO	O
any  	any  	 DT	O
susceptible  	susceptible  	 JJ	O
mammal 	mammal 	 NN	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
dogs 	dogs 	 NNS	O
,  	,  	 ,	O
horses 	horses 	 NNS	O
,  	,  	 ,	O
mice 	mice 	 NNS	O
,  	,  	 ,	O
etc. 	etc. 	 FW	O
,  	,  	 ,	O
but  	but  	 CC	O
is  	is  	 VBZ	O
particularly  	particularly  	 RB	O
preferred  	preferred  	 VBN	O
to  	to  	 TO	O
mean  	mean  	 VB	B-NP
humans 	humans 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
invention  	invention  	 NN	O
further  	further  	 RB	O
involves  	involves  	 VBZ	O
the  	the  	 DT	O
administration  	administration  	 NN	B-NP
of  	of  	 IN	O
a  	a  	 DT	O
therapeutically  	therapeutically  	 JJ	O
effective  	effective  	 JJ	O
amount 	amount 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
a  	a  	 DT	O
prophylatically  	prophylatically  	 JJ	O
effective  	effective  	 JJ	O
amount 	amount 	 NN	O
,  	,  	 ,	O
of  	of  	 IN	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
invention 	invention 	 NN	O
.  	.  	 .	O
As  	As  	 IN	O
those  	those  	 DT	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
would  	would  	 MD	O
recognize 	recognize 	 VB	O
,  	,  	 ,	O
a  	a  	 DT	O
therapeutically  	therapeutically  	 JJ	O
effective  	effective  	 JJ	O
amount  	amount  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
dose  	dose  	 NN	O
that  	that  	 IN	O
ameliorates  	ameliorates  	 JJ	O
edema 	edema 	 NN	B-NP
,  	,  	 ,	O
thrombocytopenia 	thrombocytopenia 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
uremia  	uremia  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
EHEC-mediated  	EHEC-mediated  	 NNP	B-NP
HUS 	HUS 	 NNP	I-NP
.  	.  	 .	O
Similarly 	Similarly 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
prophylactically  	prophylactically  	 JJ	O
effective  	effective  	 JJ	O
amount  	amount  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
dose  	dose  	 NN	O
that  	that  	 WDT	O
prevents  	prevents  	 VBZ	O
exposed  	exposed  	 VBN	O
individuals  	individuals  	 NNS	O
from  	from  	 IN	O
developing  	developing  	 VBG	O
these  	these  	 DT	O
symptoms 	symptoms 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
following  	following  	 JJ	O
examples  	examples  	 NNS	O
illustrate  	illustrate  	 VBP	O
specific  	specific  	 JJ	O
embodiments  	embodiments  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention 	invention 	 NN	O
.  	.  	 .	O
Humanization  	Humanization  	 NNP	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
Anti-Stx  	Anti-Stx  	 JJ	I-NP
I  	I  	 PRP	I-NP
Antibody  	Antibody  	 FW	I-NP
13C4  	13C4  	 FW	I-NP
The  	The  	 DT	O
following  	following  	 JJ	O
examples  	examples  	 NNS	O
1-3  	1-3  	 VBP	O
relate  	relate  	 VBN	O
to  	to  	 TO	O
anti-StxI  	anti-StxI  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
13C4  	13C4  	 NN	I-NP
and  	and  	 CC	O
its  	its  	 PRP$	O
humanized  	humanized  	 JJ	O
counterpart  	counterpart  	 NN	O
H13C4 	H13C4 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
hybridoma  	hybridoma  	 JJ	B-NP
cell  	cell  	 NN	I-NP
producing  	producing  	 VBG	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
13C4 	13C4 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
antibody  	antibody  	 NN	B-NP
( 	( 	 -LRB-	O
Anti-Stx  	Anti-Stx  	 NNP	B-NP
1 	1 	 CD	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
deposited  	deposited  	 VBN	O
on  	on  	 IN	O
Dec.  	Dec.  	 NNP	O
2 	2 	 CD	O
,  	,  	 ,	O
1987 	1987 	 CD	O
,  	,  	 ,	O
at  	at  	 IN	O
the  	the  	 DT	O
American  	American  	 NNP	O
Type  	Type  	 NNP	B-NP
Culture  	Culture  	 NNP	I-NP
Collection 	Collection 	 NNP	I-NP
,  	,  	 ,	O
10801  	10801  	 CD	O
University  	University  	 NNP	O
Boulevard 	Boulevard 	 NNP	O
,  	,  	 ,	O
Manassas 	Manassas 	 NNP	B-NP
,  	,  	 ,	O
Va. 	Va. 	 NNP	O
,  	,  	 ,	O
20110-2209 	20110-2209 	 NNP	O
,  	,  	 ,	O
under  	under  	 IN	O
Accession  	Accession  	 NNP	B-NP
No 	No 	 NNP	O
.  	.  	 .	O
CRL  	CRL  	 NNP	B-NP
1794 	1794 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
can  	can  	 MD	O
be  	be  	 VB	O
obtained  	obtained  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
ATCC 	ATCC 	 NNP	B-NP
,  	,  	 ,	O
or 	or 	 CC	O
,  	,  	 ,	O
as  	as  	 RB	O
here 	here 	 RB	O
,  	,  	 ,	O
from  	from  	 IN	O
Dr.  	Dr.  	 NNP	B-NP
Alison  	Alison  	 NNP	O
O 	O 	 NNP	O
' 	' 	 POS	O
Brien  	Brien  	 NNP	O
( 	( 	 -LRB-	O
for  	for  	 IN	O
details  	details  	 NNS	O
of  	of  	 IN	O
hybridoma  	hybridoma  	 JJ	B-NP
preparation 	preparation 	 NN	I-NP
,  	,  	 ,	O
see  	see  	 VB	O
Strockbine 	Strockbine 	 NNP	B-NP
,  	,  	 ,	O
N.  	N.  	 NNP	O
A.  	A.  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
Infection  	Infection  	 NNP	B-NP
and  	and  	 CC	O
Immunity 	Immunity 	 NNP	O
,  	,  	 ,	O
50 	50 	 CD	O
: 	: 	 :	O
695-700  	695-700  	 CD	O
( 	( 	 -LRB-	O
1985 	1985 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
vial  	vial  	 NN	O
of  	of  	 IN	O
cells  	cells  	 NNS	O
was  	was  	 VBD	O
thawed  	thawed  	 JJ	O
and  	and  	 CC	O
resuspended  	resuspended  	 NN	B-NP
in  	in  	 IN	O
IMDM  	IMDM  	 NNP	B-NP
( 	( 	 -LRB-	O
Mediatech 	Mediatech 	 NNP	B-NP
)  	)  	 -RRB-	O
complete  	complete  	 JJ	O
media  	media  	 NNS	O
supplemented  	supplemented  	 VBN	O
with  	with  	 IN	O
10 	10 	 CD	O
%  	%  	 NN	O
FBS  	FBS  	 NNP	B-NP
( 	( 	 -LRB-	O
Irvine 	Irvine 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Total  	Total  	 JJ	B-NP
RNA  	RNA  	 NNP	I-NP
was  	was  	 VBD	O
isolated  	isolated  	 VBN	O
from  	from  	 IN	O
1 	1 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
107  	107  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
13C4 	13C4 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
cells  	cells  	 NNS	O
using  	using  	 VBG	O
the  	the  	 DT	O
Midi  	Midi  	 NNP	B-NP
RNA  	RNA  	 NNP	I-NP
Isolation  	Isolation  	 NNP	I-NP
kit  	kit  	 NN	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
)  	)  	 -RRB-	O
following  	following  	 VBG	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure 	procedure 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
RNA  	RNA  	 NNP	B-NP
was  	was  	 VBD	O
dissolved  	dissolved  	 VBN	O
in  	in  	 IN	O
10  	10  	 CD	O
mM  	mM  	 JJ	B-NP
Tris 	Tris 	 NNP	I-NP
,  	,  	 ,	O
0.1  	0.1  	 CD	O
mM  	mM  	 JJ	B-NP
EDTA  	EDTA  	 NNP	I-NP
( 	( 	 -LRB-	O
pH  	pH  	 NNP	B-NP
8.4 	8.4 	 CD	O
)  	)  	 -RRB-	O
containing  	containing  	 VBG	O
0.03  	0.03  	 CD	O
U 	U 	 NNP	O
/ 	/ 	 NNP	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g  	g  	 JJ	B-NP
Prime  	Prime  	 NNP	I-NP
RNase  	RNase  	 NNP	I-NP
Inhibitor  	Inhibitor  	 NNP	I-NP
( 	( 	 -LRB-	O
5 	5 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
; 	; 	 :	O
-3 	-3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
; 	; 	 CD	O
)  	)  	 -RRB-	O
to  	to  	 TO	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
concentration  	concentration  	 NN	I-NP
of  	of  	 IN	O
0.25  	0.25  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 CD	O
/ 	/ 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l 	l 	 CD	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
1  	1  	 CD	O
shows  	shows  	 NNS	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
cloning  	cloning  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
gene  	gene  	 NN	O
fragments  	fragments  	 NNS	O
and  	and  	 CC	O
FIG.  	FIG.  	 CD	O
2  	2  	 CD	O
lists  	lists  	 NNS	O
the  	the  	 DT	O
oligonucleotide  	oligonucleotide  	 JJ	B-NP
primers  	primers  	 NNS	I-NP
used 	used 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
13C4 	13C4 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
total  	total  	 JJ	B-NP
RNA  	RNA  	 NNP	I-NP
( 	( 	 -LRB-	O
2  	2  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
converted  	converted  	 VBN	O
to  	to  	 TO	O
cDNA  	cDNA  	 JJ	O
by  	by  	 IN	O
using  	using  	 VBG	O
Superscript  	Superscript  	 NNP	O
1l-MMLV  	1l-MMLV  	 NNP	O
Reverse  	Reverse  	 NNP	O
Transcriptase  	Transcriptase  	 NNP	O
( 	( 	 -LRB-	O
Life  	Life  	 NNP	O
Technologies 	Technologies 	 NNPS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
mouse  	mouse  	 NN	B-NP
kappa  	kappa  	 NNS	I-NP
( 	( 	 -LRB-	O
oKA57 	oKA57 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
57 	57 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
mouse  	mouse  	 CD	O
CH1  	CH1  	 CD	B-NP
( 	( 	 -LRB-	O
JS300 	JS300 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
:  	:  	 :	O
6 	6 	 CD	O
)  	)  	 -RRB-	O
specific  	specific  	 JJ	O
priming 	priming 	 NN	O
,  	,  	 ,	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedures 	procedures 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
first  	first  	 JJ	O
strand  	strand  	 JJ	O
cDNA  	cDNA  	 JJ	B-NP
synthesis  	synthesis  	 NN	I-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
then  	then  	 RB	O
purified  	purified  	 VBP	O
using  	using  	 VBG	O
a  	a  	 DT	O
membrane  	membrane  	 JJ	O
concentrator  	concentrator  	 JJ	B-NP
device  	device  	 NN	I-NP
( 	( 	 -LRB-	O
Amicon  	Amicon  	 NNP	B-NP
Centricon  	Centricon  	 NNP	I-NP
30  	30  	 CD	O
or  	or  	 CC	O
Millipore  	Millipore  	 NNP	B-NP
UltraFree  	UltraFree  	 NNP	I-NP
15 	15 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Of  	Of  	 IN	O
the  	the  	 DT	O
cDNA  	cDNA  	 JJ	B-NP
recovered 	recovered 	 NN	I-NP
,  	,  	 ,	O
3  	3  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l  	l  	 NNS	O
was  	was  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
template  	template  	 JJ	B-NP
DNA  	DNA  	 NN	I-NP
for  	for  	 IN	I-NP
PCR 	PCR 	 NNP	I-NP
.  	.  	 .	O
Typical  	Typical  	 JJ	B-NP
PCR  	PCR  	 NNP	I-NP
amplification  	amplification  	 NN	I-NP
reactions  	reactions  	 NNS	I-NP
( 	( 	 -LRB-	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l  	l  	 LS	O
)  	)  	 -RRB-	O
contained  	contained  	 VBD	O
template  	template  	 JJ	B-NP
DNA 	DNA 	 NN	I-NP
,  	,  	 ,	O
50  	50  	 CD	O
pmoles  	pmoles  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
primers  	primers  	 NNS	O
( 	( 	 -LRB-	O
JSS9 	JSS9 	 NNP	B-NP
,  	,  	 ,	O
JSS10 	JSS10 	 NNP	B-NP
,  	,  	 ,	O
JSS11 	JSS11 	 NNP	B-NP
,  	,  	 ,	O
JSS12 	JSS12 	 NNP	B-NP
,  	,  	 ,	O
JS153  	JS153  	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x26 	x26 	 CD	B-NP
;  	;  	 :	O
JSS154 	JSS154 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x2014 	x2014 	 CD	O
; 	; 	 :	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
9-12  	9-12  	 CD	O
for  	for  	 IN	O
light  	light  	 JJ	O
chains 	chains 	 NNS	O
;  	;  	 :	O
JSS1 	JSS1 	 CD	B-NP
,  	,  	 ,	O
JSS2 	JSS2 	 NNP	B-NP
,  	,  	 ,	O
JSS3 	JSS3 	 NNP	B-NP
,  	,  	 ,	O
JSS4 	JSS4 	 NNP	B-NP
,  	,  	 ,	O
JSS8  	JSS8  	 NNP	B-NP
and  	and  	 CC	O
oKA-143 	oKA-143 	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x2014 	x2014 	 CD	O
; 	; 	 :	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
1-5  	1-5  	 CD	O
and  	and  	 CC	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
15  	15  	 CD	O
for  	for  	 IN	O
heavy  	heavy  	 JJ	O
chains 	chains 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
2.5  	2.5  	 CD	O
units  	units  	 NNS	O
of  	of  	 IN	O
ExTaq  	ExTaq  	 JJ	B-NP
polymerase  	polymerase  	 NNS	I-NP
( 	( 	 -LRB-	O
PanVera 	PanVera 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
1 	1 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
ExTaq  	ExTaq  	 JJ	B-NP
reaction  	reaction  	 NN	I-NP
buffer 	buffer 	 NN	I-NP
,  	,  	 ,	O
200  	200  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
M  	M  	 NNP	O
dNTP 	dNTP 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
2  	2  	 CD	O
mM  	mM  	 JJ	B-NP
MgCl2 	MgCl2 	 NN	I-NP
.  	.  	 .	O
Each  	Each  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
templates  	templates  	 NN	O
was  	was  	 VBD	O
denatured  	denatured  	 VBN	O
by  	by  	 IN	O
an  	an  	 DT	O
initial  	initial  	 JJ	O
incubation  	incubation  	 NN	O
at  	at  	 IN	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min 	min 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
amplified  	amplified  	 VBN	O
by  	by  	 IN	O
40  	40  	 CD	O
or  	or  	 CC	O
50  	50  	 CD	O
thermal  	thermal  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
59  	59  	 CD	O
to  	to  	 TO	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
then  	then  	 RB	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min.  	min.  	 CD	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
extension  	extension  	 NN	I-NP
step  	step  	 NN	I-NP
at  	at  	 IN	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
5  	5  	 CD	O
min 	min 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
amplified  	amplified  	 VBN	O
by  	by  	 IN	O
6  	6  	 CD	O
thermal  	thermal  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
46 	46 	 CD	O
,  	,  	 ,	O
48  	48  	 CD	O
or  	or  	 CC	O
54 	54 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
then  	then  	 RB	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min  	min  	 NNS	B-NP
followed  	followed  	 VBN	O
by  	by  	 IN	O
35  	35  	 CD	O
step  	step  	 NN	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
60 	60 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min 	min 	 NN	B-NP
,  	,  	 ,	O
then  	then  	 RB	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min.  	min.  	 CD	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
extension  	extension  	 NN	I-NP
step  	step  	 NN	I-NP
at  	at  	 IN	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
5  	5  	 CD	O
min 	min 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
PCR  	PCR  	 NNP	B-NP
products  	products  	 NNS	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
successful  	successful  	 JJ	O
reactions  	reactions  	 NNS	O
were  	were  	 VBD	O
purified  	purified  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
Wizard  	Wizard  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
system  	system  	 NN	I-NP
( 	( 	 -LRB-	O
Promega 	Promega 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
per  	per  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure 	procedure 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
and  	and  	 CC	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NN	I-NP
products  	products  	 NNS	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
then  	then  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
a  	a  	 DT	O
bacterial  	bacterial  	 JJ	B-NP
vector  	vector  	 NN	I-NP
for  	for  	 IN	I-NP
DNA  	DNA  	 NNP	I-NP
sequence  	sequence  	 NN	I-NP
determination 	determination 	 NN	I-NP
.  	.  	 .	O
Ligations  	Ligations  	 NNP	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
PCR  	PCR  	 NNP	I-NP
fragments  	fragments  	 NNS	I-NP
were  	were  	 VBD	O
carried  	carried  	 VBN	O
out  	out  	 RP	O
into  	into  	 IN	O
the  	the  	 DT	O
pCR-2.1  	pCR-2.1  	 JJ	B-NP
T 	T 	 NN	O
/ 	/ 	 VBZ	O
A  	A  	 DT	O
style  	style  	 NN	O
cloning  	cloning  	 NN	O
vector  	vector  	 NN	O
( 	( 	 -LRB-	O
Invitrogen 	Invitrogen 	 NNP	B-NP
)  	)  	 -RRB-	O
following  	following  	 VBG	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedures  	procedures  	 NNS	O
using  	using  	 VBG	O
1 	1 	 CD	O
: 	: 	 :	O
1 	1 	 CD	O
,  	,  	 ,	O
3 	3 	 LS	O
: 	: 	 :	O
1  	1  	 CD	O
and  	and  	 CC	O
5 	5 	 CD	O
: 	: 	 :	O
1  	1  	 CD	O
insert  	insert  	 NN	O
to  	to  	 TO	O
vector  	vector  	 VB	O
molar  	molar  	 JJ	B-NP
ratios 	ratios 	 NNS	I-NP
.  	.  	 .	O
One  	One  	 CD	O
half  	half  	 NN	O
of  	of  	 IN	O
each  	each  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
ligation  	ligation  	 JJ	B-NP
reactions  	reactions  	 NNS	I-NP
was  	was  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
transform  	transform  	 VB	O
competent  	competent  	 JJ	O
XL1  	XL1  	 NNP	B-NP
Blue  	Blue  	 NNP	I-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
Heavy  	Heavy  	 JJ	B-NP
chain  	chain  	 NN	I-NP
plasmid  	plasmid  	 NNS	I-NP
clones  	clones  	 VBP	I-NP
containing  	containing  	 VBG	I-NP
DNA  	DNA  	 NN	I-NP
inserts  	inserts  	 NNS	I-NP
were  	were  	 VBD	O
identified  	identified  	 VBN	O
using  	using  	 VBG	O
diagnostic  	diagnostic  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
enzyme  	enzyme  	 NN	I-NP
digests  	digests  	 NN	I-NP
with  	with  	 IN	O
EcoRI  	EcoRI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
DNA  	DNA  	 NN	B-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
plasmids  	plasmids  	 NNS	I-NP
( 	( 	 -LRB-	O
tKMC217B 	tKMC217B 	 NNP	O
)  	)  	 -RRB-	O
containing  	containing  	 VBG	B-NP
inserts  	inserts  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
size  	size  	 NN	O
( 	( 	 -LRB-	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
then  	then  	 RB	O
determined 	determined 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
consensus  	consensus  	 NN	I-NP
DNA  	DNA  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
regions  	regions  	 NNS	I-NP
is  	is  	 VBZ	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
FIG.  	FIG.  	 CD	O
3 	3 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NN	I-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
identified  	identified  	 VBN	O
differently 	differently 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
hybridoma  	hybridoma  	 JJ	B-NP
cell  	cell  	 NN	I-NP
line  	line  	 NN	I-NP
that  	that  	 WDT	O
expresses  	expresses  	 VBZ	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
13C4 	13C4 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
antibody  	antibody  	 NN	B-NP
was  	was  	 VBD	O
made  	made  	 VBN	O
by  	by  	 IN	O
fusing  	fusing  	 JJ	O
mouse  	mouse  	 NN	B-NP
splenocytes  	splenocytes  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
SP2 	SP2 	 CD	B-NP
/ 	/ 	 CD	O
0  	0  	 CD	O
myeloma  	myeloma  	 JJ	B-NP
cell  	cell  	 NN	I-NP
line 	line 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
SP2 	SP2 	 CD	B-NP
/ 	/ 	 CD	O
0  	0  	 CD	O
cell  	cell  	 NN	O
line  	line  	 NN	O
transcribes  	transcribes  	 VBD	O
a  	a  	 DT	O
pseudogene  	pseudogene  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
kappa  	kappa  	 JJ	I-NP
light  	light  	 JJ	O
chain 	chain 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
pseudogene  	pseudogene  	 JJ	B-NP
transcript 	transcript 	 NN	I-NP
,  	,  	 ,	O
when  	when  	 WRB	O
converted  	converted  	 VBN	O
to  	to  	 TO	O
cDNA  	cDNA  	 JJ	O
by  	by  	 IN	O
RT-PCR 	RT-PCR 	 NNP	B-NP
,  	,  	 ,	O
contains  	contains  	 VBZ	O
an  	an  	 DT	O
AflIII  	AflIII  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site 	site 	 NN	I-NP
.  	.  	 .	O
Light  	Light  	 JJ	B-NP
chain  	chain  	 NN	I-NP
candidate  	candidate  	 NN	I-NP
clones  	clones  	 NNS	I-NP
( 	( 	 -LRB-	O
tKMC226  	tKMC226  	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x26 	x26 	 CD	B-NP
;  	;  	 :	O
227 	227 	 CD	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
AflIII  	AflIII  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
)  	)  	 -RRB-	O
using  	using  	 VBG	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedures  	procedures  	 NNS	O
to  	to  	 TO	O
identify  	identify  	 VB	O
clones  	clones  	 NNS	O
containing  	containing  	 VBG	B-NP
inserts  	inserts  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
size  	size  	 NN	O
( 	( 	 -LRB-	O
403  	403  	 CD	O
bp 	bp 	 NNS	B-NP
;  	;  	 :	O
no  	no  	 DT	O
AflIII  	AflIII  	 JJ	B-NP
site  	site  	 NN	I-NP
is  	is  	 VBZ	O
present  	present  	 JJ	O
in  	in  	 IN	O
these  	these  	 DT	O
products 	products 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
consensus  	consensus  	 NN	I-NP
DNA  	DNA  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
regions  	regions  	 NNS	I-NP
is  	is  	 VBZ	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
FIG.  	FIG.  	 CD	O
3  	3  	 CD	O
with  	with  	 IN	O
the  	the  	 DT	O
CDRs  	CDRs  	 NN	B-NP
indicated  	indicated  	 VBD	O
by  	by  	 IN	O
underlining 	underlining 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
regions  	regions  	 NNS	I-NP
were  	were  	 VBD	O
then  	then  	 RB	O
subcloned  	subcloned  	 VBN	O
into  	into  	 IN	O
mammalian  	mammalian  	 JJ	B-NP
expression  	expression  	 NN	I-NP
plasmid  	plasmid  	 NN	I-NP
vectors  	vectors  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
recombinant  	recombinant  	 FW	B-NP
chimeric  	chimeric  	 FW	I-NP
mouse 	mouse 	 FW	I-NP
/ 	/ 	 FW	I-NP
human  	human  	 FW	I-NP
antibody  	antibody  	 FW	I-NP
molecules 	molecules 	 FW	I-NP
.  	.  	 .	O
The  	The  	 DT	O
vectors  	vectors  	 JJ	O
result  	result  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
recombinant  	recombinant  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
molecules  	molecules  	 NNS	I-NP
under  	under  	 IN	O
the  	the  	 DT	O
control  	control  	 NN	O
of  	of  	 IN	O
CMV  	CMV  	 NNP	O
transcriptional  	transcriptional  	 NN	B-NP
promoters 	promoters 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
molecules  	molecules  	 NNS	I-NP
are  	are  	 VBP	O
direct  	direct  	 JJ	O
cDNA  	cDNA  	 JJ	O
constructs  	constructs  	 NN	O
that  	that  	 IN	O
fuse  	fuse  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
sequence  	sequence  	 NN	O
directly  	directly  	 RB	O
into  	into  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
IgG1  	IgG1  	 CD	B-NP
constant  	constant  	 JJ	O
domain 	domain 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
molecules 	molecules 	 NNS	I-NP
,  	,  	 ,	O
on  	on  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
hand 	hand 	 NN	O
,  	,  	 ,	O
have  	have  	 VBP	O
a  	a  	 DT	O
mouse  	mouse  	 NN	B-NP
kappa  	kappa  	 VBZ	I-NP
intron  	intron  	 JJ	I-NP
region  	region  	 NN	I-NP
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
of  	of  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
coding  	coding  	 NN	O
fragment 	fragment 	 NN	O
.  	.  	 .	O
After  	After  	 IN	O
splicing 	splicing 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
becomes  	becomes  	 VBZ	O
fused  	fused  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 JJ	B-NP
constant  	constant  	 JJ	O
region  	region  	 NN	B-NP
exon  	exon  	 NNS	I-NP
( 	( 	 -LRB-	O
FIG.  	FIG.  	 CD	O
4 	4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
selectable  	selectable  	 JJ	B-NP
marker  	marker  	 NN	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
vector  	vector  	 NN	I-NP
in  	in  	 IN	O
mammalian  	mammalian  	 JJ	B-NP
cells  	cells  	 NNS	I-NP
is  	is  	 VBZ	O
aminoglycoside  	aminoglycoside  	 JJ	B-NP
phosphotransferase  	phosphotransferase  	 NNS	I-NP
( 	( 	 -LRB-	O
neo 	neo 	 LS	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
using  	using  	 VBG	O
the  	the  	 DT	O
drug  	drug  	 NN	B-NP
G418  	G418  	 NNP	I-NP
( 	( 	 -LRB-	O
CellTech 	CellTech 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A.  	A.  	 NNP	O
Creation  	Creation  	 NNP	O
of  	of  	 IN	O
the  	the  	 DT	O
Expression  	Expression  	 NNP	B-NP
Vectors  	Vectors  	 NNPS	I-NP
To  	To  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
expression  	expression  	 NN	I-NP
vectors  	vectors  	 VBZ	I-NP
required  	required  	 VBN	I-NP
DNA  	DNA  	 NN	I-NP
fragment  	fragment  	 NN	I-NP
ligations  	ligations  	 NNS	I-NP
and  	and  	 CC	O
site  	site  	 NN	O
directed  	directed  	 VBD	O
mutagenesis  	mutagenesis  	 JJ	B-NP
steps 	steps 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
result  	result  	 NN	O
was  	was  	 VBD	O
vectors  	vectors  	 NNS	O
that  	that  	 WDT	O
express  	express  	 VBP	O
both  	both  	 DT	O
antibody  	antibody  	 NN	B-NP
chains  	chains  	 NNS	I-NP
with  	with  	 IN	O
CMV  	CMV  	 NNP	O
promoter  	promoter  	 VBD	O
driven  	driven  	 VBN	O
transcription 	transcription 	 NN	B-NP
.  	.  	 .	O
Neomycin  	Neomycin  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
serves  	serves  	 VBZ	O
as  	as  	 IN	O
a  	a  	 DT	O
dominant  	dominant  	 JJ	O
selectable  	selectable  	 JJ	B-NP
marker  	marker  	 NN	I-NP
for  	for  	 IN	I-NP
transfection  	transfection  	 NN	I-NP
of  	of  	 IN	I-NP
mammalian  	mammalian  	 JJ	I-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
these  	these  	 DT	O
vectors  	vectors  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
allow  	allow  	 VB	O
convenient  	convenient  	 JJ	O
cloning  	cloning  	 NN	B-NP
of  	of  	 IN	O
any  	any  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
as  	as  	 IN	O
EcoRV 	EcoRV 	 JJ	B-NP
/ 	/ 	 CD	I-NP
BstBI  	BstBI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
any  	any  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
as  	as  	 IN	O
a  	a  	 DT	O
NruI 	NruI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
EcoRI  	EcoRI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
any  	any  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
constant  	constant  	 JJ	O
domain  	domain  	 NN	O
as  	as  	 IN	O
an  	an  	 DT	O
EcoRI 	EcoRI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
NotI  	NotI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
were  	were  	 VBD	O
chosen  	chosen  	 VBN	O
because  	because  	 IN	O
they  	they  	 PRP	O
occur  	occur  	 VBP	O
rarely  	rarely  	 RB	O
( 	( 	 -LRB-	O
if  	if  	 IN	O
ever 	ever 	 RB	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
human  	human  	 JJ	O
and  	and  	 CC	O
mouse  	mouse  	 JJ	O
variable  	variable  	 JJ	O
regions 	regions 	 NNS	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
mouse  	mouse  	 NN	B-NP
J  	J  	 NNP	I-NP
region 	region 	 FW	I-NP
/ 	/ 	 FW	I-NP
kappa  	kappa  	 FW	I-NP
intron  	intron  	 FW	I-NP
fragment  	fragment  	 FW	I-NP
fused  	fused  	 FW	O
to  	to  	 TO	O
a  	a  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 NNS	B-NP
exon  	exon  	 VBP	I-NP
so  	so  	 RB	O
that  	that  	 IN	O
after  	after  	 IN	O
post-transcriptional  	post-transcriptional  	 JJ	B-NP
splicing  	splicing  	 NNS	O
a  	a  	 DT	O
mouse  	mouse  	 JJ	O
human  	human  	 JJ	O
chimeric  	chimeric  	 NNS	B-NP
kappa  	kappa  	 VBP	I-NP
light  	light  	 JJ	O
chain  	chain  	 NN	O
is  	is  	 VBZ	O
produced 	produced 	 VBN	O
.  	.  	 .	O
Lastly 	Lastly 	 NNP	O
,  	,  	 ,	O
the  	the  	 DT	O
vectors  	vectors  	 NN	O
were  	were  	 VBD	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
facilitate  	facilitate  	 VB	O
excision  	excision  	 NN	O
( 	( 	 -LRB-	O
BglII 	BglII 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NheI 	NheI 	 NNP	I-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
a  	a  	 DT	O
whole  	whole  	 JJ	O
antibody  	antibody  	 NN	B-NP
expression  	expression  	 NN	I-NP
cassette  	cassette  	 NN	I-NP
from  	from  	 IN	O
one  	one  	 CD	O
vector  	vector  	 NN	B-NP
to  	to  	 TO	O
be  	be  	 VB	O
ligated  	ligated  	 VBN	O
into  	into  	 IN	O
a  	a  	 DT	O
second  	second  	 JJ	O
vector  	vector  	 NN	B-NP
cut  	cut  	 NN	I-NP
with  	with  	 IN	O
BamHI 	BamHI 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NheI 	NheI 	 NNP	I-NP
,  	,  	 ,	O
creating  	creating  	 VBG	O
an  	an  	 DT	O
expression  	expression  	 NN	B-NP
vector  	vector  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
apparatus  	apparatus  	 NN	B-NP
for  	for  	 IN	O
both  	both  	 DT	O
chains 	chains 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
backbone  	backbone  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
vector  	vector  	 NN	B-NP
was  	was  	 VBD	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pCDNA3  	pCDNA3  	 NNP	I-NP
( 	( 	 -LRB-	O
Invitrogen 	Invitrogen 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
plasmid  	plasmid  	 NN	B-NP
was  	was  	 VBD	O
cut  	cut  	 VBN	O
with  	with  	 IN	O
HindIII 	HindIII 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
XhoI  	XhoI  	 NNP	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
polylinker 	polylinker 	 NNS	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
DNA  	DNA  	 NNP	B-NP
fragment  	fragment  	 NN	I-NP
was  	was  	 VBD	O
inserted  	inserted  	 VBN	O
to  	to  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
starting  	starting  	 VBG	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
vector 	vector 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
pCDNA3.LCPL  	pCDNA3.LCPL  	 CD	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
12 	12 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
linker  	linker  	 NN	B-NP
contained  	contained  	 VBD	O
the  	the  	 DT	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
HindIII 	HindIII 	 JJ	O
,  	,  	 ,	O
KpnI 	KpnI 	 NNP	B-NP
,  	,  	 ,	O
ClaI 	ClaI 	 NNP	B-NP
,  	,  	 ,	O
PmlI 	PmlI 	 NNP	B-NP
,  	,  	 ,	O
EcoRV 	EcoRV 	 NNP	B-NP
,  	,  	 ,	O
XmaI 	XmaI 	 NNP	B-NP
,  	,  	 ,	O
BamHI  	BamHI  	 JJ	O
and  	and  	 CC	O
XhoI  	XhoI  	 JJ	O
to  	to  	 TO	O
facilitate  	facilitate  	 VB	O
subsequent  	subsequent  	 JJ	O
cloning  	cloning  	 JJ	B-NP
steps 	steps 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
SmaII 	SmaII 	 JJ	B-NP
/ 	/ 	 NNP	I-NP
BclI  	BclI  	 NNP	I-NP
DNA  	DNA  	 NNP	I-NP
fragment  	fragment  	 VBZ	O
containing  	containing  	 VBG	O
a  	a  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
leader 	leader 	 NN	I-NP
,  	,  	 ,	O
mouse  	mouse  	 JJ	B-NP
anti-CKMB  	anti-CKMB  	 JJ	I-NP
kappa  	kappa  	 JJ	I-NP
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
genomic  	genomic  	 NN	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
UTR  	UTR  	 NNP	B-NP
was  	was  	 VBD	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
EcoRV 	EcoRV 	 JJ	B-NP
/ 	/ 	 CD	I-NP
BamHI  	BamHI  	 JJ	I-NP
sites  	sites  	 NNS	I-NP
of  	of  	 IN	I-NP
pCDNA3.LCPL 	pCDNA3.LCPL 	 CD	I-NP
.  	.  	 .	O
The  	The  	 DT	O
mouse  	mouse  	 NN	B-NP
kappa  	kappa  	 NN	I-NP
intron 	intron 	 NN	I-NP
,  	,  	 ,	O
exon 	exon 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
UTR  	UTR  	 NNP	B-NP
in  	in  	 IN	O
this  	this  	 DT	O
fragment  	fragment  	 NN	O
was  	was  	 VBD	O
derived  	derived  	 VBN	O
from  	from  	 IN	O
LCPXK2  	LCPXK2  	 NNP	B-NP
received  	received  	 VBD	O
from  	from  	 IN	O
Dr.  	Dr.  	 NNP	B-NP
Richard  	Richard  	 NNP	O
Near  	Near  	 NNP	O
( 	( 	 -LRB-	O
Near 	Near 	 NNP	O
,  	,  	 ,	O
R.  	R.  	 NNP	B-NP
I.  	I.  	 NNP	I-NP
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
1990 	1990 	 CD	O
,  	,  	 ,	O
Mol 	Mol 	 NNP	B-NP
.  	.  	 .	O
Immunol.  	Immunol.  	 CD	B-NP
27 	27 	 CD	O
: 	: 	 :	O
901-909 	901-909 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Mutagenesis  	Mutagenesis  	 NNP	B-NP
was  	was  	 VBD	O
then  	then  	 RB	O
performed  	performed  	 VBN	O
to  	to  	 TO	O
eliminate  	eliminate  	 VB	O
an  	an  	 DT	O
NruI  	NruI  	 JJ	O
( 	( 	 -LRB-	O
209 	209 	 LS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
MluI  	MluI  	 NNP	B-NP
( 	( 	 -LRB-	O
229 	229 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
BstBI  	BstBI  	 NNP	B-NP
( 	( 	 -LRB-	O
2962 	2962 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
to  	to  	 TO	O
introduce  	introduce  	 VB	O
an  	an  	 DT	O
NheI  	NheI  	 JJ	O
( 	( 	 -LRB-	O
1229 	1229 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
a  	a  	 DT	O
BamHI  	BamHI  	 JJ	O
( 	( 	 -LRB-	O
1214 	1214 	 CD	O
)  	)  	 -RRB-	O
site  	site  	 NN	O
to  	to  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
pCDNA3mut.LCPL.LCVK  	pCDNA3mut.LCPL.LCVK  	 NNP	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
12 	12 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
second  	second  	 JJ	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
vector 	vector 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
pCDNA3mut.HCPL  	pCDNA3mut.HCPL  	 NNP	O
was  	was  	 VBD	O
constructed  	constructed  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
pCDNA3mut.LCPL.LCVK  	pCDNA3mut.LCPL.LCVK  	 JJ	O
plasmid  	plasmid  	 NN	O
by  	by  	 IN	O
replacing  	replacing  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
expression  	expression  	 NN	I-NP
region  	region  	 NN	I-NP
( 	( 	 -LRB-	O
HindIII 	HindIII 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
XhoI 	XhoI 	 NNP	I-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
a  	a  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
polylinker 	polylinker 	 NNS	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
consisting  	consisting  	 VBG	O
of  	of  	 IN	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
HpaI 	HpaI 	 JJ	O
,  	,  	 ,	O
BspEI 	BspEI 	 NNP	B-NP
,  	,  	 ,	O
EcoRV 	EcoRV 	 NNP	B-NP
,  	,  	 ,	O
KpnI 	KpnI 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
Xhol 	Xhol 	 NNP	B-NP
.  	.  	 .	O
This  	This  	 DT	O
plasmid  	plasmid  	 NN	B-NP
was  	was  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
EcorRV  	EcorRV  	 JJ	O
and  	and  	 CC	O
KpnI 	KpnI 	 JJ	O
.  	.  	 .	O
A  	A  	 DT	O
SmaI 	SmaI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
KpnI  	KpnI  	 JJ	I-NP
digested  	digested  	 JJ	I-NP
DNA  	DNA  	 NN	I-NP
fragment  	fragment  	 NN	I-NP
containing  	containing  	 VBG	O
a  	a  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
leader  	leader  	 NN	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
anti-CKMB  	anti-CKMB  	 JJ	O
IgG2b  	IgG2b  	 CD	O
mouse  	mouse  	 NN	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
genomic  	genomic  	 NN	I-NP
fragment  	fragment  	 NN	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
ligated  	ligated  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
EcoRV 	EcoRV 	 JJ	O
/ 	/ 	 FW	O
KpnI  	KpnI  	 FW	O
digested  	digested  	 FW	B-NP
plasmid 	plasmid 	 FW	I-NP
.  	.  	 .	O
A  	A  	 DT	O
KpnI 	KpnI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
SalI  	SalI  	 JJ	I-NP
oligonucleotide  	oligonucleotide  	 NNS	I-NP
fragment  	fragment  	 VBP	O
containing  	containing  	 VBG	O
a  	a  	 DT	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
UTR  	UTR  	 NNP	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
NotI  	NotI  	 JJ	O
upstream  	upstream  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
SalI  	SalI  	 JJ	B-NP
site  	site  	 NN	I-NP
was  	was  	 VBD	O
subsequently  	subsequently  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
KpnI 	KpnI 	 JJ	O
/ 	/ 	 FW	O
XhoI  	XhoI  	 FW	O
digested  	digested  	 FW	B-NP
plasmid 	plasmid 	 FW	I-NP
,  	,  	 ,	O
( 	( 	 -LRB-	O
knocking  	knocking  	 VBG	O
out  	out  	 RP	O
the  	the  	 DT	O
XhoI  	XhoI  	 JJ	B-NP
site 	site 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
to  	to  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
pCDNA3mut.HCPL.HCV2b  	pCDNA3mut.HCPL.HCV2b  	 NNP	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
13 	13 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 JJ	B-NP
light  	light  	 JJ	O
chain  	chain  	 NN	O
constant  	constant  	 JJ	O
domain  	domain  	 NN	O
was  	was  	 VBD	O
then  	then  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
pCDNA3mut.LCPL.LCVK  	pCDNA3mut.LCPL.LCVK  	 CD	O
as  	as  	 IN	O
a  	a  	 DT	O
EcoNI 	EcoNI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
XhoI  	XhoI  	 JJ	I-NP
fragment  	fragment  	 NN	I-NP
generating  	generating  	 VBG	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
tKMC180C2 	tKMC180C2 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
human  	human  	 JJ	O
IgG1  	IgG1  	 CD	B-NP
constant  	constant  	 JJ	O
domain  	domain  	 NN	O
was  	was  	 VBD	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
pSUN10  	pSUN10  	 CD	B-NP
as  	as  	 IN	O
a  	a  	 DT	O
EcoRI 	EcoRI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
NotI  	NotI  	 JJ	I-NP
fragment  	fragment  	 NN	I-NP
creating  	creating  	 VBG	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pJRS313 	pJRS313 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
13C4  	13C4  	 NNP	B-NP
were  	were  	 VBD	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
these  	these  	 DT	O
two  	two  	 CD	O
vectors  	vectors  	 NNS	O
( 	( 	 -LRB-	O
as  	as  	 RB	O
described  	described  	 VBN	O
above 	above 	 IN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
BglII 	BglII 	 JJ	B-NP
/ 	/ 	 CD	I-NP
NheI  	NheI  	 JJ	I-NP
fragment  	fragment  	 NN	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
vector  	vector  	 NN	O
tKMC229C  	tKMC229C  	 NN	O
was  	was  	 VBD	O
then  	then  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
vector  	vector  	 NN	I-NP
tKMC231D  	tKMC231D  	 RB	O
cut  	cut  	 VB	O
BamHI 	BamHI 	 JJ	O
/ 	/ 	 CD	O
NheI  	NheI  	 JJ	O
to  	to  	 TO	O
create  	create  	 VB	O
tKMC249A  	tKMC249A  	 NNP	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
4 	4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
B.  	B.  	 NNP	B-NP
Subcloning  	Subcloning  	 NNP	I-NP
the  	the  	 DT	O
Variable  	Variable  	 NNP	B-NP
Regions  	Regions  	 NNP	I-NP
into  	into  	 IN	O
the  	the  	 DT	O
Expression  	Expression  	 NNP	B-NP
Vectors  	Vectors  	 NNPS	I-NP
The  	The  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
gene  	gene  	 NN	O
fragments  	fragments  	 NNS	O
were  	were  	 VBD	O
re-amplified  	re-amplified  	 JJ	O
by  	by  	 IN	O
PCR  	PCR  	 NNP	B-NP
using  	using  	 VBG	O
primers  	primers  	 NNS	O
that  	that  	 WDT	O
adapted  	adapted  	 VBD	O
the  	the  	 DT	O
fragments  	fragments  	 NN	O
for  	for  	 IN	O
cloning  	cloning  	 NN	B-NP
into  	into  	 IN	O
the  	the  	 DT	O
expression  	expression  	 NN	B-NP
vectors  	vectors  	 NNS	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIGS.  	FIGS.  	 CD	O
2  	2  	 CD	O
and  	and  	 CC	O
4 	4 	 LS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
front  	front  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
oKA143 	oKA143 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
15 	15 	 CD	O
)  	)  	 -RRB-	O
includes  	includes  	 VBZ	O
a  	a  	 DT	O
5 	5 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
tail  	tail  	 NN	O
that  	that  	 IN	O
encodes  	encodes  	 VBG	O
the  	the  	 DT	O
C-terminus  	C-terminus  	 JJ	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
leader  	leader  	 NN	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
NruI  	NruI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
reverse  	reverse  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
oKA144 	oKA144 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
14 	14 	 CD	O
)  	)  	 -RRB-	O
adds  	adds  	 VBZ	O
a  	a  	 DT	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
EcoRI  	EcoRI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
front  	front  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
oKA145 	oKA145 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
16 	16 	 CD	O
)  	)  	 -RRB-	O
introduces  	introduces  	 VBZ	O
an  	an  	 DT	O
EcoRV  	EcoRV  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
N-terminus  	N-terminus  	 JJ	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
reverse  	reverse  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
oKA146 	oKA146 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
17 	17 	 CD	O
)  	)  	 -RRB-	O
adds  	adds  	 VBZ	O
a  	a  	 DT	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
DNA  	DNA  	 NNP	B-NP
sequence  	sequence  	 NN	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
joining  	joining  	 VBG	I-NP
region-kappa  	region-kappa  	 JJ	I-NP
exon  	exon  	 JJ	I-NP
splice  	splice  	 NNS	I-NP
junction  	junction  	 VBP	I-NP
followed  	followed  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
BstBI  	BstBI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
.  	.  	 .	O
PCR  	PCR  	 NNP	B-NP
reactions  	reactions  	 NNS	I-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
with  	with  	 IN	O
reagents  	reagents  	 VBG	O
as  	as  	 RB	O
described  	described  	 VBN	O
above  	above  	 IN	O
and  	and  	 CC	O
with  	with  	 IN	O
templates  	templates  	 NN	O
of  	of  	 IN	O
1-2  	1-2  	 CD	O
ng  	ng  	 NN	O
of  	of  	 IN	O
PvuI  	PvuI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
)  	)  	 -RRB-	O
digested  	digested  	 JJ	O
plasmid 	plasmid 	 NN	B-NP
;  	;  	 :	O
each  	each  	 DT	O
of  	of  	 IN	O
these  	these  	 DT	O
templates  	templates  	 NN	O
was  	was  	 VBD	O
denatured  	denatured  	 VBN	O
by  	by  	 IN	O
an  	an  	 DT	O
initial  	initial  	 JJ	O
one  	one  	 CD	O
minute  	minute  	 NN	B-NP
incubation  	incubation  	 NN	I-NP
at  	at  	 IN	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
amplified  	amplified  	 VBN	O
by  	by  	 IN	O
35  	35  	 CD	O
thermal  	thermal  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
55  	55  	 CD	O
or  	or  	 CC	O
60 	60 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
then  	then  	 RB	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min  	min  	 NNS	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
extension  	extension  	 NN	I-NP
step  	step  	 NN	I-NP
at  	at  	 IN	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
5  	5  	 CD	O
min 	min 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
amplified  	amplified  	 VBN	O
by  	by  	 IN	O
8  	8  	 CD	O
thermal  	thermal  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
55  	55  	 CD	O
or  	or  	 CC	O
60 	60 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
then  	then  	 RB	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min  	min  	 NNS	B-NP
followed  	followed  	 VBN	O
by  	by  	 IN	O
30  	30  	 CD	O
step  	step  	 NN	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
60 	60 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min 	min 	 NN	B-NP
,  	,  	 ,	O
then  	then  	 RB	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min 	min 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
extension  	extension  	 NN	I-NP
step  	step  	 NN	I-NP
at  	at  	 IN	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
5  	5  	 CD	O
min 	min 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
13C4  	13C4  	 JJ	B-NP
heavy  	heavy  	 JJ	I-NP
chain  	chain  	 NN	I-NP
PCR  	PCR  	 NNP	I-NP
product  	product  	 NN	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
purified  	purified  	 VBN	O
using  	using  	 VBG	O
Qiaquick  	Qiaquick  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
columns  	columns  	 NNS	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 RB	O
described  	described  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
instructions  	instructions  	 NNS	B-NP
and  	and  	 CC	O
subsequently  	subsequently  	 RB	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
NruI  	NruI  	 JJ	O
and  	and  	 CC	O
EcoRI  	EcoRI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
digested  	digested  	 JJ	O
PCR  	PCR  	 NN	B-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
purified  	purified  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
Wizard  	Wizard  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
system  	system  	 NN	I-NP
( 	( 	 -LRB-	O
Promega 	Promega 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
per  	per  	 IN	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure  	procedure  	 NN	O
and  	and  	 CC	O
ligated  	ligated  	 NN	O
into  	into  	 IN	O
NruI 	NruI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
EcoRI  	EcoRI  	 JJ	I-NP
digested  	digested  	 NN	I-NP
and  	and  	 CC	O
gel-purified  	gel-purified  	 NNP	O
pJRS3I3 	pJRS3I3 	 NNP	O
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
plasmid  	plasmid  	 CD	O
tKMC229C  	tKMC229C  	 CD	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
4 	4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
consensus  	consensus  	 NN	I-NP
DNA  	DNA  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
and  	and  	 CC	O
proper  	proper  	 JJ	O
splicing  	splicing  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
were  	were  	 VBD	O
confirmed  	confirmed  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
construct 	construct 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
13C4  	13C4  	 JJ	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NNP	I-NP
product  	product  	 NN	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
350  	350  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
purified  	purified  	 VBN	O
using  	using  	 VBG	O
Qiaquick  	Qiaquick  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
columns  	columns  	 NNS	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 RB	O
described  	described  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
instructions  	instructions  	 NNS	B-NP
and  	and  	 CC	O
subsequently  	subsequently  	 RB	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
EcoRV  	EcoRV  	 JJ	O
and  	and  	 CC	O
BstBI  	BstBI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
digested  	digested  	 JJ	O
PCR  	PCR  	 NN	B-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
purified  	purified  	 VBN	O
using  	using  	 VBG	O
Qiaquick  	Qiaquick  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
columns  	columns  	 NNS	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
per  	per  	 IN	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure  	procedure  	 NN	O
and  	and  	 CC	O
ligated  	ligated  	 NN	O
into  	into  	 IN	O
EcoRV 	EcoRV 	 JJ	B-NP
/ 	/ 	 CD	I-NP
BstBI  	BstBI  	 JJ	I-NP
digested  	digested  	 NN	I-NP
and  	and  	 CC	O
gel-purified  	gel-purified  	 NNP	O
tKMC180C2  	tKMC180C2  	 NNP	O
( 	( 	 -LRB-	O
as  	as  	 RB	O
described  	described  	 VBN	O
above 	above 	 IN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
plasmid  	plasmid  	 CD	O
tKMC231D  	tKMC231D  	 CD	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
4 	4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
consensus  	consensus  	 NN	I-NP
DNA  	DNA  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
and  	and  	 CC	O
proper  	proper  	 JJ	O
splicing  	splicing  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
were  	were  	 VBD	O
confirmed  	confirmed  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
construct 	construct 	 NN	O
.  	.  	 .	O
A.  	A.  	 NNP	O
Transfection  	Transfection  	 NNP	B-NP
of  	of  	 IN	O
NSO  	NSO  	 NNP	B-NP
Cells  	Cells  	 NNPS	O
The  	The  	 DT	O
plasmid  	plasmid  	 JJ	O
tKMC249A  	tKMC249A  	 NN	O
was  	was  	 VBD	O
transfected  	transfected  	 VBN	O
into  	into  	 IN	O
NSO  	NSO  	 NNP	B-NP
cells  	cells  	 NNS	O
( 	( 	 -LRB-	O
Baxter  	Baxter  	 NNP	O
International 	International 	 NNP	O
,  	,  	 ,	O
Inc. 	Inc. 	 NNP	O
,  	,  	 ,	O
Durante 	Durante 	 NNP	O
,  	,  	 ,	O
Calif. 	Calif. 	 NNP	O
)  	)  	 -RRB-	O
using  	using  	 VBG	O
electroporation  	electroporation  	 NN	B-NP
after  	after  	 IN	O
linearization  	linearization  	 NN	B-NP
with  	with  	 IN	O
PvuI  	PvuI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
40  	40  	 CD	O
micrograms  	micrograms  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
digested  	digested  	 JJ	O
plasmid  	plasmid  	 NN	B-NP
was  	was  	 VBD	O
mixed  	mixed  	 VBN	O
with  	with  	 IN	O
1 	1 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
107  	107  	 CD	O
cells  	cells  	 NNS	O
in  	in  	 IN	O
a  	a  	 DT	O
total  	total  	 JJ	B-NP
volume  	volume  	 NN	I-NP
of  	of  	 IN	O
800  	800  	 CD	O
microliters  	microliters  	 NN	B-NP
in  	in  	 IN	O
a  	a  	 DT	O
0.4  	0.4  	 CD	O
centimeter  	centimeter  	 CD	B-NP
cuvette  	cuvette  	 NNS	I-NP
and  	and  	 CC	O
subjected  	subjected  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
pulse  	pulse  	 NN	O
of  	of  	 IN	O
250  	250  	 CD	O
mA 	mA 	 NN	O
,  	,  	 ,	O
960  	960  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
F 	F 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
cells  	cells  	 NNS	O
were  	were  	 VBD	O
plated  	plated  	 VBN	O
out  	out  	 RP	O
after  	after  	 IN	O
24  	24  	 CD	O
hours  	hours  	 NNS	O
into  	into  	 IN	O
96-well  	96-well  	 CD	O
tissue  	tissue  	 NN	O
culture  	culture  	 NN	O
plates 	plates 	 NN	O
,  	,  	 ,	O
6  	6  	 CD	O
plates  	plates  	 NN	O
with  	with  	 IN	O
200  	200  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l 	l 	 CD	B-NP
/ 	/ 	 CD	I-NP
well 	well 	 RB	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
incubated  	incubated  	 NN	O
at  	at  	 IN	O
37 	37 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
and  	and  	 CC	O
10 	10 	 CD	O
%  	%  	 NN	O
CO2 	CO2 	 NN	B-NP
.  	.  	 .	O
As  	As  	 IN	O
colonies  	colonies  	 NNS	O
appeared 	appeared 	 VBD	O
,  	,  	 ,	O
the  	the  	 DT	O
supernatants  	supernatants  	 NN	B-NP
were  	were  	 VBD	O
assayed  	assayed  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
humanized 	humanized 	 NNS	O
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
antibody  	antibody  	 NN	B-NP
and  	and  	 CC	O
for  	for  	 IN	O
the  	the  	 DT	O
capability  	capability  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
expressed  	expressed  	 JJ	O
antibody  	antibody  	 NN	B-NP
to  	to  	 TO	O
bind  	bind  	 VB	O
to  	to  	 TO	O
Stx1 	Stx1 	 CD	B-NP
.  	.  	 .	O
B.  	B.  	 NNP	B-NP
Assay  	Assay  	 NNP	I-NP
for  	for  	 IN	I-NP
Antibody  	Antibody  	 NNP	I-NP
Production  	Production  	 NNPS	I-NP
Antibody  	Antibody  	 NN	O
production  	production  	 NN	O
and  	and  	 CC	O
activity  	activity  	 NN	O
assays  	assays  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
stable  	stable  	 JJ	O
transfectants  	transfectants  	 NN	B-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
as  	as  	 RB	O
described  	described  	 VBN	O
below 	below 	 RB	O
.  	.  	 .	O
These  	These  	 DT	O
assays  	assays  	 JJ	O
demonstrate  	demonstrate  	 NN	O
that  	that  	 IN	O
the  	the  	 DT	O
transfection  	transfection  	 NN	B-NP
of  	of  	 IN	O
cells  	cells  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
plasmid  	plasmid  	 JJ	O
construct  	construct  	 NN	O
can  	can  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
stable  	stable  	 JJ	O
cell  	cell  	 NN	O
line  	line  	 NN	O
that  	that  	 WDT	O
produces  	produces  	 VBZ	O
a  	a  	 DT	O
humanized  	humanized  	 JJ	O
chimeric  	chimeric  	 JJ	B-NP
version  	version  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
13C4  	13C4  	 FW	I-NP
mouse  	mouse  	 FW	I-NP
hybridoma  	hybridoma  	 FW	I-NP
antibody  	antibody  	 FW	I-NP
( 	( 	 -LRB-	O
designated  	designated  	 VBN	O
H13C4 	H13C4 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Antibody  	Antibody  	 NN	B-NP
production  	production  	 NN	I-NP
ELISA  	ELISA  	 NNP	I-NP
assays  	assays  	 NN	I-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
8-well  	8-well  	 CD	O
strips  	strips  	 NNS	O
from  	from  	 IN	O
96-well  	96-well  	 FW	O
microtiter  	microtiter  	 FW	B-NP
plates  	plates  	 FW	I-NP
( 	( 	 -LRB-	O
Maxisorp  	Maxisorp  	 NNP	B-NP
F8 	F8 	 NNP	I-NP
;  	;  	 :	O
Nunc 	Nunc 	 NNP	B-NP
,  	,  	 ,	O
Inc. 	Inc. 	 NNP	O
)  	)  	 -RRB-	O
coated  	coated  	 VBN	O
at  	at  	 IN	O
a  	a  	 DT	O
1 	1 	 CD	O
: 	: 	 :	O
500  	500  	 CD	O
dilution  	dilution  	 NN	O
with  	with  	 IN	O
Goat  	Goat  	 NNP	B-NP
anti-Human  	anti-Human  	 JJ	I-NP
IgG  	IgG  	 JJ	I-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	O
Pierce  	Pierce  	 NNP	O
or  	or  	 CC	O
Biodesign  	Biodesign  	 NNP	B-NP
International 	International 	 NNP	O
)  	)  	 -RRB-	O
using  	using  	 VBG	O
a  	a  	 DT	O
Tris-HCl  	Tris-HCl  	 JJ	B-NP
coating  	coating  	 NN	I-NP
buffer 	buffer 	 NN	I-NP
,  	,  	 ,	O
pH  	pH  	 JJ	O
8.5 	8.5 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
plates  	plates  	 NN	O
were  	were  	 VBD	O
covered  	covered  	 VBN	O
and  	and  	 CC	O
incubated  	incubated  	 JJ	O
overnight  	overnight  	 JJ	O
at  	at  	 IN	O
4 	4 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	B-NP
Plates  	Plates  	 NNP	I-NP
were  	were  	 VBD	O
then  	then  	 RB	O
washed  	washed  	 VBN	O
once  	once  	 RB	O
with  	with  	 IN	O
a  	a  	 DT	O
wash  	wash  	 JJ	B-NP
storage  	storage  	 NN	I-NP
buffer  	buffer  	 NN	I-NP
( 	( 	 -LRB-	O
Tris-HCl 	Tris-HCl 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NaCl 	NaCl 	 NNP	I-NP
/ 	/ 	 CD	O
0.1 	0.1 	 CD	O
%  	%  	 NN	O
NaN3 	NaN3 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
50  	50  	 CD	O
microliters  	microliters  	 NN	B-NP
of  	of  	 IN	I-NP
culture  	culture  	 NN	I-NP
supernatant  	supernatant  	 NNS	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
applied  	applied  	 VBN	O
to  	to  	 TO	O
each  	each  	 DT	O
well  	well  	 NN	O
that  	that  	 WDT	O
had  	had  	 VBD	O
been  	been  	 VBN	O
filled  	filled  	 VBN	O
previously  	previously  	 RB	O
with  	with  	 IN	O
50  	50  	 CD	O
microliters  	microliters  	 NN	B-NP
of  	of  	 IN	I-NP
a  	a  	 DT	I-NP
sample 	sample 	 FW	I-NP
/ 	/ 	 FW	I-NP
conjugate  	conjugate  	 FW	I-NP
diluent  	diluent  	 FW	I-NP
( 	( 	 -LRB-	O
Tris-HCl 	Tris-HCl 	 FW	B-NP
/ 	/ 	 FW	I-NP
NaCl 	NaCl 	 FW	I-NP
/ 	/ 	 FW	I-NP
gelatin 	gelatin 	 FW	I-NP
/ 	/ 	 FW	I-NP
Tween-20 	Tween-20 	 FW	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
plates  	plates  	 NN	O
were  	were  	 VBD	O
allowed  	allowed  	 VBN	O
to  	to  	 TO	O
incubate  	incubate  	 VB	O
for  	for  	 IN	O
30  	30  	 CD	O
to  	to  	 TO	O
60  	60  	 CD	O
minutes  	minutes  	 NNS	O
on  	on  	 IN	O
a  	a  	 DT	O
rotator  	rotator  	 NN	B-NP
at  	at  	 IN	O
room  	room  	 NN	B-NP
temperature 	temperature 	 NN	I-NP
.  	.  	 .	O
They  	They  	 PRP	O
were  	were  	 VBD	O
then  	then  	 RB	O
washed  	washed  	 VBD	O
three  	three  	 CD	O
times  	times  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
wash  	wash  	 JJ	B-NP
solution  	solution  	 NN	I-NP
( 	( 	 -LRB-	O
imidazole 	imidazole 	 FW	B-NP
/ 	/ 	 FW	I-NP
NaCl 	NaCl 	 FW	I-NP
/ 	/ 	 FW	I-NP
Tween-20 	Tween-20 	 FW	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
goat  	goat  	 JJ	B-NP
anti-human  	anti-human  	 JJ	I-NP
kappa-HRP  	kappa-HRP  	 NN	I-NP
( 	( 	 -LRB-	O
Southern  	Southern  	 NNP	O
Biotechnologies 	Biotechnologies 	 NNP	O
)  	)  	 -RRB-	O
conjugate  	conjugate  	 NN	B-NP
was  	was  	 VBD	O
diluted  	diluted  	 VBN	O
1 	1 	 CD	O
: 	: 	 :	O
250  	250  	 CD	O
in  	in  	 IN	O
the  	the  	 DT	O
sample 	sample 	 FW	B-NP
/ 	/ 	 FW	I-NP
conjugate  	conjugate  	 FW	I-NP
diluent  	diluent  	 FW	I-NP
and  	and  	 CC	O
100  	100  	 CD	O
microliters  	microliters  	 NNS	B-NP
was  	was  	 VBD	O
added  	added  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
wells 	wells 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
plates  	plates  	 NN	O
were  	were  	 VBD	O
incubated  	incubated  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
rotator  	rotator  	 NN	B-NP
for  	for  	 IN	O
30  	30  	 CD	O
to  	to  	 TO	O
60  	60  	 CD	O
minutes  	minutes  	 NNS	O
at  	at  	 IN	O
room  	room  	 NN	B-NP
temperature 	temperature 	 NN	I-NP
.  	.  	 .	O
They  	They  	 PRP	O
were  	were  	 VBD	O
washed  	washed  	 VBN	O
6  	6  	 CD	O
times  	times  	 NNS	O
using  	using  	 VBG	O
the  	the  	 DT	O
wash  	wash  	 JJ	B-NP
buffer 	buffer 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
then  	then  	 RB	O
incubated  	incubated  	 VBN	O
with  	with  	 IN	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L 	L 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
well  	well  	 RB	I-NP
of  	of  	 IN	I-NP
ABTS  	ABTS  	 NNP	I-NP
developing  	developing  	 VBG	O
substrate  	substrate  	 NNS	O
( 	( 	 -LRB-	O
Kirkgaard  	Kirkgaard  	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x26 	x26 	 CD	B-NP
;  	;  	 :	O
Perry  	Perry  	 NNP	O
Laboratories 	Laboratories 	 NNPS	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
8  	8  	 CD	O
minutes  	minutes  	 NNS	O
at  	at  	 IN	O
room  	room  	 NN	B-NP
temperature 	temperature 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
reaction  	reaction  	 NN	O
was  	was  	 VBD	O
stopped  	stopped  	 VBN	O
with  	with  	 IN	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L 	L 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
well  	well  	 RB	I-NP
of  	of  	 IN	O
diluted  	diluted  	 JJ	O
Quench  	Quench  	 JJ	O
buffer  	buffer  	 NN	B-NP
( 	( 	 -LRB-	O
Kirkgaard  	Kirkgaard  	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x26 	x26 	 CD	B-NP
;  	;  	 :	O
Perry  	Perry  	 NNP	O
Laboratories 	Laboratories 	 NNPS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
absorbance  	absorbance  	 JJ	B-NP
value  	value  	 NN	I-NP
at  	at  	 IN	O
405  	405  	 CD	O
nm  	nm  	 NNS	B-NP
was  	was  	 VBD	O
determined  	determined  	 VBN	O
using  	using  	 VBG	O
an  	an  	 DT	O
automated  	automated  	 FW	B-NP
microtiter  	microtiter  	 FW	I-NP
plate  	plate  	 FW	I-NP
ELISA  	ELISA  	 FW	I-NP
reader  	reader  	 FW	I-NP
( 	( 	 -LRB-	O
Ceres  	Ceres  	 NNP	B-NP
UV900HI 	UV900HI 	 NNP	O
,  	,  	 ,	O
Bioteck 	Bioteck 	 NNP	B-NP
,  	,  	 ,	O
Winooski 	Winooski 	 NNP	B-NP
,  	,  	 ,	O
Vt. 	Vt. 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
controls  	controls  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
ELISA  	ELISA  	 NNP	B-NP
assay  	assay  	 NN	I-NP
were  	were  	 VBD	O
a  	a  	 DT	O
human  	human  	 JJ	O
IgG1K  	IgG1K  	 FW	O
myeloma  	myeloma  	 FW	O
protein  	protein  	 FW	O
( 	( 	 -LRB-	O
Biodesign  	Biodesign  	 NNP	B-NP
International 	International 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
supernatant  	supernatant  	 VB	O
collected  	collected  	 VBN	O
from  	from  	 IN	O
non-transfected  	non-transfected  	 NNP	O
NSO  	NSO  	 NNP	B-NP
cells 	cells 	 NNS	O
.  	.  	 .	O
This  	This  	 DT	O
assay  	assay  	 NN	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
8 	8 	 CD	O
)  	)  	 -RRB-	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
transfection  	transfection  	 NN	B-NP
of  	of  	 IN	O
cells  	cells  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
plasmid  	plasmid  	 JJ	O
construct  	construct  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
cells  	cells  	 NNS	O
producing  	producing  	 VBG	O
a  	a  	 DT	O
molecule  	molecule  	 NN	B-NP
containing  	containing  	 VBG	O
both  	both  	 DT	O
human  	human  	 JJ	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
( 	( 	 -LRB-	O
IgG 	IgG 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
light  	light  	 JJ	O
chain  	chain  	 NN	O
( 	( 	 -LRB-	O
kappa 	kappa 	 LS	B-NP
)  	)  	 -RRB-	O
domains 	domains 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
supernatants  	supernatants  	 NN	B-NP
were  	were  	 VBD	O
then  	then  	 RB	O
assayed  	assayed  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
expressed  	expressed  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
bind  	bind  	 VB	O
to  	to  	 TO	O
Stx1  	Stx1  	 CD	B-NP
protein  	protein  	 NN	I-NP
by  	by  	 IN	O
ELISA 	ELISA 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
activity  	activity  	 NN	O
assays  	assays  	 NNS	O
were  	were  	 VBD	O
preformed  	preformed  	 VBN	O
in  	in  	 IN	O
8-well  	8-well  	 CD	O
strips  	strips  	 NNS	O
from  	from  	 IN	O
96-well  	96-well  	 FW	O
microtiter  	microtiter  	 FW	B-NP
plates  	plates  	 FW	I-NP
( 	( 	 -LRB-	O
Maxisorp  	Maxisorp  	 NNP	B-NP
F8 	F8 	 NNP	I-NP
;  	;  	 :	O
Nunc 	Nunc 	 NNP	B-NP
,  	,  	 ,	O
Inc. 	Inc. 	 NNP	O
)  	)  	 -RRB-	O
coated  	coated  	 VBN	O
with  	with  	 IN	O
approximately  	approximately  	 RB	O
0.1  	0.1  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 CD	B-NP
/ 	/ 	 CD	I-NP
well  	well  	 RB	I-NP
purified  	purified  	 JJ	O
Stx1  	Stx1  	 NN	B-NP
received  	received  	 VBD	O
from  	from  	 IN	O
Alison  	Alison  	 NNP	B-NP
O 	O 	 NNP	I-NP
' 	' 	 POS	O
Brien  	Brien  	 NNP	O
( 	( 	 -LRB-	O
or  	or  	 CC	O
obtained  	obtained  	 VBD	O
as  	as  	 RB	O
described  	described  	 VBN	O
in  	in  	 IN	O
Example  	Example  	 NNP	O
7 	7 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
plate  	plate  	 NN	O
coating  	coating  	 NN	O
and  	and  	 CC	O
ELISA  	ELISA  	 NNP	B-NP
procedure  	procedure  	 NN	I-NP
was  	was  	 VBD	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
manner  	manner  	 NN	O
as  	as  	 IN	O
the  	the  	 DT	O
antibody  	antibody  	 NN	B-NP
assay  	assay  	 NN	I-NP
above  	above  	 IN	O
with  	with  	 IN	O
the  	the  	 DT	O
substitution  	substitution  	 NN	B-NP
of  	of  	 IN	I-NP
TMB  	TMB  	 NNP	I-NP
( 	( 	 -LRB-	O
Kirkgaard  	Kirkgaard  	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x26 	x26 	 CD	B-NP
;  	;  	 :	O
Perry  	Perry  	 NNP	O
Laboratories 	Laboratories 	 NNPS	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
ABTS  	ABTS  	 NNP	B-NP
as  	as  	 IN	O
a  	a  	 DT	O
developing  	developing  	 VBG	O
substrate 	substrate 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
absorbance  	absorbance  	 JJ	B-NP
value  	value  	 NN	I-NP
at  	at  	 IN	O
450  	450  	 CD	O
nm  	nm  	 NNS	B-NP
was  	was  	 VBD	O
determined  	determined  	 VBN	O
using  	using  	 VBG	O
an  	an  	 DT	O
automated  	automated  	 FW	B-NP
microtiter  	microtiter  	 FW	I-NP
plate  	plate  	 FW	I-NP
ELISA  	ELISA  	 FW	I-NP
reader  	reader  	 FW	I-NP
( 	( 	 -LRB-	O
Ceres  	Ceres  	 NNP	B-NP
UV900HI 	UV900HI 	 NNP	O
,  	,  	 ,	O
Bioteck 	Bioteck 	 NNP	B-NP
,  	,  	 ,	O
Winooski 	Winooski 	 NNP	B-NP
,  	,  	 ,	O
Vt. 	Vt. 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
As  	As  	 IN	O
a  	a  	 DT	O
positive  	positive  	 JJ	B-NP
control 	control 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
original  	original  	 JJ	B-NP
mouse  	mouse  	 NN	I-NP
monoclonal  	monoclonal  	 NN	I-NP
antibody  	antibody  	 NN	I-NP
13C4  	13C4  	 NN	I-NP
was  	was  	 VBD	O
used 	used 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
assayed  	assayed  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
goat  	goat  	 JJ	B-NP
anti-mouse  	anti-mouse  	 JJ	I-NP
IgG  	IgG  	 JJ	I-NP
conjugate  	conjugate  	 NNS	I-NP
( 	( 	 -LRB-	O
Jackson  	Jackson  	 NNP	O
Laboratories 	Laboratories 	 NNPS	O
)  	)  	 -RRB-	O
at  	at  	 IN	O
a  	a  	 DT	O
1 	1 	 CD	O
: 	: 	 :	O
2000  	2000  	 CD	O
dilution 	dilution 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
assay  	assay  	 NN	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
9 	9 	 CD	O
)  	)  	 -RRB-	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
transfection  	transfection  	 NN	B-NP
of  	of  	 IN	O
cells  	cells  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
plasmid  	plasmid  	 JJ	O
construct  	construct  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
cells  	cells  	 NNS	O
producing  	producing  	 VBG	B-NP
immunoglobulin  	immunoglobulin  	 NN	I-NP
that  	that  	 IN	O
binds  	binds  	 VBG	O
to  	to  	 TO	O
Stx1 	Stx1 	 CD	B-NP
.  	.  	 .	O
Neither  	Neither  	 DT	O
mouse  	mouse  	 NN	O
nor  	nor  	 CC	O
human  	human  	 JJ	O
IgG  	IgG  	 JJ	O
1K  	1K  	 NN	O
lacking  	lacking  	 VBG	O
the  	the  	 DT	O
anti-Stx  	anti-Stx  	 JJ	B-NP
variable  	variable  	 JJ	O
region  	region  	 NN	O
bound  	bound  	 VBN	O
the  	the  	 DT	O
toxin 	toxin 	 NN	B-NP
.  	.  	 .	O
Humanization  	Humanization  	 NNP	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
EHEC  	EHEC  	 NNP	I-NP
Anti-Stx2  	Anti-Stx2  	 NNP	I-NP
Antibody 	Antibody 	 NNP	I-NP
:  	:  	 :	O
11E10  	11E10  	 LS	B-NP
The  	The  	 DT	O
following  	following  	 JJ	O
examples  	examples  	 NNS	O
4-7  	4-7  	 VBP	O
relate  	relate  	 VBN	O
to  	to  	 TO	O
anti-Stx2  	anti-Stx2  	 CD	B-NP
and  	and  	 CC	O
-Stx2  	-Stx2  	 CD	O
variant  	variant  	 JJ	O
antibody  	antibody  	 NN	B-NP
11E10  	11E10  	 NN	I-NP
and  	and  	 CC	O
its  	its  	 PRP$	O
humanized  	humanized  	 JJ	O
counterpart  	counterpart  	 NN	O
H11E10 	H11E10 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
hybridoma  	hybridoma  	 JJ	B-NP
cell  	cell  	 NN	I-NP
line  	line  	 NN	I-NP
producing  	producing  	 VBG	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11  	11  	 CD	O
E10 	E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
antibody  	antibody  	 NN	B-NP
( 	( 	 -LRB-	O
Anti-Stx2 	Anti-Stx2 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
deposited  	deposited  	 VBN	O
on  	on  	 IN	O
Aug.  	Aug.  	 NNP	O
1 	1 	 CD	O
,  	,  	 ,	O
1990 	1990 	 CD	O
,  	,  	 ,	O
at  	at  	 IN	O
the  	the  	 DT	O
American  	American  	 NNP	O
Type  	Type  	 NNP	B-NP
Culture  	Culture  	 NNP	I-NP
Collection 	Collection 	 NNP	I-NP
,  	,  	 ,	O
10801  	10801  	 CD	O
University  	University  	 NNP	O
Boulevard 	Boulevard 	 NNP	O
,  	,  	 ,	O
Manassas 	Manassas 	 NNP	B-NP
,  	,  	 ,	O
Va. 	Va. 	 NNP	O
,  	,  	 ,	O
20110-2209 	20110-2209 	 NNP	O
,  	,  	 ,	O
under  	under  	 IN	O
Accession  	Accession  	 NNP	B-NP
No 	No 	 NNP	O
.  	.  	 .	O
CRL  	CRL  	 NNP	B-NP
1987 	1987 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
can  	can  	 MD	O
be  	be  	 VB	O
obtained  	obtained  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
ATCC 	ATCC 	 NNP	B-NP
,  	,  	 ,	O
or 	or 	 CC	O
,  	,  	 ,	O
as  	as  	 RB	O
here 	here 	 RB	O
,  	,  	 ,	O
from  	from  	 IN	O
Dr.  	Dr.  	 NNP	B-NP
Alison  	Alison  	 NNP	O
O 	O 	 NNP	O
' 	' 	 POS	O
Brien  	Brien  	 NNP	O
( 	( 	 -LRB-	O
for  	for  	 IN	O
details  	details  	 NNS	O
of  	of  	 IN	O
hybridoma  	hybridoma  	 JJ	B-NP
preparation 	preparation 	 NN	I-NP
,  	,  	 ,	O
see  	see  	 VB	O
Perera 	Perera 	 NNP	O
,  	,  	 ,	O
L.  	L.  	 NNP	B-NP
P.  	P.  	 NNP	I-NP
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
J  	J  	 NNP	B-NP
Clinical  	Clinical  	 NNP	I-NP
Microbil. 	Microbil. 	 NNP	I-NP
,  	,  	 ,	O
26 	26 	 CD	O
: 	: 	 :	O
2127-2131 	2127-2131 	 CD	O
( 	( 	 -LRB-	O
1988 	1988 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
vial  	vial  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
cell  	cell  	 NN	O
line  	line  	 NN	O
was  	was  	 VBD	O
thawed 	thawed 	 CD	O
,  	,  	 ,	O
washed  	washed  	 VBN	O
with  	with  	 IN	O
serum  	serum  	 JJ	B-NP
free  	free  	 JJ	O
medium  	medium  	 NN	O
and  	and  	 CC	O
then  	then  	 RB	O
resuspended  	resuspended  	 VBN	O
in  	in  	 IN	O
IMDM  	IMDM  	 NNP	B-NP
( 	( 	 -LRB-	O
Mediatech 	Mediatech 	 NNP	B-NP
)  	)  	 -RRB-	O
complete  	complete  	 JJ	O
media  	media  	 NNS	O
supplemented  	supplemented  	 VBN	O
with  	with  	 IN	O
10 	10 	 CD	O
%  	%  	 NN	O
FBS  	FBS  	 NNP	B-NP
( 	( 	 -LRB-	O
Irvine 	Irvine 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Total  	Total  	 JJ	B-NP
RNA  	RNA  	 NNP	I-NP
was  	was  	 VBD	O
isolated  	isolated  	 VBN	O
from  	from  	 IN	O
1 	1 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
107  	107  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11E10 	11E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
cells  	cells  	 NNS	O
using  	using  	 VBG	O
the  	the  	 DT	O
RNeasy  	RNeasy  	 JJ	B-NP
RNA  	RNA  	 NNP	I-NP
Isolation  	Isolation  	 NNP	I-NP
kit  	kit  	 NN	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
)  	)  	 -RRB-	O
following  	following  	 VBG	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure 	procedure 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
RNA  	RNA  	 NNP	B-NP
was  	was  	 VBD	O
dissolved  	dissolved  	 VBN	O
in  	in  	 IN	O
10  	10  	 CD	O
mM  	mM  	 JJ	B-NP
Tris 	Tris 	 NNP	I-NP
,  	,  	 ,	O
0.1  	0.1  	 CD	O
mM  	mM  	 JJ	B-NP
EDTA  	EDTA  	 NNP	I-NP
( 	( 	 -LRB-	O
pH  	pH  	 NNP	B-NP
8.4 	8.4 	 CD	O
)  	)  	 -RRB-	O
containing  	containing  	 VBG	O
0.03  	0.03  	 CD	O
U 	U 	 NNP	O
/ 	/ 	 NNP	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g  	g  	 JJ	B-NP
Prime  	Prime  	 NNP	I-NP
RNase  	RNase  	 NNP	I-NP
Inhibitor  	Inhibitor  	 NNP	I-NP
( 	( 	 -LRB-	O
5 	5 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
; 	; 	 :	O
-3 	-3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
; 	; 	 CD	O
)  	)  	 -RRB-	O
to  	to  	 TO	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
concentration  	concentration  	 NN	I-NP
of  	of  	 IN	O
0.63  	0.63  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 CD	O
/ 	/ 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l 	l 	 CD	O
.  	.  	 .	O
FIG.  	FIG.  	 CD	O
1  	1  	 CD	O
shows  	shows  	 NNS	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
for  	for  	 IN	O
cloning  	cloning  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
gene  	gene  	 NN	O
fragments  	fragments  	 NNS	O
and  	and  	 CC	O
FIG.  	FIG.  	 CD	O
5  	5  	 CD	O
lists  	lists  	 NNS	O
the  	the  	 DT	O
oligonucleotide  	oligonucleotide  	 JJ	B-NP
primers  	primers  	 NNS	I-NP
used 	used 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11E10 	11E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
total  	total  	 JJ	B-NP
RNA  	RNA  	 NNP	I-NP
( 	( 	 -LRB-	O
2.5  	2.5  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
converted  	converted  	 VBN	O
to  	to  	 TO	O
cDNA  	cDNA  	 JJ	O
by  	by  	 IN	O
using  	using  	 VBG	O
Superscript  	Superscript  	 NNP	O
11-MMLV  	11-MMLV  	 NNP	O
Reverse  	Reverse  	 NNP	O
Transcriptase  	Transcriptase  	 NNP	O
( 	( 	 -LRB-	O
Life  	Life  	 NNP	O
Technologies 	Technologies 	 NNPS	O
)  	)  	 -RRB-	O
according  	according  	 VBG	O
to  	to  	 TO	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedures 	procedures 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
mouse  	mouse  	 NN	O
light  	light  	 NN	O
chain  	chain  	 NN	O
( 	( 	 -LRB-	O
JS153 	JS153 	 NNP	B-NP
,  	,  	 ,	O
JS154 	JS154 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
11  	11  	 CD	O
and  	and  	 CC	O
12 	12 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
mouse  	mouse  	 JJ	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
( 	( 	 -LRB-	O
JS300 	JS300 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
6 	6 	 CD	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
specific  	specific  	 JJ	O
primers 	primers 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
first  	first  	 JJ	O
strand  	strand  	 JJ	O
cDNA  	cDNA  	 JJ	B-NP
synthesis  	synthesis  	 NN	I-NP
products  	products  	 NNS	I-NP
were  	were  	 VBD	O
then  	then  	 RB	O
purified  	purified  	 VBP	O
using  	using  	 VBG	O
a  	a  	 DT	O
Centricon-30  	Centricon-30  	 JJ	B-NP
concentrator  	concentrator  	 JJ	I-NP
device  	device  	 NN	I-NP
( 	( 	 -LRB-	O
Amicon 	Amicon 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Of  	Of  	 IN	O
the  	the  	 DT	O
70  	70  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l  	l  	 NN	O
of  	of  	 IN	O
cDNA  	cDNA  	 JJ	B-NP
recovered 	recovered 	 NN	I-NP
,  	,  	 ,	O
3.5  	3.5  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l  	l  	 NNS	O
was  	was  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
template  	template  	 JJ	B-NP
DNA  	DNA  	 NN	I-NP
for  	for  	 IN	I-NP
PCR 	PCR 	 NNP	I-NP
.  	.  	 .	O
Typical  	Typical  	 JJ	B-NP
PCR  	PCR  	 NNP	I-NP
amplification  	amplification  	 NN	I-NP
reactions  	reactions  	 NNS	I-NP
( 	( 	 -LRB-	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l 	l 	 LS	O
)  	)  	 -RRB-	O
contained  	contained  	 VBD	O
template  	template  	 JJ	B-NP
DNA 	DNA 	 NN	I-NP
,  	,  	 ,	O
50  	50  	 CD	O
pmoles  	pmoles  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
primers  	primers  	 NNS	O
( 	( 	 -LRB-	O
JS153 	JS153 	 NNP	B-NP
,  	,  	 ,	O
JS154  	JS154  	 NNP	B-NP
and  	and  	 CC	O
JS009 	JS009 	 NNP	B-NP
,  	,  	 ,	O
JS010 	JS010 	 NNP	B-NP
,  	,  	 ,	O
JS011 	JS011 	 NNP	B-NP
,  	,  	 ,	O
JS012 	JS012 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
7-12  	7-12  	 CD	O
for  	for  	 IN	O
light  	light  	 JJ	O
chains 	chains 	 NNS	O
,  	,  	 ,	O
JS160 	JS160 	 NNP	B-NP
,  	,  	 ,	O
JS161 	JS161 	 NNP	B-NP
,  	,  	 ,	O
JS162  	JS162  	 NNP	B-NP
and  	and  	 CC	O
JS001 	JS001 	 NNP	B-NP
,  	,  	 ,	O
JS002 	JS002 	 NNP	B-NP
,  	,  	 ,	O
JS003 	JS003 	 NNP	B-NP
,  	,  	 ,	O
JS004 	JS004 	 NNP	B-NP
,  	,  	 ,	O
JS008 	JS008 	 NNP	B-NP
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
28-30 	28-30 	 CD	O
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
2-5  	2-5  	 CD	O
for  	for  	 IN	O
heavy  	heavy  	 JJ	O
chains 	chains 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
2.5  	2.5  	 CD	O
units  	units  	 NNS	O
of  	of  	 IN	O
ExTaq  	ExTaq  	 JJ	B-NP
polymerase  	polymerase  	 NNS	I-NP
( 	( 	 -LRB-	O
PanVera 	PanVera 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
1 	1 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
ExTaq  	ExTaq  	 JJ	B-NP
reaction  	reaction  	 NN	I-NP
buffer 	buffer 	 NN	I-NP
,  	,  	 ,	O
200  	200  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
M  	M  	 NNP	O
dNTP 	dNTP 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
2  	2  	 CD	O
mM  	mM  	 JJ	B-NP
MgCl2 	MgCl2 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
template  	template  	 NN	B-NP
was  	was  	 VBD	O
denatured  	denatured  	 VBN	O
by  	by  	 IN	O
an  	an  	 DT	O
initial  	initial  	 JJ	O
five  	five  	 CD	O
minute  	minute  	 NN	B-NP
incubation  	incubation  	 NN	I-NP
at  	at  	 IN	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
The  	The  	 DT	O
products  	products  	 NNS	O
were  	were  	 VBD	O
amplified  	amplified  	 VBN	O
by  	by  	 IN	O
35  	35  	 CD	O
thermal  	thermal  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min. 	min. 	 CD	B-NP
,  	,  	 ,	O
55 	55 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec 	sec 	 NN	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
5  	5  	 CD	O
min.  	min.  	 CD	B-NP
at  	at  	 IN	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
The  	The  	 NNP	O
PCR  	PCR  	 NNP	B-NP
products  	products  	 NNS	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
successful  	successful  	 JJ	O
reactions  	reactions  	 NNS	O
were  	were  	 VBD	O
purified  	purified  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
Wizard  	Wizard  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
system  	system  	 NN	I-NP
( 	( 	 -LRB-	O
Promega 	Promega 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
per  	per  	 IN	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure 	procedure 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NN	I-NP
products  	products  	 NNS	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NN	I-NP
products  	products  	 NNS	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
350  	350  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
then  	then  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
a  	a  	 DT	O
bacterial  	bacterial  	 JJ	B-NP
vector  	vector  	 NN	I-NP
for  	for  	 IN	I-NP
DNA  	DNA  	 NNP	I-NP
sequence  	sequence  	 NN	I-NP
determination 	determination 	 NN	I-NP
.  	.  	 .	O
Ligations  	Ligations  	 NNP	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
PCR  	PCR  	 NNP	I-NP
fragments  	fragments  	 NNS	I-NP
were  	were  	 VBD	O
carried  	carried  	 VBN	O
out  	out  	 RP	O
into  	into  	 IN	O
the  	the  	 DT	O
pCR2.1  	pCR2.1  	 JJ	O
T 	T 	 NN	B-NP
/ 	/ 	 VBZ	I-NP
A  	A  	 DT	I-NP
style  	style  	 NN	I-NP
cloning  	cloning  	 NN	I-NP
vector  	vector  	 NN	I-NP
( 	( 	 -LRB-	O
Invitrogen 	Invitrogen 	 NNP	B-NP
)  	)  	 -RRB-	O
following  	following  	 VBG	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedures  	procedures  	 NNS	O
using  	using  	 VBG	O
a  	a  	 DT	O
3 	3 	 CD	O
: 	: 	 :	O
1  	1  	 CD	O
insert  	insert  	 NN	O
to  	to  	 TO	O
vector  	vector  	 VB	O
molar  	molar  	 JJ	B-NP
ratio 	ratio 	 NN	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l  	l  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
ligation  	ligation  	 JJ	B-NP
reactions  	reactions  	 NNS	I-NP
were  	were  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
transform  	transform  	 VB	O
the  	the  	 DT	O
INV 	INV 	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
F 	F 	 NNP	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
competent  	competent  	 JJ	O
cells  	cells  	 NNS	O
( 	( 	 -LRB-	O
Invitrogen 	Invitrogen 	 NNP	B-NP
)  	)  	 -RRB-	O
as  	as  	 IN	O
per  	per  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
procedure 	procedure 	 NN	O
.  	.  	 .	O
Plasmid  	Plasmid  	 JJ	B-NP
clones  	clones  	 NNS	I-NP
containing  	containing  	 VBG	I-NP
DNA  	DNA  	 NN	I-NP
inserts  	inserts  	 NNS	I-NP
were  	were  	 VBD	O
identified  	identified  	 VBN	O
using  	using  	 VBG	O
diagnostic  	diagnostic  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
enzyme  	enzyme  	 NN	I-NP
digests 	digests 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
EcoRI  	EcoRI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
DNA  	DNA  	 NN	B-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
plasmids  	plasmids  	 NNS	I-NP
containing  	containing  	 VBG	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
inserts  	inserts  	 NNS	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
size  	size  	 NN	O
( 	( 	 -LRB-	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
then  	then  	 RB	O
determined 	determined 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
consensus  	consensus  	 NN	I-NP
DNA  	DNA  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
of  	of  	 IN	I-NP
11E10  	11E10  	 NNP	I-NP
is  	is  	 VBZ	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
FIG.  	FIG.  	 CD	O
6  	6  	 CD	O
with  	with  	 IN	O
the  	the  	 DT	O
CDRs  	CDRs  	 NN	B-NP
indicated  	indicated  	 VBD	O
by  	by  	 IN	O
underlining 	underlining 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
plasmid  	plasmid  	 NNS	I-NP
clones  	clones  	 VBP	I-NP
needed  	needed  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
further  	further  	 RB	O
characterized  	characterized  	 VBN	O
because  	because  	 IN	O
the  	the  	 DT	O
hybridoma  	hybridoma  	 JJ	B-NP
cell  	cell  	 NN	I-NP
line  	line  	 NN	I-NP
that  	that  	 WDT	O
expresses  	expresses  	 VBZ	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11E10 	11E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
antibody  	antibody  	 NN	B-NP
was  	was  	 VBD	O
made  	made  	 VBN	O
by  	by  	 IN	O
fusing  	fusing  	 JJ	O
mouse  	mouse  	 NN	B-NP
splenocytes  	splenocytes  	 NN	I-NP
with  	with  	 IN	O
SP20  	SP20  	 CD	B-NP
myeloma  	myeloma  	 CD	I-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
SP20  	SP20  	 JJ	B-NP
cell  	cell  	 NN	I-NP
line  	line  	 NN	I-NP
transcribes  	transcribes  	 VBD	O
a  	a  	 DT	O
pseudogene  	pseudogene  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
kappa  	kappa  	 JJ	I-NP
light  	light  	 JJ	O
chain 	chain 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
pseudogene  	pseudogene  	 JJ	B-NP
transcript 	transcript 	 NN	I-NP
,  	,  	 ,	O
when  	when  	 WRB	O
converted  	converted  	 VBN	O
to  	to  	 TO	O
cDNA  	cDNA  	 JJ	O
by  	by  	 IN	O
RT-PCR 	RT-PCR 	 NNP	B-NP
,  	,  	 ,	O
contains  	contains  	 VBZ	O
an  	an  	 DT	O
AflIII  	AflIII  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site 	site 	 NN	I-NP
.  	.  	 .	O
For  	For  	 IN	O
this  	this  	 DT	O
reason 	reason 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
clones  	clones  	 NNS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
were  	were  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
AflIII  	AflIII  	 JJ	O
and  	and  	 CC	O
those  	those  	 DT	O
products  	products  	 NNS	O
that  	that  	 WDT	O
did  	did  	 VBD	O
not  	not  	 RB	O
cut  	cut  	 VB	O
were  	were  	 VBD	O
then  	then  	 RB	O
submitted  	submitted  	 VBN	O
for  	for  	 IN	O
DNA  	DNA  	 NNP	B-NP
sequencing 	sequencing 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
consensus  	consensus  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
is  	is  	 VBZ	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
FIG.  	FIG.  	 CD	O
6 	6 	 CD	O
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
CDRs  	CDRs  	 NN	B-NP
indicated  	indicated  	 VBD	O
by  	by  	 IN	O
underlining 	underlining 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
gene  	gene  	 NN	O
fragments  	fragments  	 NNS	O
were  	were  	 VBD	O
re-amplified  	re-amplified  	 JJ	O
by  	by  	 IN	O
PCR  	PCR  	 NNP	B-NP
using  	using  	 VBG	O
primers  	primers  	 NNS	O
that  	that  	 WDT	O
adapted  	adapted  	 VBD	O
the  	the  	 DT	O
fragments  	fragments  	 NN	O
for  	for  	 IN	O
cloning  	cloning  	 NN	B-NP
into  	into  	 IN	O
the  	the  	 DT	O
expression  	expression  	 NN	B-NP
vector  	vector  	 NN	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIGS.  	FIGS.  	 CD	O
5  	5  	 CD	O
and  	and  	 CC	O
7 	7 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
front  	front  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
11E10HF 	11E10HF 	 NNP	O
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
37 	37 	 CD	O
)  	)  	 -RRB-	O
includes  	includes  	 VBZ	O
a  	a  	 DT	O
5 	5 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
tail  	tail  	 NN	O
that  	that  	 IN	O
encodes  	encodes  	 VBG	O
the  	the  	 DT	O
C-terminus  	C-terminus  	 JJ	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
leader  	leader  	 NN	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
NruI  	NruI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
reverse  	reverse  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
11E10HB 	11E10HB 	 NNP	O
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
38 	38 	 CD	O
)  	)  	 -RRB-	O
adds  	adds  	 VBZ	O
a  	a  	 DT	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
EcoRI  	EcoRI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
front  	front  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
11E10LF 	11E10LF 	 NNP	O
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
39 	39 	 CD	O
)  	)  	 -RRB-	O
includes  	includes  	 VBZ	O
a  	a  	 DT	O
5 	5 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
tail  	tail  	 NN	O
that  	that  	 IN	O
encodes  	encodes  	 VBG	O
the  	the  	 DT	O
C-terminus  	C-terminus  	 JJ	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
leader  	leader  	 NN	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
EcoRV  	EcoRV  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
N-terminus  	N-terminus  	 JJ	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
,  	,  	 ,	O
while  	while  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
reverse  	reverse  	 NN	I-NP
primer  	primer  	 NNS	I-NP
( 	( 	 -LRB-	O
11E10LB 	11E10LB 	 NNP	O
,  	,  	 ,	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
: 	: 	 :	O
40 	40 	 CD	O
)  	)  	 -RRB-	O
adds  	adds  	 VBZ	O
a  	a  	 DT	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
DNA  	DNA  	 NNP	B-NP
sequence  	sequence  	 NN	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
joining  	joining  	 VBG	I-NP
region-kappa  	region-kappa  	 JJ	I-NP
exon  	exon  	 JJ	I-NP
splice  	splice  	 NNS	I-NP
junction  	junction  	 VBP	I-NP
followed  	followed  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
BstBI  	BstBI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
site  	site  	 NN	I-NP
for  	for  	 IN	I-NP
cloning 	cloning 	 NN	I-NP
.  	.  	 .	O
PCRs  	PCRs  	 NNP	B-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
as  	as  	 RB	O
described  	described  	 VBN	O
above  	above  	 IN	O
except 	except 	 NN	O
,  	,  	 ,	O
following  	following  	 VBG	O
a  	a  	 DT	O
5  	5  	 CD	O
min.  	min.  	 CD	B-NP
incubation  	incubation  	 NN	O
at  	at  	 IN	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C. 	C. 	 NNP	O
,  	,  	 ,	O
the  	the  	 DT	O
PCR  	PCR  	 NNP	B-NP
parameters  	parameters  	 NNS	I-NP
were  	were  	 VBD	O
30  	30  	 CD	O
thermal  	thermal  	 JJ	B-NP
cycles  	cycles  	 NNS	I-NP
of  	of  	 IN	O
96 	96 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
1  	1  	 CD	O
min. 	min. 	 CD	B-NP
,  	,  	 ,	O
62 	62 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
70 	70 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
30  	30  	 CD	O
sec. 	sec. 	 CD	O
,  	,  	 ,	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
5  	5  	 CD	O
min.  	min.  	 CD	B-NP
at  	at  	 IN	O
72 	72 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C 	C 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
PCR  	PCR  	 NNP	I-NP
product  	product  	 NN	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
subcloned  	subcloned  	 VBN	O
into  	into  	 IN	O
a  	a  	 DT	O
mammalian  	mammalian  	 FW	B-NP
expression  	expression  	 FW	I-NP
plasmid  	plasmid  	 FW	I-NP
vector  	vector  	 FW	I-NP
( 	( 	 -LRB-	O
pJRS315 	pJRS315 	 NNP	B-NP
,  	,  	 ,	O
produced  	produced  	 VBD	O
as  	as  	 RB	O
set  	set  	 VBN	O
forth  	forth  	 RB	O
below  	below  	 RB	O
in  	in  	 IN	O
Example  	Example  	 NNP	O
5 	5 	 CD	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
production  	production  	 NN	O
of  	of  	 IN	O
recombinant  	recombinant  	 FW	B-NP
chimeric  	chimeric  	 FW	I-NP
mouse 	mouse 	 FW	I-NP
/ 	/ 	 FW	I-NP
human  	human  	 FW	I-NP
antibody  	antibody  	 FW	I-NP
molecules 	molecules 	 FW	I-NP
.  	.  	 .	O
The  	The  	 DT	O
resulting  	resulting  	 VBG	O
vector  	vector  	 JJ	B-NP
clone  	clone  	 NN	I-NP
was  	was  	 VBD	O
designated  	designated  	 VBN	B-NP
pACE1 	pACE1 	 CD	I-NP
.  	.  	 .	O
Before  	Before  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
could  	could  	 MD	O
be  	be  	 VB	O
subcloned  	subcloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
mammalian  	mammalian  	 JJ	B-NP
expression  	expression  	 NN	I-NP
vector 	vector 	 NN	I-NP
,  	,  	 ,	O
it  	it  	 PRP	O
was  	was  	 VBD	O
subcloned  	subcloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
pCR2.1  	pCR2.1  	 JJ	O
T 	T 	 NN	B-NP
/ 	/ 	 VBZ	I-NP
A  	A  	 DT	I-NP
style  	style  	 NN	I-NP
cloning  	cloning  	 NNS	I-NP
vector  	vector  	 VBP	O
previously  	previously  	 RB	O
described 	described 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
resulting  	resulting  	 VBG	B-NP
plasmid  	plasmid  	 NNS	I-NP
was  	was  	 VBD	O
designated  	designated  	 VBN	O
pACELC  	pACELC  	 JJ	O
and  	and  	 CC	O
digested 	digested 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
BstBI 	BstBI 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
EcoRV 	EcoRV 	 NNP	I-NP
,  	,  	 ,	O
to  	to  	 TO	O
cut  	cut  	 VB	O
out  	out  	 RP	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region 	region 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
was  	was  	 VBD	O
then  	then  	 RB	O
subcloned  	subcloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
mammalian  	mammalian  	 JJ	B-NP
expression  	expression  	 NN	I-NP
vector  	vector  	 NN	I-NP
containing  	containing  	 VBG	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11E10 	11E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
( 	( 	 -LRB-	O
pACE1 	pACE1 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
expression  	expression  	 NN	I-NP
vector  	vector  	 NN	I-NP
clone  	clone  	 NNS	I-NP
was  	was  	 VBD	O
designated  	designated  	 VBN	B-NP
pACE4 	pACE4 	 CD	I-NP
.  	.  	 .	O
This  	This  	 DT	O
vector  	vector  	 JJ	B-NP
results  	results  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
recombinant  	recombinant  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
molecules  	molecules  	 NNS	I-NP
under  	under  	 IN	O
the  	the  	 DT	O
control  	control  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
CMV  	CMV  	 NNP	O
transcriptional  	transcriptional  	 NN	B-NP
promoters 	promoters 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
molecules  	molecules  	 NNS	I-NP
are  	are  	 VBP	O
direct  	direct  	 JJ	O
cDNA  	cDNA  	 JJ	O
constructs  	constructs  	 NN	O
that  	that  	 IN	O
fuse  	fuse  	 VBG	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
sequence  	sequence  	 NN	O
directly  	directly  	 RB	O
into  	into  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
IgG1  	IgG1  	 CD	B-NP
constant  	constant  	 JJ	O
domain 	domain 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
molecules 	molecules 	 NNS	I-NP
,  	,  	 ,	O
on  	on  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
hand 	hand 	 NN	O
,  	,  	 ,	O
have  	have  	 VBP	O
a  	a  	 DT	O
mouse  	mouse  	 NN	B-NP
kappa  	kappa  	 VBZ	I-NP
intron  	intron  	 JJ	I-NP
region  	region  	 NN	I-NP
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
of  	of  	 IN	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
coding  	coding  	 NN	O
fragment 	fragment 	 NN	O
.  	.  	 .	O
After  	After  	 IN	O
splicing 	splicing 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
region  	region  	 NN	O
becomes  	becomes  	 VBZ	O
fused  	fused  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 JJ	B-NP
constant  	constant  	 JJ	O
region  	region  	 NN	B-NP
exon  	exon  	 NNS	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
7 	7 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
selectable  	selectable  	 JJ	B-NP
marker  	marker  	 NN	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
vector  	vector  	 NN	I-NP
in  	in  	 IN	O
mammalian  	mammalian  	 JJ	B-NP
cells  	cells  	 NNS	I-NP
is  	is  	 VBZ	O
neomycin  	neomycin  	 JJ	O
( 	( 	 -LRB-	O
G418 	G418 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
pACE1 	pACE1 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11E10 	11E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NNP	I-NP
product  	product  	 NN	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
NruI  	NruI  	 JJ	O
and  	and  	 CC	O
EcoRI  	EcoRI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
purified  	purified  	 VBZ	O
using  	using  	 VBG	O
a  	a  	 DT	O
Qiaquick  	Qiaquick  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
column  	column  	 NN	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
as  	as  	 RB	O
described  	described  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
ligated  	ligated  	 NN	O
into  	into  	 IN	O
NruI 	NruI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
EcoRI  	EcoRI  	 JJ	I-NP
digested  	digested  	 NN	I-NP
and  	and  	 CC	O
gel-purified  	gel-purified  	 NNP	B-NP
pJRS315 	pJRS315 	 NNP	I-NP
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
plasmid  	plasmid  	 CD	B-NP
pACE1  	pACE1  	 CD	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
7 	7 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
11E10 	11E10 	 CD	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
PCR  	PCR  	 NNP	I-NP
product  	product  	 NN	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
350  	350  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
T 	T 	 NN	B-NP
/ 	/ 	 VBZ	I-NP
A  	A  	 DT	I-NP
cloning  	cloning  	 JJ	I-NP
vector  	vector  	 NN	I-NP
as  	as  	 IN	O
per  	per  	 IN	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
instructions 	instructions 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
resulting  	resulting  	 JJ	O
clone 	clone 	 NN	B-NP
,  	,  	 ,	O
pACELC 	pACELC 	 NNP	B-NP
,  	,  	 ,	O
was  	was  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
EcoRV  	EcoRV  	 JJ	O
and  	and  	 CC	O
BstBI  	BstBI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
fragment  	fragment  	 NN	I-NP
was  	was  	 VBD	O
gel-purified 	gel-purified 	 JJ	B-NP
.  	.  	 .	O
This  	This  	 DT	O
fragment  	fragment  	 NN	O
was  	was  	 VBD	O
then  	then  	 RB	O
ligated  	ligated  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
EcoRV 	EcoRV 	 JJ	B-NP
/ 	/ 	 CD	I-NP
BstBI  	BstBI  	 JJ	I-NP
digested  	digested  	 NN	I-NP
and  	and  	 CC	O
gel-purified  	gel-purified  	 NNP	B-NP
pACE1 	pACE1 	 NNP	I-NP
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
plasmid  	plasmid  	 CD	B-NP
pACE4  	pACE4  	 CD	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
7 	7 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
sequence  	sequence  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
regions  	regions  	 NNS	I-NP
was  	was  	 VBD	O
verified  	verified  	 VBN	O
prior  	prior  	 RB	O
to  	to  	 TO	O
mammalian  	mammalian  	 VB	O
cell  	cell  	 NN	B-NP
transfection 	transfection 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pJRS315  	pJRS315  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
expression  	expression  	 NN	B-NP
plasmid  	plasmid  	 NN	I-NP
into  	into  	 IN	O
which  	which  	 WDT	O
the  	the  	 DT	O
variable  	variable  	 JJ	O
regions  	regions  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
11E10  	11E10  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
were  	were  	 VBD	O
cloned 	cloned 	 VBN	O
.  	.  	 .	O
This  	This  	 DT	O
plasmid  	plasmid  	 NN	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
derivative  	derivative  	 JJ	O
of  	of  	 IN	O
a  	a  	 DT	O
basic  	basic  	 JJ	O
expression  	expression  	 NN	B-NP
vector 	vector 	 NN	I-NP
,  	,  	 ,	O
plasmid  	plasmid  	 CD	B-NP
pSUN15 	pSUN15 	 CD	I-NP
,  	,  	 ,	O
that  	that  	 WDT	O
contains  	contains  	 VBZ	O
no  	no  	 DT	O
antibody  	antibody  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
coding  	coding  	 NN	I-NP
information 	information 	 NN	I-NP
,  	,  	 ,	O
pJRS315  	pJRS315  	 NNP	B-NP
was  	was  	 VBD	O
created  	created  	 VBN	O
using  	using  	 VBG	O
DNA  	DNA  	 NN	B-NP
fragment  	fragment  	 NN	I-NP
ligations  	ligations  	 NNS	I-NP
and  	and  	 CC	O
site  	site  	 NN	O
directed  	directed  	 VBD	O
mutagenesis  	mutagenesis  	 JJ	B-NP
steps 	steps 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
result  	result  	 NN	O
was  	was  	 VBD	O
a  	a  	 DT	O
vector  	vector  	 NN	B-NP
that  	that  	 WDT	O
expresses  	expresses  	 VBZ	O
both  	both  	 DT	O
antibody  	antibody  	 NN	B-NP
chains  	chains  	 NNS	I-NP
with  	with  	 IN	O
CMV  	CMV  	 NNP	O
promoter  	promoter  	 FW	O
driven  	driven  	 FW	O
transcription  	transcription  	 FW	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
17 	17 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Neomycin  	Neomycin  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
serves  	serves  	 VBZ	O
as  	as  	 IN	O
the  	the  	 DT	O
dominant  	dominant  	 JJ	O
selectable  	selectable  	 JJ	B-NP
marker  	marker  	 NN	I-NP
for  	for  	 IN	I-NP
transfection  	transfection  	 NN	I-NP
of  	of  	 IN	I-NP
mammalian  	mammalian  	 JJ	I-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
designed  	designed  	 VBN	O
to  	to  	 TO	O
allow  	allow  	 VB	O
convenient  	convenient  	 JJ	O
cloning  	cloning  	 NN	B-NP
of  	of  	 IN	O
any  	any  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
as  	as  	 IN	O
an  	an  	 DT	O
EcoRV 	EcoRV 	 JJ	B-NP
/ 	/ 	 CD	I-NP
BstBI  	BstBI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
any  	any  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
as  	as  	 IN	O
a  	a  	 DT	O
NruI 	NruI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
EcoRI  	EcoRI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
any  	any  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	O
constant  	constant  	 JJ	O
domain  	domain  	 NN	O
as  	as  	 IN	O
an  	an  	 DT	O
EcoRI 	EcoRI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
NotI  	NotI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
were  	were  	 VBD	O
chosen  	chosen  	 VBN	O
because  	because  	 IN	O
they  	they  	 PRP	O
occur  	occur  	 VBP	O
rarely  	rarely  	 RB	O
( 	( 	 -LRB-	O
if  	if  	 IN	O
ever 	ever 	 RB	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
human  	human  	 JJ	O
and  	and  	 CC	O
mouse  	mouse  	 JJ	O
variable  	variable  	 JJ	O
regions 	regions 	 NNS	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
mouse  	mouse  	 NN	B-NP
J  	J  	 NNP	I-NP
region 	region 	 FW	I-NP
/ 	/ 	 FW	I-NP
kappa  	kappa  	 FW	I-NP
intron  	intron  	 FW	I-NP
fragment  	fragment  	 FW	I-NP
fused  	fused  	 FW	O
to  	to  	 TO	O
a  	a  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 NNS	B-NP
exon  	exon  	 VBP	I-NP
so  	so  	 RB	O
that  	that  	 IN	O
after  	after  	 IN	O
post-transcriptional  	post-transcriptional  	 FW	B-NP
splicing  	splicing  	 FW	O
a  	a  	 FW	O
mouse 	mouse 	 FW	B-NP
/ 	/ 	 FW	I-NP
human  	human  	 FW	I-NP
chimeric  	chimeric  	 FW	I-NP
kappa  	kappa  	 FW	I-NP
light  	light  	 JJ	O
chain  	chain  	 NN	O
is  	is  	 VBZ	O
produced 	produced 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
backbone  	backbone  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
vector  	vector  	 NN	B-NP
was  	was  	 VBD	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pCDNA3  	pCDNA3  	 NNP	I-NP
( 	( 	 -LRB-	O
Invitrogen 	Invitrogen 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
plasmid  	plasmid  	 NN	B-NP
was  	was  	 VBD	O
cut  	cut  	 VBN	O
with  	with  	 IN	O
HindIII 	HindIII 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
XhoI  	XhoI  	 NNP	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
polylinker 	polylinker 	 NNS	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
DNA  	DNA  	 NNP	B-NP
fragment  	fragment  	 NN	I-NP
was  	was  	 VBD	O
inserted  	inserted  	 VBN	O
to  	to  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
starting  	starting  	 VBG	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
vector 	vector 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
; 	; 	 :	O
.  	.  	 .	O
This  	This  	 DT	O
linker  	linker  	 NN	B-NP
contained  	contained  	 VBD	O
the  	the  	 DT	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
HindIII 	HindIII 	 JJ	O
,  	,  	 ,	O
KpnI 	KpnI 	 NNP	B-NP
,  	,  	 ,	O
ClaI 	ClaI 	 NNP	B-NP
,  	,  	 ,	O
PmlI 	PmlI 	 NNP	B-NP
,  	,  	 ,	O
EcoRV 	EcoRV 	 NNP	B-NP
,  	,  	 ,	O
XmaI 	XmaI 	 NNP	B-NP
,  	,  	 ,	O
BamHI  	BamHI  	 JJ	O
and  	and  	 CC	O
XhoI  	XhoI  	 JJ	O
to  	to  	 TO	O
facilitate  	facilitate  	 VB	O
subsequent  	subsequent  	 JJ	O
cloning  	cloning  	 JJ	B-NP
steps  	steps  	 NNS	I-NP
to  	to  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pCDNA3.LCPL 	pCDNA3.LCPL 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
SmaI 	SmaI 	 JJ	B-NP
/ 	/ 	 NNP	I-NP
BclI  	BclI  	 NNP	I-NP
DNA  	DNA  	 NNP	I-NP
fragment  	fragment  	 VBZ	O
containing  	containing  	 VBG	O
a  	a  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
leader 	leader 	 NN	I-NP
,  	,  	 ,	O
anti-CKMB  	anti-CKMB  	 JJ	B-NP
kappa  	kappa  	 JJ	I-NP
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
genomic  	genomic  	 NN	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
UTR  	UTR  	 NNP	B-NP
was  	was  	 VBD	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
EcoRV 	EcoRV 	 JJ	B-NP
/ 	/ 	 CD	I-NP
BamHI  	BamHI  	 JJ	I-NP
sites  	sites  	 NNS	I-NP
of  	of  	 IN	I-NP
pCDNA3.LCPL 	pCDNA3.LCPL 	 CD	I-NP
.  	.  	 .	O
The  	The  	 DT	O
mouse  	mouse  	 NN	B-NP
kappa  	kappa  	 NN	I-NP
intron 	intron 	 NN	I-NP
,  	,  	 ,	O
exon  	exon  	 NN	B-NP
and  	and  	 CC	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
UTR  	UTR  	 NNP	B-NP
in  	in  	 IN	O
this  	this  	 DT	O
fragment  	fragment  	 NN	O
was  	was  	 VBD	O
derived  	derived  	 VBN	O
from  	from  	 IN	O
LCPXK2  	LCPXK2  	 NNP	B-NP
received  	received  	 VBD	O
from  	from  	 IN	O
Dr.  	Dr.  	 NNP	B-NP
Richard  	Richard  	 NNP	O
Near  	Near  	 NNP	O
( 	( 	 -LRB-	O
Near 	Near 	 NNP	O
,  	,  	 ,	O
R.  	R.  	 NNP	B-NP
I.  	I.  	 NNP	I-NP
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
Mol 	Mol 	 NNP	B-NP
.  	.  	 .	O
Immunol.  	Immunol.  	 CD	B-NP
27 	27 	 CD	O
: 	: 	 :	O
901-909 	901-909 	 CD	O
,  	,  	 ,	O
( 	( 	 -LRB-	O
1990 	1990 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Mutagenesis  	Mutagenesis  	 NNP	B-NP
was  	was  	 VBD	O
then  	then  	 RB	O
performed  	performed  	 VBN	O
to  	to  	 TO	O
eliminate  	eliminate  	 VB	O
an  	an  	 DT	O
NruI  	NruI  	 JJ	O
( 	( 	 -LRB-	O
209 	209 	 LS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
MluI  	MluI  	 NNP	B-NP
( 	( 	 -LRB-	O
229 	229 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
BstBI  	BstBI  	 NNP	B-NP
( 	( 	 -LRB-	O
2962 	2962 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
to  	to  	 TO	O
introduce  	introduce  	 VB	O
an  	an  	 DT	O
NheI  	NheI  	 JJ	O
( 	( 	 -LRB-	O
1229 	1229 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
a  	a  	 DT	O
BamHI  	BamHI  	 JJ	O
( 	( 	 -LRB-	O
1214 	1214 	 CD	O
)  	)  	 -RRB-	O
site  	site  	 NN	O
to  	to  	 TO	O
create  	create  	 VB	O
pcDNA3mut.LCPL.LCVK  	pcDNA3mut.LCPL.LCVK  	 NNP	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
12 	12 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
second  	second  	 JJ	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
vector 	vector 	 NN	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
was  	was  	 VBD	O
constructed  	constructed  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
pcDNA3mut.LCPL.LCVK  	pcDNA3mut.LCPL.LCVK  	 JJ	O
plasmid  	plasmid  	 NN	O
by  	by  	 IN	O
replacing  	replacing  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
expression  	expression  	 NN	I-NP
region  	region  	 NN	I-NP
( 	( 	 -LRB-	O
HindIII 	HindIII 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
XhoI 	XhoI 	 NNP	I-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
a  	a  	 DT	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
polylinker 	polylinker 	 NNS	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
consisting  	consisting  	 VBG	O
of  	of  	 IN	O
restriction  	restriction  	 NN	B-NP
sites  	sites  	 NNS	I-NP
HpaI 	HpaI 	 JJ	O
,  	,  	 ,	O
BspEI 	BspEI 	 NNP	B-NP
,  	,  	 ,	O
EcoRV 	EcoRV 	 NNP	B-NP
,  	,  	 ,	O
KpnI 	KpnI 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
XhoI 	XhoI 	 JJ	O
.  	.  	 .	O
This  	This  	 DT	O
plasmid  	plasmid  	 NN	B-NP
was  	was  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
EcorRV  	EcorRV  	 JJ	O
and  	and  	 CC	O
KpnI 	KpnI 	 JJ	O
.  	.  	 .	O
A  	A  	 DT	O
SmaI 	SmaI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
KpnI  	KpnI  	 JJ	I-NP
digested  	digested  	 JJ	I-NP
DNA  	DNA  	 NN	I-NP
fragment  	fragment  	 NN	I-NP
containing  	containing  	 VBG	O
a  	a  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
leader  	leader  	 NN	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
anti-CKMB  	anti-CKMB  	 JJ	O
IgG2b  	IgG2b  	 CD	O
mouse  	mouse  	 NN	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
genomic  	genomic  	 NN	I-NP
fragment  	fragment  	 NN	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
ligated  	ligated  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
EcoRV 	EcoRV 	 JJ	O
/ 	/ 	 FW	O
KpnI  	KpnI  	 FW	O
digested  	digested  	 FW	B-NP
plasmid 	plasmid 	 FW	I-NP
.  	.  	 .	O
A  	A  	 DT	O
KpnI 	KpnI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
SalI  	SalI  	 JJ	I-NP
oligonucleotide  	oligonucleotide  	 NNS	I-NP
fragment  	fragment  	 VBP	O
containing  	containing  	 VBG	O
a  	a  	 DT	O
3 	3 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
;  	;  	 :	O
UTR  	UTR  	 NNP	B-NP
and  	and  	 CC	O
a  	a  	 DT	O
NotI  	NotI  	 JJ	O
upstream  	upstream  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
SalI  	SalI  	 JJ	B-NP
site  	site  	 NN	I-NP
was  	was  	 VBD	O
subsequently  	subsequently  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
KpnI 	KpnI 	 JJ	O
/ 	/ 	 FW	O
XhoI  	XhoI  	 FW	O
digested  	digested  	 FW	B-NP
plasmid  	plasmid  	 FW	I-NP
( 	( 	 -LRB-	O
knocking  	knocking  	 VBG	O
out  	out  	 RP	O
the  	the  	 DT	O
XhoI  	XhoI  	 JJ	B-NP
site 	site 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
to  	to  	 TO	O
create  	create  	 VB	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
pCDNA3mUt.HCPL.HCV2b  	pCDNA3mUt.HCPL.HCV2b  	 NNP	O
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
13 	13 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
From  	From  	 IN	O
this  	this  	 DT	O
point 	point 	 NN	O
,  	,  	 ,	O
two  	two  	 CD	O
vectors  	vectors  	 NNS	O
were  	were  	 VBD	O
created  	created  	 VBN	O
that  	that  	 WDT	O
did  	did  	 VBD	O
not  	not  	 RB	O
have  	have  	 VB	O
any  	any  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
anti-CKMB  	anti-CKMB  	 JJ	B-NP
variable  	variable  	 NN	I-NP
or  	or  	 CC	O
constant  	constant  	 JJ	O
domain  	domain  	 NN	B-NP
DNA  	DNA  	 NN	I-NP
sequences 	sequences 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
was  	was  	 VBD	O
done  	done  	 VBN	O
by  	by  	 IN	O
cutting  	cutting  	 VBG	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	O
pcDNA3mut.LCPL.LCVK  	pcDNA3mut.LCPL.LCVK  	 NN	O
with  	with  	 IN	O
EcoRV 	EcoRV 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
XhoI  	XhoI  	 NNP	I-NP
and  	and  	 CC	O
inserting  	inserting  	 VBG	O
a  	a  	 DT	O
linker  	linker  	 JJ	B-NP
oligonucleotide  	oligonucleotide  	 NNS	I-NP
fragment  	fragment  	 VBP	O
containing  	containing  	 VBG	O
EcoRV 	EcoRV 	 JJ	O
,  	,  	 ,	O
BstBI 	BstBI 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
XhoI  	XhoI  	 JJ	B-NP
sites  	sites  	 NNS	I-NP
to  	to  	 TO	O
create  	create  	 VB	O
pSUN9  	pSUN9  	 NNP	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
14 	14 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
similar  	similar  	 JJ	O
way 	way 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
anti-CKMB  	anti-CKMB  	 JJ	B-NP
fragment  	fragment  	 NN	I-NP
in  	in  	 IN	O
pCDNA3mut.HCPL.HCV2b  	pCDNA3mut.HCPL.HCV2b  	 NNP	O
( 	( 	 -LRB-	O
NruI 	NruI 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NotI 	NotI 	 NNP	I-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
replaced  	replaced  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
linker  	linker  	 JJ	B-NP
oligonucleotide  	oligonucleotide  	 NNS	I-NP
fragment  	fragment  	 VBP	O
containing  	containing  	 VBG	O
NruI 	NruI 	 JJ	O
,  	,  	 ,	O
EcoRI  	EcoRI  	 JJ	O
and  	and  	 CC	O
NotI  	NotI  	 JJ	B-NP
sites  	sites  	 NNS	I-NP
to  	to  	 TO	O
create  	create  	 VB	O
pSUN10  	pSUN10  	 NNP	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
15 	15 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 JJ	B-NP
light  	light  	 JJ	O
chain  	chain  	 NN	O
constant  	constant  	 JJ	O
domain  	domain  	 NN	O
was  	was  	 VBD	O
then  	then  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
pSUN9  	pSUN9  	 CD	B-NP
as  	as  	 IN	O
a  	a  	 DT	O
BstBI 	BstBI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
XhoI  	XhoI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
a  	a  	 DT	O
human  	human  	 JJ	O
IgG1  	IgG1  	 CD	B-NP
constant  	constant  	 JJ	O
domain  	domain  	 NN	O
was  	was  	 VBD	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
pSUN10  	pSUN10  	 CD	B-NP
as  	as  	 IN	O
a  	a  	 DT	O
EcoRI 	EcoRI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
NotI  	NotI  	 JJ	I-NP
fragment 	fragment 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
BglII 	BglII 	 JJ	B-NP
/ 	/ 	 CD	I-NP
NheI  	NheI  	 JJ	I-NP
fragment  	fragment  	 NN	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
vector  	vector  	 NN	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
cloned  	cloned  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
vector  	vector  	 NN	I-NP
cut  	cut  	 NN	I-NP
with  	with  	 IN	O
BamHI 	BamHI 	 JJ	O
/ 	/ 	 CD	O
NheI  	NheI  	 JJ	O
to  	to  	 TO	O
create  	create  	 VB	O
pSUN15  	pSUN15  	 NNP	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
16 	16 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pJRS315  	pJRS315  	 NN	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
constructed  	constructed  	 VBN	O
using  	using  	 VBG	O
pSUN15  	pSUN15  	 NN	B-NP
through  	through  	 IN	O
the  	the  	 DT	O
following  	following  	 JJ	O
process 	process 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
region  	region  	 NN	I-NP
from  	from  	 IN	O
another 	another 	 DT	O
,  	,  	 ,	O
unrelated 	unrelated 	 JJ	O
,  	,  	 ,	O
hybridoma  	hybridoma  	 JJ	B-NP
cell  	cell  	 NN	I-NP
line  	line  	 NN	I-NP
( 	( 	 -LRB-	O
approximately  	approximately  	 RB	O
400  	400  	 CD	O
bp 	bp 	 CD	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
digested  	digested  	 VBN	O
with  	with  	 IN	O
NruI  	NruI  	 JJ	O
and  	and  	 CC	O
EcoRI  	EcoRI  	 NNP	B-NP
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
purified  	purified  	 VBZ	O
using  	using  	 VBG	O
a  	a  	 DT	O
Qiaquick  	Qiaquick  	 NNP	B-NP
PCR  	PCR  	 NNP	I-NP
Purification  	Purification  	 NNP	I-NP
column  	column  	 NN	I-NP
( 	( 	 -LRB-	O
Qiagen 	Qiagen 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
as  	as  	 RB	O
described  	described  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
ligated  	ligated  	 NN	O
into  	into  	 IN	O
NruI 	NruI 	 JJ	B-NP
/ 	/ 	 CD	I-NP
EcoRI  	EcoRI  	 JJ	I-NP
digested  	digested  	 NN	I-NP
and  	and  	 CC	O
gel-purified  	gel-purified  	 NNP	B-NP
pSUN15 	pSUN15 	 NNP	I-NP
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
plasmid  	plasmid  	 CD	B-NP
pJRS311  	pJRS311  	 CD	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
16 	16 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
At  	At  	 IN	O
this  	this  	 DT	O
point 	point 	 NN	O
,  	,  	 ,	O
a  	a  	 DT	O
BstBI 	BstBI 	 JJ	O
/ 	/ 	 NNP	O
NotI  	NotI  	 NNP	O
( 	( 	 -LRB-	O
New  	New  	 NNP	B-NP
England  	England  	 NNP	I-NP
Biolabs 	Biolabs 	 NNP	I-NP
)  	)  	 -RRB-	O
DNA  	DNA  	 NNP	B-NP
fragment  	fragment  	 FW	I-NP
containing  	containing  	 FW	O
a  	a  	 FW	O
mouse  	mouse  	 FW	B-NP
kappa  	kappa  	 FW	I-NP
J-kappa  	J-kappa  	 FW	I-NP
intron  	intron  	 FW	I-NP
fragment  	fragment  	 FW	I-NP
fused  	fused  	 FW	O
to  	to  	 TO	O
a  	a  	 DT	O
human  	human  	 JJ	O
kappa  	kappa  	 JJ	B-NP
exon  	exon  	 JJ	I-NP
fragment  	fragment  	 NN	I-NP
was  	was  	 VBD	O
digested  	digested  	 VBN	O
and  	and  	 CC	O
gel-purified  	gel-purified  	 JJ	B-NP
from  	from  	 IN	O
the  	the  	 DT	O
vector  	vector  	 JJ	O
tKMC180C2 	tKMC180C2 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
fragment  	fragment  	 NN	O
was  	was  	 VBD	O
ligated  	ligated  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
backbone  	backbone  	 NN	O
of  	of  	 IN	O
pJRS311  	pJRS311  	 CD	B-NP
digested  	digested  	 NN	I-NP
with  	with  	 IN	O
BstBI 	BstBI 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
NotI  	NotI  	 NNP	I-NP
and  	and  	 CC	O
gel-purified  	gel-purified  	 JJ	B-NP
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
the  	the  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pJRS315  	pJRS315  	 NNP	I-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
17 	17 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A.  	A.  	 NNP	O
Transfection  	Transfection  	 NNP	B-NP
of  	of  	 IN	O
NSO  	NSO  	 NNP	B-NP
Cells  	Cells  	 NNPS	O
The  	The  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pACE4  	pACE4  	 NN	I-NP
was  	was  	 VBD	O
transfected  	transfected  	 VBN	O
into  	into  	 IN	O
NSO  	NSO  	 NNP	B-NP
cells  	cells  	 NNS	O
using  	using  	 VBG	O
electroporation 	electroporation 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
plasmid  	plasmid  	 NN	B-NP
was  	was  	 VBD	O
linearized  	linearized  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
PvuI  	PvuI  	 JJ	B-NP
restriction  	restriction  	 NN	I-NP
enzyme  	enzyme  	 VBD	O
digestion.  	digestion.  	 CD	O
40  	40  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g  	g  	 NN	O
of  	of  	 IN	O
digested  	digested  	 JJ	O
plasmid  	plasmid  	 JJ	B-NP
DNA  	DNA  	 NN	I-NP
was  	was  	 VBD	O
mixed  	mixed  	 VBN	O
with  	with  	 IN	O
7 	7 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
106  	106  	 CD	O
cells  	cells  	 NNS	O
in  	in  	 IN	O
a  	a  	 DT	O
total  	total  	 JJ	B-NP
volume  	volume  	 NN	I-NP
of  	of  	 IN	O
400  	400  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L  	L  	 NNP	O
and  	and  	 CC	O
incubated  	incubated  	 NN	O
at  	at  	 IN	O
room  	room  	 NN	B-NP
temperature  	temperature  	 NN	I-NP
with  	with  	 IN	O
gentle  	gentle  	 JJ	O
agitation  	agitation  	 NN	B-NP
for  	for  	 IN	O
one  	one  	 CD	O
minute.  	minute.  	 CD	O
10  	10  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L  	L  	 NNP	O
of  	of  	 IN	O
DMSO  	DMSO  	 NNP	B-NP
( 	( 	 -LRB-	O
Sigma 	Sigma 	 NNP	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
added  	added  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
final  	final  	 JJ	B-NP
concentration  	concentration  	 NN	I-NP
of  	of  	 IN	O
1.25 	1.25 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
cells 	cells 	 NNS	B-NP
/ 	/ 	 NNP	I-NP
DNA 	DNA 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
DMSO  	DMSO  	 NNP	I-NP
mix  	mix  	 NN	I-NP
was  	was  	 VBD	O
transferred  	transferred  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
cold  	cold  	 JJ	O
0.4  	0.4  	 CD	O
centimeter  	centimeter  	 CD	B-NP
cuvette  	cuvette  	 NNS	I-NP
and  	and  	 CC	O
subjected  	subjected  	 VBN	O
to  	to  	 TO	O
one  	one  	 CD	O
pulse  	pulse  	 NN	O
of  	of  	 IN	O
250  	250  	 CD	O
volts 	volts 	 NN	O
,  	,  	 ,	O
960  	960  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
F 	F 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
cells  	cells  	 NNS	O
were  	were  	 VBD	O
transferred  	transferred  	 VBN	O
to  	to  	 TO	O
one  	one  	 CD	O
well  	well  	 RB	O
of  	of  	 IN	O
a  	a  	 DT	O
six-well  	six-well  	 JJ	B-NP
plate  	plate  	 NN	I-NP
containing  	containing  	 VBG	O
5  	5  	 CD	O
ml  	ml  	 NN	O
of  	of  	 IN	O
non-selective  	non-selective  	 JJ	B-NP
media  	media  	 NNS	I-NP
supplemented  	supplemented  	 VBN	O
with  	with  	 IN	O
DMSO  	DMSO  	 NNP	B-NP
( 	( 	 -LRB-	O
final  	final  	 JJ	B-NP
concentration  	concentration  	 NN	I-NP
of  	of  	 IN	O
1.25 	1.25 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
After  	After  	 IN	O
24  	24  	 CD	O
hours  	hours  	 NNS	O
at  	at  	 IN	O
37 	37 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
and  	and  	 CC	O
10 	10 	 CD	O
%  	%  	 NN	O
C02 	C02 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
cells  	cells  	 NNS	O
were  	were  	 VBD	O
plated  	plated  	 VBN	O
out  	out  	 RP	O
into  	into  	 IN	O
96-well  	96-well  	 CD	O
microtiter  	microtiter  	 CD	B-NP
plates 	plates 	 NNS	I-NP
.  	.  	 .	O
As  	As  	 IN	O
colonies  	colonies  	 NNS	O
appeared 	appeared 	 VBD	O
,  	,  	 ,	O
the  	the  	 DT	O
supernatants  	supernatants  	 NN	B-NP
were  	were  	 VBD	O
assayed  	assayed  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
& 	& 	 CC	O
# 	# 	 #	O
x201c 	x201c 	 CD	O
; 	; 	 :	O
humanized 	humanized 	 NNS	O
& 	& 	 CC	O
# 	# 	 #	O
x201d 	x201d 	 CD	O
;  	;  	 :	O
antibody  	antibody  	 NN	B-NP
and  	and  	 CC	O
for  	for  	 IN	O
the  	the  	 DT	O
capability  	capability  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
expressed  	expressed  	 JJ	O
antibody  	antibody  	 NN	B-NP
to  	to  	 TO	O
bind  	bind  	 VB	O
to  	to  	 TO	O
the  	the  	 DT	O
Stx2  	Stx2  	 JJ	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
B.  	B.  	 NNP	B-NP
Assay  	Assay  	 NNP	I-NP
for  	for  	 IN	I-NP
Antibody  	Antibody  	 NNP	I-NP
Production  	Production  	 NNPS	I-NP
Antibody  	Antibody  	 NN	O
production  	production  	 NN	O
and  	and  	 CC	O
activity  	activity  	 NN	O
assays  	assays  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
stable  	stable  	 JJ	O
transfectants  	transfectants  	 NN	B-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
8-well  	8-well  	 CD	O
strips  	strips  	 NNS	O
from  	from  	 IN	O
96-well  	96-well  	 FW	O
microtiter  	microtiter  	 FW	B-NP
plates  	plates  	 FW	I-NP
( 	( 	 -LRB-	O
Maxisorp  	Maxisorp  	 NNP	B-NP
F8 	F8 	 NNP	I-NP
;  	;  	 :	O
Nunc 	Nunc 	 NNP	B-NP
,  	,  	 ,	O
Inc. 	Inc. 	 NNP	O
)  	)  	 -RRB-	O
coated  	coated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
1 	1 	 CD	O
: 	: 	 :	O
500  	500  	 CD	O
dilution  	dilution  	 NN	O
of  	of  	 IN	O
goat  	goat  	 JJ	B-NP
anti-Human  	anti-Human  	 JJ	I-NP
F 	F 	 NN	O
( 	( 	 -LRB-	O
ab 	ab 	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x2032 	x2032 	 CD	O
; 	; 	 :	O
) 	) 	 CD	O
2  	2  	 CD	O
anti-IgG  	anti-IgG  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	O
Southern  	Southern  	 NNP	O
Biotechnology 	Biotechnology 	 NNP	O
)  	)  	 -RRB-	O
using  	using  	 VBG	O
a  	a  	 DT	O
bicarbonate  	bicarbonate  	 JJ	B-NP
coating  	coating  	 NN	I-NP
buffer 	buffer 	 NN	I-NP
,  	,  	 ,	O
pH  	pH  	 JJ	O
8.5 	8.5 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
plates  	plates  	 NN	O
were  	were  	 VBD	O
covered  	covered  	 VBN	O
with  	with  	 IN	O
pressure  	pressure  	 NN	O
sensitive  	sensitive  	 JJ	B-NP
film  	film  	 NN	I-NP
( 	( 	 -LRB-	O
Falcon 	Falcon 	 NNP	O
,  	,  	 ,	O
Becton  	Becton  	 NNP	O
Dickinson 	Dickinson 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
incubated  	incubated  	 JJ	O
overnight  	overnight  	 JJ	O
at  	at  	 IN	O
4 	4 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	B-NP
Plates  	Plates  	 NNPS	I-NP
are  	are  	 VBP	O
then  	then  	 RB	O
washed  	washed  	 VBN	O
once  	once  	 RB	O
with  	with  	 IN	O
wash  	wash  	 JJ	B-NP
solution  	solution  	 NN	I-NP
( 	( 	 -LRB-	O
imidazole 	imidazole 	 FW	B-NP
/ 	/ 	 FW	I-NP
NaCl 	NaCl 	 FW	I-NP
/ 	/ 	 NNP	O
0.4 	0.4 	 CD	O
%  	%  	 NN	O
Tween-20 	Tween-20 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L  	L  	 NNP	O
of  	of  	 IN	O
culture  	culture  	 NN	B-NP
supernatant  	supernatant  	 NNS	I-NP
was  	was  	 VBD	O
then  	then  	 RB	O
applied  	applied  	 VBN	O
and  	and  	 CC	O
allowed  	allowed  	 VBN	O
to  	to  	 TO	O
incubate  	incubate  	 VB	O
for  	for  	 IN	O
30  	30  	 CD	O
minutes  	minutes  	 NNS	O
on  	on  	 IN	O
a  	a  	 DT	O
plate  	plate  	 NN	B-NP
rotator  	rotator  	 NN	I-NP
at  	at  	 IN	O
room  	room  	 NN	B-NP
temperature 	temperature 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
plates  	plates  	 NN	O
were  	were  	 VBD	O
washed  	washed  	 VBN	O
five  	five  	 CD	O
times  	times  	 NNS	O
with  	with  	 IN	O
wash  	wash  	 JJ	B-NP
solution  	solution  	 NN	I-NP
( 	( 	 -LRB-	O
imidazole 	imidazole 	 FW	B-NP
/ 	/ 	 FW	I-NP
NaCl 	NaCl 	 FW	I-NP
/ 	/ 	 NNP	O
0.4 	0.4 	 CD	O
%  	%  	 NN	O
Tween-20 	Tween-20 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
goat  	goat  	 JJ	B-NP
anti-human  	anti-human  	 JJ	I-NP
kappa-HRP  	kappa-HRP  	 NN	I-NP
( 	( 	 -LRB-	O
Southern  	Southern  	 NNP	O
Biotechnology 	Biotechnology 	 NNP	O
)  	)  	 -RRB-	O
conjugate  	conjugate  	 NN	B-NP
was  	was  	 VBD	O
diluted  	diluted  	 VBN	O
1 	1 	 CD	O
: 	: 	 :	O
800  	800  	 CD	O
in  	in  	 IN	O
the  	the  	 DT	O
sample 	sample 	 FW	B-NP
/ 	/ 	 FW	I-NP
conjugate  	conjugate  	 FW	I-NP
diluent  	diluent  	 FW	I-NP
and  	and  	 CC	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L  	L  	 NNP	O
was  	was  	 VBD	O
added  	added  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
samples 	samples 	 NNS	O
,  	,  	 ,	O
then  	then  	 RB	O
incubated  	incubated  	 VBN	O
on  	on  	 IN	O
a  	a  	 DT	O
plate  	plate  	 NN	B-NP
rotator  	rotator  	 NN	I-NP
for  	for  	 IN	O
30  	30  	 CD	O
minutes  	minutes  	 NNS	O
at  	at  	 IN	O
room  	room  	 NN	B-NP
temperature 	temperature 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
samples  	samples  	 NNS	O
were  	were  	 VBD	O
washed  	washed  	 VBN	O
as  	as  	 IN	O
above  	above  	 JJ	O
and  	and  	 CC	O
then  	then  	 RB	O
incubated  	incubated  	 VBN	O
with  	with  	 IN	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
L  	L  	 NNP	O
per  	per  	 IN	O
well  	well  	 RB	O
of  	of  	 IN	O
ABTS  	ABTS  	 NNP	B-NP
developing  	developing  	 VBG	O
substrate  	substrate  	 NNS	O
( 	( 	 -LRB-	O
Kirkgaard  	Kirkgaard  	 NNP	B-NP
& 	& 	 CC	O
# 	# 	 #	O
x26 	x26 	 CD	B-NP
;  	;  	 :	O
Perry  	Perry  	 NNP	O
Laboratories 	Laboratories 	 NNPS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
absorbance  	absorbance  	 JJ	B-NP
value  	value  	 NN	I-NP
at  	at  	 IN	O
405  	405  	 CD	O
nm  	nm  	 NNS	B-NP
was  	was  	 VBD	O
determined  	determined  	 VBN	O
using  	using  	 VBG	O
an  	an  	 DT	O
automated  	automated  	 JJ	O
microtiter  	microtiter  	 JJ	B-NP
plate  	plate  	 NN	I-NP
ELISA  	ELISA  	 NNP	I-NP
Reader  	Reader  	 NNP	I-NP
( 	( 	 -LRB-	O
Ceres  	Ceres  	 NNP	B-NP
UV900Hl 	UV900Hl 	 NNP	O
,  	,  	 ,	O
BioTek  	BioTek  	 NNP	O
Instruments 	Instruments 	 NNP	O
,  	,  	 ,	O
Winooski 	Winooski 	 NNP	B-NP
,  	,  	 ,	O
Vt. 	Vt. 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
assay  	assay  	 NN	B-NP
( 	( 	 -LRB-	O
see  	see  	 VB	O
FIG.  	FIG.  	 CD	O
10 	10 	 CD	O
)  	)  	 -RRB-	O
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
transfection  	transfection  	 NN	B-NP
of  	of  	 IN	O
cells  	cells  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
plasmid  	plasmid  	 JJ	O
construct  	construct  	 JJ	O
results  	results  	 NNS	O
in  	in  	 IN	O
cells  	cells  	 NNS	O
producing  	producing  	 VBG	O
a  	a  	 DT	O
molecule  	molecule  	 NN	B-NP
containing  	containing  	 VBG	O
both  	both  	 DT	O
human  	human  	 JJ	O
IgG  	IgG  	 JJ	O
and  	and  	 CC	O
kappa  	kappa  	 JJ	B-NP
domains 	domains 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
supernatants  	supernatants  	 NN	B-NP
were  	were  	 VBD	O
then  	then  	 RB	O
assayed  	assayed  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
expressed  	expressed  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
bind  	bind  	 VB	O
to  	to  	 TO	O
EHEC  	EHEC  	 NNP	B-NP
Stx2  	Stx2  	 NNP	I-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
activity  	activity  	 NN	B-NP
assay  	assay  	 NNS	I-NP
was  	was  	 VBD	O
performed 	performed 	 VBN	O
,  	,  	 ,	O
as  	as  	 RB	O
above 	above 	 RB	O
,  	,  	 ,	O
using  	using  	 VBG	O
plates  	plates  	 JJ	O
coated  	coated  	 NN	O
at  	at  	 IN	O
1  	1  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml  	ml  	 NN	I-NP
with  	with  	 IN	O
Stx2  	Stx2  	 CD	B-NP
toxin  	toxin  	 NN	I-NP
( 	( 	 -LRB-	O
obtained  	obtained  	 VBN	O
as  	as  	 IN	O
in  	in  	 IN	O
Example  	Example  	 NNP	O
7  	7  	 CD	O
from  	from  	 IN	O
Dr.  	Dr.  	 NNP	B-NP
O 	O 	 NNP	O
' 	' 	 POS	O
Brien 	Brien 	 NNP	O
's  	's  	 POS	O
lab 	lab 	 NN	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
a  	a  	 DT	O
bicarbonate  	bicarbonate  	 JJ	B-NP
coating  	coating  	 NN	I-NP
buffer 	buffer 	 NN	I-NP
,  	,  	 ,	O
pH  	pH  	 JJ	O
8.5 	8.5 	 CD	O
.  	.  	 .	O
This  	This  	 DT	O
assay  	assay  	 NN	B-NP
demonstrates  	demonstrates  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
transfection  	transfection  	 NN	B-NP
of  	of  	 IN	O
cells  	cells  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
plasmid  	plasmid  	 JJ	O
construct  	construct  	 NN	O
can  	can  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
humanized  	humanized  	 JJ	O
chimeric  	chimeric  	 JJ	B-NP
version  	version  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
11E10  	11E10  	 JJ	I-NP
mouse  	mouse  	 NN	I-NP
monoclonal  	monoclonal  	 NN	I-NP
antibody  	antibody  	 NN	I-NP
which  	which  	 WDT	O
effectively  	effectively  	 RB	O
binds  	binds  	 JJ	O
Shiga  	Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
type  	type  	 NN	I-NP
2  	2  	 CD	O
( 	( 	 -LRB-	O
FIG.  	FIG.  	 CD	O
11 	11 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Together 	Together 	 RB	O
,  	,  	 ,	O
these  	these  	 DT	O
assays  	assays  	 JJ	O
demonstrate  	demonstrate  	 NN	O
that  	that  	 IN	O
the  	the  	 DT	O
transfection  	transfection  	 NN	B-NP
of  	of  	 IN	O
cells  	cells  	 NNS	O
with  	with  	 IN	O
this  	this  	 DT	O
plasmid  	plasmid  	 JJ	O
construct  	construct  	 NN	O
can  	can  	 MD	O
result  	result  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
production  	production  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
stable  	stable  	 JJ	O
cell  	cell  	 NN	O
line  	line  	 NN	O
that  	that  	 WDT	O
produces  	produces  	 VBZ	O
a  	a  	 DT	O
humanized  	humanized  	 JJ	O
chimeric  	chimeric  	 JJ	B-NP
version  	version  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
11E10  	11E10  	 JJ	I-NP
mouse  	mouse  	 NN	I-NP
hybridoma  	hybridoma  	 NN	I-NP
antibody 	antibody 	 NN	I-NP
.  	.  	 .	O
A.  	A.  	 NNP	O
Vero  	Vero  	 NNP	B-NP
Cell  	Cell  	 NNP	I-NP
Cytotoxicity  	Cytotoxicity  	 NNP	I-NP
Assay  	Assay  	 NNPS	I-NP
The  	The  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxin  	toxin  	 NN	I-NP
obtained  	obtained  	 VBD	O
as  	as  	 RB	O
detailed  	detailed  	 VBN	O
in  	in  	 IN	O
Examples  	Examples  	 NNP	O
1  	1  	 CD	O
through  	through  	 IN	O
6  	6  	 CD	O
was  	was  	 VBD	O
determined  	determined  	 VBN	O
by  	by  	 IN	O
assaying  	assaying  	 VBG	O
their  	their  	 PRP$	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
protect  	protect  	 VB	O
Vero  	Vero  	 JJ	O
cells  	cells  	 NNS	O
from  	from  	 IN	O
toxin 	toxin 	 NN	B-NP
.  	.  	 .	O
Cytotoxicity  	Cytotoxicity  	 JJ	B-NP
assays  	assays  	 NN	I-NP
were  	were  	 VBD	O
performed  	performed  	 VBN	O
essentially  	essentially  	 RB	O
as  	as  	 RB	O
described  	described  	 VBN	O
by  	by  	 IN	O
Gentry  	Gentry  	 NNP	O
and  	and  	 CC	O
Dalrymple 	Dalrymple 	 NNP	O
,  	,  	 ,	O
J.  	J.  	 NNP	B-NP
Clin 	Clin 	 NNP	I-NP
.  	.  	 .	O
Microbiol 	Microbiol 	 NNP	B-NP
,  	,  	 ,	O
12 	12 	 CD	O
:  	:  	 :	O
361-366  	361-366  	 CD	O
( 	( 	 -LRB-	O
1980 	1980 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Briefly 	Briefly 	 RB	O
,  	,  	 ,	O
toxin  	toxin  	 NN	B-NP
was  	was  	 VBD	O
obtained  	obtained  	 VBN	O
from  	from  	 IN	O
cultures  	cultures  	 NNS	O
of  	of  	 IN	O
E.  	E.  	 NNP	O
coli  	coli  	 VBD	O
K-12  	K-12  	 CD	B-NP
strains  	strains  	 NNS	I-NP
that  	that  	 WDT	O
contained  	contained  	 VBD	O
either  	either  	 DT	O
plasmid  	plasmid  	 JJ	B-NP
pLPSH3  	pLPSH3  	 NNP	I-NP
( 	( 	 -LRB-	O
encodes  	encodes  	 UH	O
Stx 	Stx 	 UH	B-NP
;  	;  	 :	O
J.  	J.  	 NNP	B-NP
Infect 	Infect 	 NNP	I-NP
.  	.  	 .	O
Disease  	Disease  	 NNP	O
164 	164 	 CD	O
: 	: 	 :	O
344-352  	344-352  	 CD	O
( 	( 	 -LRB-	O
1991 	1991 	 CD	O
) 	) 	 -RRB-	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
pMJ  	pMJ  	 JJ	O
100  	100  	 CD	O
( 	( 	 -LRB-	O
encodes  	encodes  	 FW	O
Stx2 	Stx2 	 FW	B-NP
;  	;  	 :	O
Inf.  	Inf.  	 CD	B-NP
and  	and  	 CC	O
Immunity 	Immunity 	 NNP	O
,  	,  	 ,	O
57 	57 	 CD	O
: 	: 	 :	O
3743-3750  	3743-3750  	 CD	O
( 	( 	 -LRB-	O
1989 	1989 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Bacteria  	Bacteria  	 NNS	O
were  	were  	 VBD	O
disrupted  	disrupted  	 VBN	O
by  	by  	 IN	O
sonic  	sonic  	 JJ	B-NP
lysis  	lysis  	 NN	I-NP
and  	and  	 CC	O
clarified  	clarified  	 VBN	O
by  	by  	 IN	O
centrifugation 	centrifugation 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
extracts  	extracts  	 NN	O
were  	were  	 VBD	O
serially  	serially  	 VBN	O
diluted  	diluted  	 VBN	O
in  	in  	 IN	O
tissue  	tissue  	 NN	O
culture  	culture  	 NN	O
medium  	medium  	 NN	O
( 	( 	 -LRB-	O
Dulbecco  	Dulbecco  	 NNP	B-NP
modified  	modified  	 VBD	O
Eagle  	Eagle  	 NNP	O
medium  	medium  	 NN	O
containing  	containing  	 VBG	O
10 	10 	 CD	O
%  	%  	 NN	O
fetal  	fetal  	 JJ	B-NP
calf  	calf  	 JJ	I-NP
serum 	serum 	 NN	I-NP
,  	,  	 ,	O
0.8  	0.8  	 CD	O
mM  	mM  	 JJ	B-NP
glutamine 	glutamine 	 NN	I-NP
,  	,  	 ,	O
500  	500  	 CD	O
U  	U  	 NNP	O
of  	of  	 IN	O
penicillin  	penicillin  	 JJ	B-NP
G  	G  	 NNP	I-NP
per  	per  	 FW	O
ml 	ml 	 FW	O
,  	,  	 ,	O
and  	and  	 CC	O
500  	500  	 CD	O
mg  	mg  	 NN	B-NP
of  	of  	 IN	O
streptomycin  	streptomycin  	 FW	O
per  	per  	 FW	O
ml 	ml 	 FW	O
) 	) 	 -RRB-	O
.  	.  	 .	O
One  	One  	 CD	O
hundred  	hundred  	 CD	O
microliters  	microliters  	 NN	B-NP
of  	of  	 IN	O
10-fold  	10-fold  	 JJ	O
dilutions  	dilutions  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
lysates  	lysates  	 NN	B-NP
were  	were  	 VBD	O
added  	added  	 VBN	O
to  	to  	 TO	O
microtiter  	microtiter  	 VB	O
plate  	plate  	 NN	O
wells  	wells  	 NNS	O
containing  	containing  	 VBG	O
about  	about  	 IN	O
104  	104  	 CD	O
Vero  	Vero  	 JJ	O
cells  	cells  	 NNS	O
in  	in  	 IN	O
100  	100  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
l  	l  	 NN	O
of  	of  	 IN	O
medium 	medium 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
tissue  	tissue  	 NN	O
culture  	culture  	 NN	O
cells  	cells  	 NNS	O
were  	were  	 VBD	O
incubated  	incubated  	 VBN	O
at  	at  	 IN	O
37 	37 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
in  	in  	 IN	O
5 	5 	 CD	O
%  	%  	 NN	O
CO2  	CO2  	 NN	B-NP
for  	for  	 IN	O
48  	48  	 CD	O
hours  	hours  	 NNS	O
and  	and  	 CC	O
then  	then  	 RB	O
fixed  	fixed  	 VBN	O
and  	and  	 CC	O
stained  	stained  	 NN	O
with  	with  	 IN	O
crystal  	crystal  	 NN	O
violet 	violet 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
intensity  	intensity  	 NN	O
of  	of  	 IN	O
color  	color  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
fixed  	fixed  	 JJ	O
and  	and  	 CC	O
stained  	stained  	 JJ	O
cells  	cells  	 NNS	O
was  	was  	 VBD	O
measured  	measured  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
Titertek  	Titertek  	 JJ	B-NP
reader  	reader  	 NN	I-NP
at  	at  	 IN	O
620  	620  	 CD	O
nm 	nm 	 NNS	B-NP
.  	.  	 .	O
Incubation  	Incubation  	 NNP	O
without  	without  	 IN	O
antibody  	antibody  	 NN	B-NP
provides  	provides  	 VBZ	O
a  	a  	 DT	O
standard  	standard  	 JJ	O
toxicity  	toxicity  	 JJ	O
curve  	curve  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
Stx 	Stx 	 NNP	B-NP
.  	.  	 .	O
B.  	B.  	 NNP	B-NP
Antisera  	Antisera  	 NNP	I-NP
Neutralization  	Neutralization  	 NNP	I-NP
Assay  	Assay  	 NNPS	I-NP
Humanized  	Humanized  	 JJ	O
mouse  	mouse  	 NN	O
antibodies  	antibodies  	 NNS	O
obtained  	obtained  	 VBD	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
methods  	methods  	 NNS	O
described  	described  	 VBN	O
in  	in  	 IN	O
Examples  	Examples  	 NNP	O
1  	1  	 CD	O
through  	through  	 IN	O
6  	6  	 CD	O
were  	were  	 VBD	O
tested  	tested  	 VBN	O
for  	for  	 IN	O
toxin  	toxin  	 NN	B-NP
neutralization 	neutralization 	 NN	I-NP
.  	.  	 .	O
Neutralization  	Neutralization  	 NN	B-NP
of  	of  	 IN	I-NP
cytotoxic  	cytotoxic  	 JJ	I-NP
activity  	activity  	 NN	I-NP
was  	was  	 VBD	O
described  	described  	 VBN	O
in  	in  	 IN	O
great  	great  	 JJ	O
detail  	detail  	 NN	O
in  	in  	 IN	O
Schmitt  	Schmitt  	 NNP	O
et  	et  	 NNP	O
al. 	al. 	 NNP	O
,  	,  	 ,	O
Infect.  	Infect.  	 NNP	B-NP
and  	and  	 CC	O
Immun. 	Immun. 	 NNP	B-NP
,  	,  	 ,	O
59 	59 	 CD	O
: 	: 	 :	O
1065-1073  	1065-1073  	 CD	O
( 	( 	 -LRB-	O
1991 	1991 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Briefly 	Briefly 	 RB	O
,  	,  	 ,	O
lysates  	lysates  	 NN	B-NP
were  	were  	 VBD	O
incubated  	incubated  	 VBN	O
with  	with  	 IN	O
serial  	serial  	 JJ	O
dilutions  	dilutions  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
mouse  	mouse  	 NN	B-NP
antibodies  	antibodies  	 NNS	I-NP
at  	at  	 IN	O
37 	37 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xb0 	xb0 	 CD	B-NP
;  	;  	 :	O
C.  	C.  	 NNP	O
for  	for  	 IN	O
2  	2  	 CD	O
hours 	hours 	 NNS	O
.  	.  	 .	O
One  	One  	 CD	O
hundred  	hundred  	 CD	O
microliters  	microliters  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
samples  	samples  	 NNS	O
were  	were  	 VBD	O
then  	then  	 RB	O
added  	added  	 VBD	O
to  	to  	 TO	O
Vero  	Vero  	 NNP	O
cells  	cells  	 NNS	O
as  	as  	 RB	O
described  	described  	 VBN	O
above 	above 	 IN	O
.  	.  	 .	O
TABLE  	TABLE  	 NN	O
1  	1  	 CD	O
Vero  	Vero  	 NNP	B-NP
Cell  	Cell  	 NNP	I-NP
Neutralization  	Neutralization  	 NNP	I-NP
Assay  	Assay  	 NNP	I-NP
Antibody  	Antibody  	 NNP	I-NP
Required  	Required  	 NNP	I-NP
ng  	ng  	 VBD	I-NP
to  	to  	 TO	O
Neut.  	Neut.  	 CD	B-NP
1  	1  	 CD	O
CD50*  	CD50*  	 CD	B-NP
Mouse  	Mouse  	 CD	I-NP
13C4  	13C4  	 CD	I-NP
25  	25  	 CD	O
Humanized  	Humanized  	 CD	B-NP
13C4  	13C4  	 CD	I-NP
26  	26  	 CD	O
Mouse  	Mouse  	 CD	B-NP
11E10  	11E10  	 CD	I-NP
2.7  	2.7  	 CD	O
Humanized  	Humanized  	 CD	B-NP
11E10  	11E10  	 CD	I-NP
82.8  	82.8  	 CD	O
* 	* 	 CD	O
( 	( 	 -LRB-	O
1  	1  	 CD	O
CD50  	CD50  	 CD	O
=  	=  	 SYM	O
1  	1  	 CD	O
pg  	pg  	 CD	O
pure  	pure  	 JJ	O
toxin 	toxin 	 NN	O
)  	)  	 -RRB-	O
A.  	A.  	 NNP	O
Protection  	Protection  	 NNP	O
Against  	Against  	 NNP	O
Injection  	Injection  	 NNP	B-NP
with  	with  	 IN	O
Crude  	Crude  	 NNP	B-NP
Stx1  	Stx1  	 NNP	I-NP
Toxin 	Toxin 	 NNP	I-NP
.  	.  	 .	O
At  	At  	 IN	O
day  	day  	 NN	O
zero 	zero 	 CD	O
,  	,  	 ,	O
groups  	groups  	 NNS	O
of  	of  	 IN	O
five  	five  	 CD	O
CD-1  	CD-1  	 CD	B-NP
mice  	mice  	 NNS	I-NP
were  	were  	 VBD	O
injected  	injected  	 VBN	O
intraperitoneally  	intraperitoneally  	 NNS	O
( 	( 	 -LRB-	O
0.1  	0.1  	 CD	O
ml 	ml 	 CD	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
antibody  	antibody  	 CD	O
H13C4  	H13C4  	 CD	O
( 	( 	 -LRB-	O
humanized  	humanized  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx1B 	-Stx1B 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
13C4  	13C4  	 NNP	B-NP
( 	( 	 -LRB-	O
mouse  	mouse  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx1B 	-Stx1B 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
H11E10  	H11E10  	 NNP	O
( 	( 	 -LRB-	O
humanized  	humanized  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx2A 	-Stx2A 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
or  	or  	 CC	O
phosphate  	phosphate  	 FW	B-NP
buffered  	buffered  	 FW	I-NP
saline  	saline  	 FW	I-NP
( 	( 	 -LRB-	O
PBS 	PBS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
injections  	injections  	 NNS	O
were  	were  	 VBD	O
repeated  	repeated  	 VBN	O
at  	at  	 IN	O
day  	day  	 NN	O
1 	1 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
mice  	mice  	 NNS	O
were  	were  	 VBD	O
then  	then  	 RB	O
challenged  	challenged  	 VBN	O
by  	by  	 IN	O
intravenous  	intravenous  	 JJ	B-NP
injection  	injection  	 NN	I-NP
with  	with  	 IN	O
crude  	crude  	 JJ	O
Stx1  	Stx1  	 CD	B-NP
toxin  	toxin  	 NN	I-NP
( 	( 	 -LRB-	O
obtained  	obtained  	 VBN	O
as  	as  	 RB	O
described  	described  	 VBN	O
in  	in  	 IN	O
Example  	Example  	 NNP	O
7 	7 	 CD	O
)  	)  	 -RRB-	O
at  	at  	 IN	O
doses  	doses  	 NNS	O
of  	of  	 IN	O
1.7 	1.7 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
105  	105  	 CD	O
or  	or  	 CC	O
1.7 	1.7 	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
xd7 	xd7 	 CD	B-NP
; 	; 	 :	O
106  	106  	 CD	O
CD50 	CD50 	 CD	B-NP
.  	.  	 .	O
These  	These  	 DT	O
doses  	doses  	 NN	O
of  	of  	 IN	O
toxin  	toxin  	 NN	B-NP
were  	were  	 VBD	O
chosen  	chosen  	 VBN	O
following  	following  	 VBG	O
preliminary  	preliminary  	 JJ	B-NP
experiments  	experiments  	 NNS	I-NP
with  	with  	 IN	O
varying  	varying  	 VBG	B-NP
amounts  	amounts  	 NNS	I-NP
of  	of  	 IN	I-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
Mice  	Mice  	 NNS	O
were  	were  	 VBD	O
monitored  	monitored  	 VBN	O
for  	for  	 IN	O
21  	21  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
( 	( 	 -LRB-	O
Table  	Table  	 NNP	O
2 	2 	 CD	O
)  	)  	 -RRB-	O
show  	show  	 VBP	O
clearly  	clearly  	 RB	O
that  	that  	 IN	O
the  	the  	 DT	O
injected  	injected  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
protect  	protect  	 VB	O
the  	the  	 DT	O
mice  	mice  	 NNS	O
against  	against  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
10  	10  	 CD	O
times  	times  	 NNS	O
the  	the  	 DT	O
normal  	normal  	 JJ	B-NP
lethal  	lethal  	 JJ	I-NP
toxin  	toxin  	 NN	I-NP
dose 	dose 	 NN	I-NP
.  	.  	 .	O
As  	As  	 IN	O
a  	a  	 DT	O
negative  	negative  	 JJ	B-NP
control 	control 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
antibodies  	antibodies  	 NNS	B-NP
to  	to  	 TO	O
Stx2  	Stx2  	 NNP	B-NP
did  	did  	 VBD	O
not  	not  	 RB	O
protect  	protect  	 VB	O
against  	against  	 IN	O
Stx1  	Stx1  	 CD	B-NP
toxin  	toxin  	 NN	I-NP
challenge 	challenge 	 NN	I-NP
,  	,  	 ,	O
indicating  	indicating  	 VBG	O
that  	that  	 IN	O
the  	the  	 DT	O
protection  	protection  	 NN	O
was  	was  	 VBD	O
specific  	specific  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
toxin 	toxin 	 NN	B-NP
/ 	/ 	 CD	I-NP
antibody  	antibody  	 NN	I-NP
pair 	pair 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
was  	was  	 VBD	O
not  	not  	 RB	O
an  	an  	 DT	O
artifact  	artifact  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
preparation  	preparation  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
TABLE  	TABLE  	 NN	O
2  	2  	 CD	O
CD-1  	CD-1  	 CD	B-NP
Mice  	Mice  	 NNP	I-NP
Injected  	Injected  	 NNP	O
Intravenously  	Intravenously  	 NNP	O
with  	with  	 IN	O
Crude  	Crude  	 NNP	B-NP
Stx1  	Stx1  	 NNP	I-NP
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 NN	I-NP
of  	of  	 IN	I-NP
Ab  	Ab  	 NNP	I-NP
to  	to  	 TO	O
Protect  	Protect  	 NNP	O
from  	from  	 IN	O
Antibody  	Antibody  	 NNP	B-NP
( 	( 	 -LRB-	O
dose 	dose 	 FW	B-NP
/ 	/ 	 FW	I-NP
mouse 	mouse 	 FW	I-NP
)  	)  	 -RRB-	O
# 	# 	 #	O
LD50  	LD50  	 CD	B-NP
Protected  	Protected  	 NNP	O
Against  	Against  	 NNP	O
1LD50*  	1LD50*  	 NNP	B-NP
Murine  	Murine  	 NNP	I-NP
13C4  	13C4  	 NNP	I-NP
( 	( 	 -LRB-	O
1.4  	1.4  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
10  	10  	 CD	O
6.1  	6.1  	 CD	O
Humanized  	Humanized  	 NNP	B-NP
13C4  	13C4  	 NNP	I-NP
( 	( 	 -LRB-	O
4.1  	4.1  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
20  	20  	 CD	O
8.9  	8.9  	 CD	O
Humanized  	Humanized  	 NNP	B-NP
11E10  	11E10  	 NNP	I-NP
( 	( 	 -LRB-	O
232  	232  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
0  	0  	 CD	O
No  	No  	 DT	O
protection  	protection  	 NN	O
* 	* 	 NNP	O
( 	( 	 -LRB-	O
1  	1  	 CD	O
LD50  	LD50  	 CD	O
=  	=  	 SYM	O
30  	30  	 CD	O
ng  	ng  	 JJ	O
crude  	crude  	 NN	O
Stx1 	Stx1 	 CD	O
)  	)  	 -RRB-	O
B.  	B.  	 NNP	O
Protection  	Protection  	 NNP	O
Against  	Against  	 NNP	O
Oral  	Oral  	 NNP	B-NP
Infection  	Infection  	 NNP	I-NP
with  	with  	 IN	O
Stx2-Producing  	Stx2-Producing  	 NNP	B-NP
EHEC  	EHEC  	 NNP	I-NP
Strains 	Strains 	 NNP	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
different  	different  	 JJ	O
strains  	strains  	 NNS	O
of  	of  	 IN	O
mice  	mice  	 NNS	O
and  	and  	 CC	O
bacteria  	bacteria  	 NNS	O
were  	were  	 VBD	O
used  	used  	 VBN	O
in  	in  	 IN	O
these  	these  	 DT	O
studies  	studies  	 NNS	O
to  	to  	 TO	O
test  	test  	 VB	O
efficacy  	efficacy  	 VBN	O
against  	against  	 IN	O
both  	both  	 DT	O
Stx2  	Stx2  	 NNP	B-NP
and  	and  	 CC	O
Stx2-variant 	Stx2-variant 	 NNP	B-NP
.  	.  	 .	O
DBA 	DBA 	 NNP	B-NP
/ 	/ 	 CD	O
2J  	2J  	 CD	O
mice  	mice  	 NNS	O
were  	were  	 VBD	O
challenged  	challenged  	 VBN	O
with  	with  	 IN	O
EHEC  	EHEC  	 NNP	B-NP
strain  	strain  	 FW	I-NP
86-24  	86-24  	 FW	O
( 	( 	 -LRB-	O
O157 	O157 	 NNP	B-NP
: 	: 	 :	O
H7 	H7 	 CD	O
,  	,  	 ,	O
Stx2+ 	Stx2+ 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
CD-1  	CD-1  	 CD	B-NP
mice  	mice  	 NNS	I-NP
were  	were  	 VBD	O
challenged  	challenged  	 VBN	O
with  	with  	 IN	O
strain  	strain  	 NN	O
B2F1  	B2F1  	 NNP	B-NP
( 	( 	 -LRB-	O
O91 	O91 	 NNP	B-NP
: 	: 	 :	O
H21 	H21 	 CD	B-NP
,  	,  	 ,	O
Stx2-variant+ 	Stx2-variant+ 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
While  	While  	 IN	O
E.  	E.  	 NNP	O
coli  	coli  	 FW	O
strain  	strain  	 FW	O
B2F1  	B2F1  	 FW	B-NP
is  	is  	 VBZ	O
normally  	normally  	 RB	O
fatal  	fatal  	 JJ	O
to  	to  	 TO	O
both  	both  	 DT	O
mice  	mice  	 JJ	O
strains 	strains 	 NNS	O
,  	,  	 ,	O
E.  	E.  	 NNP	B-NP
coli  	coli  	 FW	I-NP
strain  	strain  	 FW	I-NP
86-24  	86-24  	 FW	O
is  	is  	 VBZ	O
fatal  	fatal  	 JJ	O
to  	to  	 TO	O
DBA 	DBA 	 NNP	B-NP
/ 	/ 	 CD	O
2J  	2J  	 CD	O
mice 	mice 	 NNS	O
,  	,  	 ,	O
while  	while  	 IN	O
CD-1  	CD-1  	 CD	B-NP
mice  	mice  	 NNS	I-NP
will  	will  	 MD	O
survive  	survive  	 VB	O
86-24  	86-24  	 CD	O
infection 	infection 	 NN	B-NP
.  	.  	 .	O
At  	At  	 IN	O
day  	day  	 NN	O
zero 	zero 	 CD	O
,  	,  	 ,	O
antibody  	antibody  	 FW	O
H11E10  	H11E10  	 FW	O
( 	( 	 -LRB-	O
humanized  	humanized  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx2A 	-Stx2A 	 CD	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
11E10  	11E10  	 NNP	B-NP
( 	( 	 -LRB-	O
mouse  	mouse  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx2A 	-Stx2A 	 CD	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
injected  	injected  	 VBN	O
intraperitoneally  	intraperitoneally  	 NNS	O
( 	( 	 -LRB-	O
0.1  	0.1  	 CD	O
ml 	ml 	 CD	O
)  	)  	 -RRB-	O
into  	into  	 IN	O
groups  	groups  	 NNS	O
of  	of  	 IN	O
four  	four  	 CD	O
or  	or  	 CC	O
five  	five  	 CD	O
mice 	mice 	 NNS	O
.  	.  	 .	O
Control  	Control  	 NN	B-NP
groups  	groups  	 NNS	I-NP
included  	included  	 VBD	O
mice  	mice  	 NNS	O
that  	that  	 WDT	O
had  	had  	 VBD	O
received  	received  	 VBN	B-NP
antibody  	antibody  	 NN	I-NP
13C4  	13C4  	 NNP	I-NP
( 	( 	 -LRB-	O
mouse  	mouse  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx1B 	-Stx1B 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
mice  	mice  	 NNS	O
that  	that  	 WDT	O
had  	had  	 VBD	O
received  	received  	 VBN	B-NP
11E10  	11E10  	 CD	I-NP
ascites  	ascites  	 JJ	I-NP
fluid  	fluid  	 NN	I-NP
( 	( 	 -LRB-	O
mouse  	mouse  	 NN	O
& 	& 	 CC	O
# 	# 	 #	O
x3b1 	x3b1 	 CD	O
; 	; 	 :	O
-Stx2A 	-Stx2A 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
or  	or  	 CC	O
mice  	mice  	 NNS	O
that  	that  	 WDT	O
had  	had  	 VBD	O
received  	received  	 VBN	B-NP
PBS  	PBS  	 NNP	I-NP
instead  	instead  	 RB	O
of  	of  	 IN	O
antibody 	antibody 	 NN	B-NP
.  	.  	 .	O
Mice  	Mice  	 NNS	O
were  	were  	 VBD	O
given  	given  	 VBN	O
streptomycin  	streptomycin  	 NNS	O
( 	( 	 -LRB-	O
5  	5  	 CD	O
g 	g 	 CD	B-NP
/ 	/ 	 CD	I-NP
L 	L 	 NNP	I-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
their  	their  	 PRP$	O
drinking  	drinking  	 NN	B-NP
water  	water  	 NN	I-NP
to  	to  	 TO	O
decrease  	decrease  	 VB	O
normal  	normal  	 JJ	B-NP
intestinal  	intestinal  	 JJ	I-NP
flora  	flora  	 NNS	I-NP
and  	and  	 CC	O
their  	their  	 PRP$	O
food  	food  	 NN	O
was  	was  	 VBD	O
removed 	removed 	 VBN	O
.  	.  	 .	O
Streptomycin  	Streptomycin  	 JJ	O
resistant  	resistant  	 JJ	O
derivatives  	derivatives  	 NNS	O
of  	of  	 IN	O
strains  	strains  	 CD	O
86-24  	86-24  	 CD	O
( 	( 	 -LRB-	O
O157 	O157 	 NNP	B-NP
: 	: 	 :	O
H7 	H7 	 CD	O
,  	,  	 ,	O
Stx2+ 	Stx2+ 	 CD	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
B2F1  	B2F1  	 NNP	B-NP
( 	( 	 -LRB-	O
O91 	O91 	 NNP	B-NP
: 	: 	 :	O
H21 	H21 	 CD	B-NP
,  	,  	 ,	O
Stx2-variant+ 	Stx2-variant+ 	 CD	B-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
grown  	grown  	 VBN	O
overnight  	overnight  	 JJ	O
in  	in  	 IN	O
L  	L  	 NNP	O
broth 	broth 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
following  	following  	 JJ	O
day  	day  	 NN	O
( 	( 	 -LRB-	O
day  	day  	 NN	O
1 	1 	 CD	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
mice  	mice  	 NNS	O
received  	received  	 VBD	O
a  	a  	 DT	O
second  	second  	 JJ	O
injection  	injection  	 NN	B-NP
of  	of  	 IN	I-NP
test  	test  	 NN	I-NP
antibody 	antibody 	 NN	I-NP
,  	,  	 ,	O
control  	control  	 NN	B-NP
antibody 	antibody 	 NN	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
PBS 	PBS 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
mice  	mice  	 NNS	O
were  	were  	 VBD	O
immediately  	immediately  	 RB	O
fed  	fed  	 VBN	O
1010  	1010  	 CD	O
CFU  	CFU  	 NN	B-NP
of  	of  	 IN	O
86-24  	86-24  	 NNP	O
that  	that  	 WDT	O
had  	had  	 VBD	O
been  	been  	 VBN	O
pelleted  	pelleted  	 NNS	O
and  	and  	 CC	O
resuspended  	resuspended  	 NN	B-NP
in  	in  	 IN	O
20 	20 	 CD	O
%  	%  	 NN	O
sucrose  	sucrose  	 NNS	B-NP
or  	or  	 CC	O
103  	103  	 CD	O
CFU  	CFU  	 NN	B-NP
of  	of  	 IN	O
B2F1  	B2F1  	 NNP	B-NP
that  	that  	 WDT	O
had  	had  	 VBD	O
been  	been  	 VBN	O
serially  	serially  	 RB	O
diluted  	diluted  	 VBN	O
in  	in  	 IN	O
20 	20 	 CD	O
%  	%  	 NN	O
sucrose 	sucrose 	 NN	B-NP
.  	.  	 .	O
Food  	Food  	 NNP	O
was  	was  	 VBD	O
returned  	returned  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
cage  	cage  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
mice  	mice  	 NNS	O
were  	were  	 VBD	O
monitored  	monitored  	 VBN	O
for  	for  	 IN	O
21  	21  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
( 	( 	 -LRB-	O
CFU=Colony  	CFU=Colony  	 NNP	B-NP
Forming  	Forming  	 NNP	O
Units 	Units 	 NNP	O
)  	)  	 -RRB-	O
As  	As  	 RB	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
Table  	Table  	 NNP	O
3 	3 	 CD	O
,  	,  	 ,	O
immunization  	immunization  	 VBG	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
mice  	mice  	 NNS	O
with  	with  	 IN	O
the  	the  	 DT	O
either  	either  	 RB	O
the  	the  	 DT	O
murine  	murine  	 NN	B-NP
or  	or  	 CC	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
anti-Stx2  	anti-Stx2  	 CD	B-NP
antibodies  	antibodies  	 NNS	I-NP
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
complete  	complete  	 JJ	O
protection  	protection  	 NN	O
from  	from  	 IN	O
a  	a  	 DT	O
lethal  	lethal  	 JJ	B-NP
oral  	oral  	 JJ	I-NP
dose  	dose  	 NN	I-NP
of  	of  	 IN	I-NP
EHEC 	EHEC 	 NNP	I-NP
.  	.  	 .	O
Immunization  	Immunization  	 NNP	B-NP
with  	with  	 IN	O
mouse  	mouse  	 CD	B-NP
13C4  	13C4  	 CD	I-NP
antibody 	antibody 	 NN	I-NP
,  	,  	 ,	O
prepared  	prepared  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
way  	way  	 NN	O
but  	but  	 CC	O
immunoreactive  	immunoreactive  	 NN	B-NP
with  	with  	 IN	O
the  	the  	 DT	O
Stx1  	Stx1  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
instead  	instead  	 RB	O
of  	of  	 IN	O
the  	the  	 DT	O
Stx2  	Stx2  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
protect  	protect  	 VB	O
the  	the  	 DT	O
mice  	mice  	 NNS	O
from  	from  	 IN	O
challenge  	challenge  	 NN	O
with  	with  	 IN	O
86-24 	86-24 	 NNP	O
,  	,  	 ,	O
a  	a  	 DT	O
result  	result  	 NN	O
that  	that  	 WDT	O
indicates  	indicates  	 VBZ	O
the  	the  	 DT	O
immunospecificity  	immunospecificity  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
response 	response 	 NN	O
.  	.  	 .	O
TABLE  	TABLE  	 NN	O
3  	3  	 CD	O
DBA 	DBA 	 NNP	B-NP
/ 	/ 	 NNP	O
2J  	2J  	 NNP	O
Mice  	Mice  	 NNP	O
Fed  	Fed  	 NNP	O
1010  	1010  	 CD	O
CFU  	CFU  	 CD	B-NP
0157  	0157  	 CD	O
( 	( 	 -LRB-	O
Stx2 	Stx2 	 NNP	B-NP
)  	)  	 -RRB-	O
Antibody  	Antibody  	 NNP	B-NP
( 	( 	 -LRB-	O
dose 	dose 	 FW	B-NP
/ 	/ 	 FW	I-NP
mouse 	mouse 	 FW	I-NP
)  	)  	 -RRB-	O
Survivors  	Survivors  	 NNP	O
Murine  	Murine  	 NNP	B-NP
13C4  	13C4  	 NNP	I-NP
( 	( 	 -LRB-	O
1.4  	1.4  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
0 	0 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Murine  	Murine  	 NNP	B-NP
11E10  	11E10  	 NNP	I-NP
( 	( 	 -LRB-	O
1.0  	1.0  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
5 	5 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Humanized  	Humanized  	 NNP	B-NP
11E10  	11E10  	 NNP	I-NP
( 	( 	 -LRB-	O
1.0  	1.0  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
5 	5 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Similar  	Similar  	 JJ	B-NP
results  	results  	 NNS	I-NP
are  	are  	 VBP	O
illustrated  	illustrated  	 VBN	O
in  	in  	 IN	O
Table  	Table  	 NNP	O
4 	4 	 CD	O
,  	,  	 ,	O
where  	where  	 WRB	O
the  	the  	 DT	O
more  	more  	 RBR	O
resistant  	resistant  	 JJ	O
CD-1  	CD-1  	 CD	B-NP
mice  	mice  	 NNS	I-NP
were  	were  	 VBD	O
fed  	fed  	 VBN	O
the  	the  	 DT	O
B2F1  	B2F1  	 NNP	B-NP
E.  	E.  	 NNP	O
coli  	coli  	 JJ	B-NP
strain  	strain  	 NN	I-NP
which  	which  	 WDT	O
produces  	produces  	 VBZ	O
Stx2-variant  	Stx2-variant  	 CD	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
Without  	Without  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
antibody 	antibody 	 NN	B-NP
,  	,  	 ,	O
mortality  	mortality  	 NN	O
was  	was  	 VBD	O
total 	total 	 JJ	O
,  	,  	 ,	O
but  	but  	 CC	O
both  	both  	 PDT	O
the  	the  	 DT	O
mouse  	mouse  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
humanized  	humanized  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
protected  	protected  	 VBN	O
against  	against  	 IN	O
Stx2-variant  	Stx2-variant  	 CD	B-NP
in  	in  	 IN	O
a  	a  	 DT	O
dose  	dose  	 JJ	O
dependent  	dependent  	 JJ	O
manner 	manner 	 NN	O
.  	.  	 .	O
TABLE  	TABLE  	 NN	O
4  	4  	 CD	O
CD-1  	CD-1  	 CD	B-NP
Mice  	Mice  	 NNP	I-NP
Fed  	Fed  	 NNP	O
103  	103  	 CD	O
CFU  	CFU  	 NNP	B-NP
O91 	O91 	 NNP	O
: 	: 	 :	O
H21  	H21  	 CD	B-NP
( 	( 	 -LRB-	O
Stx2-variant 	Stx2-variant 	 NNP	B-NP
)  	)  	 -RRB-	O
Antibody  	Antibody  	 NNP	B-NP
( 	( 	 -LRB-	O
dose 	dose 	 FW	B-NP
/ 	/ 	 FW	I-NP
mouse 	mouse 	 FW	I-NP
)  	)  	 -RRB-	O
Survivors  	Survivors  	 NNP	O
PBS  	PBS  	 NNP	B-NP
0 	0 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Murine  	Murine  	 NNP	B-NP
11E10  	11E10  	 NNP	I-NP
( 	( 	 -LRB-	O
8.7  	8.7  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
& 	& 	 CC	O
# 	# 	 #	O
x2002 	x2002 	 CD	O
; 	; 	 :	O
1 	1 	 CD	O
/ 	/ 	 CD	O
4*  	4*  	 CD	O
Murine  	Murine  	 NNP	O
11E10  	11E10  	 NNP	O
( 	( 	 -LRB-	O
6.45  	6.45  	 CD	O
mg 	mg 	 CD	B-NP
)  	)  	 -RRB-	O
5 	5 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Humanized  	Humanized  	 NNP	B-NP
11E10  	11E10  	 NNP	I-NP
( 	( 	 -LRB-	O
23.2  	23.2  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
0 	0 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Humanized  	Humanized  	 NNP	B-NP
11E10  	11E10  	 NNP	I-NP
( 	( 	 -LRB-	O
232  	232  	 CD	O
& 	& 	 CC	O
# 	# 	 #	O
x3bc 	x3bc 	 CD	O
; 	; 	 :	O
g 	g 	 LS	O
)  	)  	 -RRB-	O
5 	5 	 CD	O
/ 	/ 	 CD	O
5  	5  	 CD	O
Protective  	Protective  	 JJ	B-NP
dose  	dose  	 NN	I-NP
between  	between  	 IN	O
10.1  	10.1  	 CD	O
and  	and  	 CC	O
1.0  	1.0  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 CD	I-NP
*Delayed  	*Delayed  	 CD	O
mean  	mean  	 JJ	O
time  	time  	 NN	O
to  	to  	 TO	O
death  	death  	 NN	O
by  	by  	 IN	O
3.4  	3.4  	 CD	O
days  	days  	 NNS	O
The  	The  	 DT	O
subject  	subject  	 JJ	O
invention  	invention  	 NN	O
also  	also  	 RB	O
provides  	provides  	 VBZ	O
for  	for  	 IN	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
methods  	methods  	 NNS	O
of  	of  	 IN	O
treating 	treating 	 VBG	O
,  	,  	 ,	O
ameliorating 	ameliorating 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
preventing 	preventing 	 VBG	O
,  	,  	 ,	O
the  	the  	 DT	O
diseases  	diseases  	 NNS	O
and  	and  	 CC	O
effects  	effects  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
exposure  	exposure  	 NN	O
to  	to  	 TO	O
Shiga  	Shiga  	 NNP	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
Positive  	Positive  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
responses  	responses  	 NNS	I-NP
in  	in  	 IN	O
humans  	humans  	 NNS	O
have  	have  	 VBP	O
been  	been  	 VBN	O
obtained  	obtained  	 VBN	O
with  	with  	 IN	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies 	antibodies 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
one  	one  	 CD	O
skilled  	skilled  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
would  	would  	 MD	O
know  	know  	 VB	O
how  	how  	 WRB	O
to  	to  	 TO	O
employ  	employ  	 VB	O
anti-Stx  	anti-Stx  	 JJ	B-NP
humanized  	humanized  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
in  	in  	 IN	O
humans 	humans 	 NNS	O
.  	.  	 .	O
( 	( 	 -LRB-	O
See  	See  	 FW	O
Fagerberg  	Fagerberg  	 FW	O
et  	et  	 FW	O
al. 	al. 	 FW	O
,  	,  	 ,	O
Cancer  	Cancer  	 NNP	B-NP
Research 	Research 	 NNP	I-NP
,  	,  	 ,	O
55 	55 	 CD	O
: 	: 	 :	O
1824-27  	1824-27  	 CD	O
( 	( 	 -LRB-	O
1995 	1995 	 CD	O
) 	) 	 -RRB-	O
;  	;  	 :	O
Eur 	Eur 	 NNP	B-NP
.  	.  	 .	O
J.  	J.  	 NNP	B-NP
Cancer 	Cancer 	 NNP	I-NP
,  	,  	 ,	O
2 	2 	 CD	O
: 	: 	 :	O
261-267  	261-267  	 CD	O
( 	( 	 -LRB-	O
1995 	1995 	 CD	O
) 	) 	 -RRB-	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
precise  	precise  	 JJ	O
dosage  	dosage  	 NN	O
of  	of  	 IN	O
humanized  	humanized  	 JJ	O
anti-Shiga  	anti-Shiga  	 JJ	B-NP
toxin  	toxin  	 NN	I-NP
antibody  	antibody  	 NN	I-NP
administered  	administered  	 VBN	O
to  	to  	 TO	O
a  	a  	 DT	O
patient  	patient  	 NN	O
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
diseases  	diseases  	 NNS	O
will  	will  	 MD	O
vary  	vary  	 VB	O
in  	in  	 IN	O
accordance  	accordance  	 NN	O
with  	with  	 IN	O
factors  	factors  	 NNS	O
appreciated  	appreciated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
typical  	typical  	 JJ	O
clinician 	clinician 	 NN	B-NP
.  	.  	 .	O
These  	These  	 DT	O
factors  	factors  	 NNS	O
include  	include  	 VBP	O
( 	( 	 -LRB-	O
but  	but  	 CC	O
are  	are  	 VBP	O
not  	not  	 RB	O
limited  	limited  	 VBN	O
to 	to 	 TO	O
)  	)  	 -RRB-	O
size 	size 	 NN	O
,  	,  	 ,	O
age 	age 	 NN	O
,  	,  	 ,	O
overall  	overall  	 JJ	O
health 	health 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
extent  	extent  	 NN	O
of  	of  	 IN	O
infection 	infection 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
other  	other  	 JJ	O
medications  	medications  	 NNS	O
being  	being  	 VBG	O
administered  	administered  	 VBN	O
to  	to  	 TO	O
said  	said  	 VBD	O
patient 	patient 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
precise  	precise  	 JJ	O
treatment  	treatment  	 NN	B-NP
regimen  	regimen  	 NN	I-NP
will  	will  	 MD	O
require  	require  	 VB	O
optimization  	optimization  	 VBN	O
through  	through  	 IN	O
routine  	routine  	 JJ	B-NP
medical  	medical  	 JJ	I-NP
procedures  	procedures  	 NNS	I-NP
well  	well  	 RB	O
known  	known  	 VBN	O
to  	to  	 TO	O
those  	those  	 DT	O
in  	in  	 IN	O
the  	the  	 DT	O
medical  	medical  	 JJ	B-NP
arts 	arts 	 NNS	I-NP
.  	.  	 .	O
Examples  	Examples  	 NNS	O
of  	of  	 IN	O
potential  	potential  	 JJ	B-NP
patient  	patient  	 NN	I-NP
groups  	groups  	 NNS	I-NP
would  	would  	 MD	O
include  	include  	 VB	O
( 	( 	 -LRB-	O
but  	but  	 CC	O
not  	not  	 RB	O
be  	be  	 VB	O
limited  	limited  	 VBN	O
to 	to 	 TO	O
)  	)  	 -RRB-	O
young  	young  	 JJ	O
children  	children  	 NNS	O
with  	with  	 IN	O
bloody  	bloody  	 JJ	O
diarrhea  	diarrhea  	 NN	O
but  	but  	 CC	O
no  	no  	 DT	O
white  	white  	 JJ	O
cells  	cells  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
stool 	stool 	 NN	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
indications  	indications  	 NNS	O
of  	of  	 IN	O
HUS 	HUS 	 NNP	B-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
positive  	positive  	 JJ	B-NP
stool  	stool  	 JJ	I-NP
sample  	sample  	 NN	I-NP
tests  	tests  	 NNS	I-NP
for  	for  	 IN	I-NP
Shiga  	Shiga  	 NNP	I-NP
toxin 	toxin 	 NN	I-NP
,  	,  	 ,	O
siblings  	siblings  	 NNS	O
or  	or  	 CC	O
daycare  	daycare  	 JJ	B-NP
cohorts  	cohorts  	 NNS	I-NP
in  	in  	 IN	O
contact  	contact  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
case  	case  	 NN	O
( 	( 	 -LRB-	O
as  	as  	 IN	O
a  	a  	 DT	O
passive  	passive  	 JJ	B-NP
preventative  	preventative  	 JJ	I-NP
measure 	measure 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
any  	any  	 DT	O
patient  	patient  	 NN	O
with  	with  	 IN	O
diarrhea  	diarrhea  	 NNS	O
( 	( 	 -LRB-	O
not  	not  	 RB	O
necessarily  	necessarily  	 RB	O
bloody 	bloody 	 JJ	O
)  	)  	 -RRB-	O
that  	that  	 WDT	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
in  	in  	 IN	O
contact  	contact  	 NN	O
with  	with  	 IN	O
an  	an  	 DT	O
identified  	identified  	 JJ	O
case 	case 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
typical  	typical  	 JJ	O
dosage  	dosage  	 NN	O
of  	of  	 IN	O
about  	about  	 IN	O
5  	5  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 JJ	I-NP
body  	body  	 NN	I-NP
weight  	weight  	 NN	I-NP
of  	of  	 IN	O
humanized  	humanized  	 NNS	O
13C4  	13C4  	 VBP	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
about  	about  	 IN	O
10  	10  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 JJ	I-NP
body  	body  	 NN	I-NP
weight  	weight  	 NN	I-NP
of  	of  	 IN	O
humanized  	humanized  	 JJ	O
11E10  	11E10  	 NN	B-NP
would  	would  	 MD	O
be  	be  	 VB	O
contemplated 	contemplated 	 VBN	O
.  	.  	 .	O
This  	This  	 DT	O
combined  	combined  	 JJ	O
formulation  	formulation  	 NN	B-NP
could  	could  	 MD	O
be  	be  	 VB	O
administered  	administered  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
patient  	patient  	 NN	O
twice  	twice  	 RB	O
to  	to  	 TO	O
ensure  	ensure  	 VB	O
effectiveness 	effectiveness 	 NN	O
.  	.  	 .	O
Inclusion  	Inclusion  	 NN	O
of  	of  	 IN	O
both  	both  	 DT	O
types  	types  	 NNS	O
of  	of  	 IN	O
humanized  	humanized  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
together  	together  	 RB	O
provides  	provides  	 VBZ	O
assurance  	assurance  	 NN	O
that  	that  	 IN	O
the  	the  	 DT	O
patient  	patient  	 NN	O
will  	will  	 MD	O
be  	be  	 VB	O
protected  	protected  	 VBN	O
against  	against  	 IN	O
all  	all  	 DT	O
types  	types  	 NNS	O
of  	of  	 IN	O
Shiga  	Shiga  	 NNP	B-NP
toxin 	toxin 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
person  	person  	 NN	O
skilled  	skilled  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
would  	would  	 MD	O
understand  	understand  	 VB	O
how  	how  	 WRB	O
to  	to  	 TO	O
use  	use  	 VB	O
and  	and  	 CC	O
practice  	practice  	 VB	O
the  	the  	 DT	O
invention  	invention  	 NN	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
above  	above  	 JJ	O
disclosure 	disclosure 	 NN	O
.  	.  	 .	O
Other  	Other  	 JJ	O
embodiments  	embodiments  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
will  	will  	 MD	O
be  	be  	 VB	O
apparent  	apparent  	 JJ	O
to  	to  	 TO	O
those  	those  	 DT	O
skilled  	skilled  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
art  	art  	 NN	O
from  	from  	 IN	O
consideration  	consideration  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
specification  	specification  	 NN	I-NP
and  	and  	 CC	O
practice  	practice  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
disclosed  	disclosed  	 VBD	O
herein 	herein 	 VBN	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
intended  	intended  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
specification  	specification  	 NN	B-NP
and  	and  	 CC	O
examples  	examples  	 NNS	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
as  	as  	 IN	O
exemplary  	exemplary  	 VBG	O
only 	only 	 RB	O
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
true  	true  	 JJ	O
scope  	scope  	 NN	O
and  	and  	 CC	O
spirit  	spirit  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
invention  	invention  	 NN	O
being  	being  	 VBG	O
indicated  	indicated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
following  	following  	 JJ	O
claims 	claims 	 NNS	O
.  	.  	 .	O
What  	What  	 WP	O
is  	is  	 VBZ	O
claimed  	claimed  	 VBN	O
is 	is 	 VBZ	O
:  	:  	 :	O
1 	1 	 LS	O
.  	.  	 .	O
An  	An  	 DT	O
isolated  	isolated  	 FW	B-NP
nucleic  	nucleic  	 FW	I-NP
acid  	acid  	 FW	I-NP
molecule  	molecule  	 FW	I-NP
comprising  	comprising  	 FW	O
a  	a  	 FW	O
sequence  	sequence  	 FW	O
encoding  	encoding  	 FW	O
an  	an  	 FW	O
anti-Stx2  	anti-Stx2  	 FW	B-NP
antibody  	antibody  	 FW	I-NP
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain 	domain 	 NN	I-NP
,  	,  	 ,	O
wherein  	wherein  	 NN	O
said  	said  	 VBD	O
anti-Stx2  	anti-Stx2  	 CD	B-NP
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
a  	a  	 DT	O
CDR  	CDR  	 NNP	B-NP
selected  	selected  	 VBD	O
from  	from  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
consisting  	consisting  	 VBG	O
of 	of 	 IN	O
:  	:  	 :	O
CDR1  	CDR1  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
11-15  	11-15  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44 	44 	 CD	O
,  	,  	 ,	O
CDR2  	CDR2  	 FW	B-NP
amino  	amino  	 FW	I-NP
acids  	acids  	 FW	I-NP
50-66  	50-66  	 FW	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44 	44 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
CDR3  	CDR3  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
99-108  	99-108  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44.  	44.  	 CD	O
2 	2 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
1 	1 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44.  	44.  	 CD	O
3 	3 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
1 	1 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
murine  	murine  	 JJ	I-NP
11E10  	11E10  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	O
ATCC  	ATCC  	 UH	B-NP
Accession  	Accession  	 UH	O
No 	No 	 UH	O
.  	.  	 .	O
CRL  	CRL  	 NNP	B-NP
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
4 	4 	 LS	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
2 	2 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
43.  	43.  	 CD	O
5 	5 	 CD	O
.  	.  	 .	O
An  	An  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
comprising  	comprising  	 VBG	O
a  	a  	 DT	O
sequence  	sequence  	 NN	O
encoding  	encoding  	 VBD	O
an  	an  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
light  	light  	 NN	I-NP
chain  	chain  	 NN	I-NP
variable  	variable  	 NN	I-NP
domain 	domain 	 NN	I-NP
,  	,  	 ,	O
wherein  	wherein  	 NN	O
said  	said  	 VBD	O
anti-Stx2  	anti-Stx2  	 CD	B-NP
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
a  	a  	 DT	O
CDR  	CDR  	 NNP	B-NP
selected  	selected  	 VBD	O
from  	from  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
consisting  	consisting  	 VBG	O
of 	of 	 IN	O
:  	:  	 :	O
CDR1  	CDR1  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
4-40  	4-40  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42 	42 	 CD	O
,  	,  	 ,	O
CDR2  	CDR2  	 FW	B-NP
amino  	amino  	 FW	I-NP
acids  	acids  	 FW	I-NP
56-62  	56-62  	 FW	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42 	42 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
CDR3  	CDR3  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
95-103  	95-103  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42.  	42.  	 CD	O
6 	6 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
5 	5 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42.  	42.  	 CD	O
7 	7 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
5 	5 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
murine  	murine  	 JJ	I-NP
11E10  	11E10  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	O
ATCC  	ATCC  	 UH	B-NP
Accession  	Accession  	 UH	O
No 	No 	 UH	O
.  	.  	 .	O
CRL  	CRL  	 NNP	B-NP
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
8 	8 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
6 	6 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
41.  	41.  	 CD	O
9 	9 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claims  	claims  	 NNS	O
1  	1  	 CD	O
or  	or  	 CC	O
5 	5 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 NN	O
said  	said  	 VBD	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
further  	further  	 RB	O
comprises  	comprises  	 VBZ	O
a  	a  	 DT	O
sequence  	sequence  	 NN	O
encoding  	encoding  	 VBD	O
a  	a  	 DT	O
human  	human  	 JJ	O
constant  	constant  	 JJ	O
region.  	region.  	 CD	O
10 	10 	 CD	O
.  	.  	 .	O
An  	An  	 DT	O
isolated  	isolated  	 JJ	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
comprising  	comprising  	 VBG	O
a  	a  	 DT	O
sequence  	sequence  	 NN	O
encoding  	encoding  	 VBD	O
an  	an  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
antibody 	antibody 	 NN	I-NP
,  	,  	 ,	O
said  	said  	 VBD	O
antibody  	antibody  	 VBN	O
comprising  	comprising  	 VBG	O
a  	a  	 DT	O
heavy  	heavy  	 JJ	O
and  	and  	 CC	O
a  	a  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain 	domain 	 NN	I-NP
,  	,  	 ,	O
wherein  	wherein  	 NN	O
said  	said  	 VBD	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
a  	a  	 DT	O
CDR  	CDR  	 NNP	B-NP
selected  	selected  	 VBD	O
from  	from  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
consisting  	consisting  	 VBG	O
of 	of 	 IN	O
:  	:  	 :	O
CDR1  	CDR1  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
11-15  	11-15  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44 	44 	 CD	O
,  	,  	 ,	O
CDR2  	CDR2  	 FW	B-NP
amino  	amino  	 FW	I-NP
acids  	acids  	 FW	I-NP
50-66  	50-66  	 FW	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44 	44 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
CDR3  	CDR3  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
99-108  	99-108  	 CD	O
and  	and  	 CC	O
SEQ  	SEQ  	 UH	B-NP
ID  	ID  	 UH	I-NP
NO 	NO 	 UH	O
:  	:  	 :	O
44.  	44.  	 CD	O
11 	11 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
10 	10 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
44.  	44.  	 CD	O
12 	12 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
10 	10 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
murine  	murine  	 JJ	I-NP
11E10  	11E10  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	O
ATCC  	ATCC  	 UH	B-NP
Accession  	Accession  	 UH	O
No 	No 	 UH	O
.  	.  	 .	O
CRL  	CRL  	 NNP	B-NP
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
13 	13 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
11 	11 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
heavy  	heavy  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
43.  	43.  	 CD	O
14 	14 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
10 	10 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
comprises  	comprises  	 VBZ	O
a  	a  	 DT	O
CDR  	CDR  	 NNP	B-NP
selected  	selected  	 VBD	O
from  	from  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
consisting  	consisting  	 VBG	O
of 	of 	 IN	O
:  	:  	 :	O
CDR1  	CDR1  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
4-40  	4-40  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42 	42 	 CD	O
,  	,  	 ,	O
CDR2  	CDR2  	 FW	B-NP
amino  	amino  	 FW	I-NP
acids  	acids  	 FW	I-NP
56-62  	56-62  	 FW	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42 	42 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
CDR3  	CDR3  	 CD	B-NP
amino  	amino  	 CD	I-NP
acids  	acids  	 CD	I-NP
95-103  	95-103  	 CD	O
of  	of  	 IN	O
SEQ  	SEQ  	 NNP	B-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42.  	42.  	 CD	O
15 	15 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
according  	according  	 VBG	O
to  	to  	 TO	O
claim  	claim  	 VB	O
14 	14 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
42.  	42.  	 CD	O
16 	16 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
14 	14 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
amino  	amino  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
murine  	murine  	 JJ	I-NP
11E10  	11E10  	 CD	I-NP
antibody  	antibody  	 NN	I-NP
( 	( 	 -LRB-	O
ATCC  	ATCC  	 UH	B-NP
Accession  	Accession  	 UH	O
No 	No 	 UH	O
.  	.  	 .	O
CRL  	CRL  	 NNP	B-NP
1987 	1987 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
17 	17 	 CD	O
.  	.  	 .	O
The  	The  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
15 	15 	 CD	O
,  	,  	 ,	O
wherein  	wherein  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
chain  	chain  	 NN	B-NP
variable  	variable  	 NN	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
antibody  	antibody  	 NN	I-NP
comprises  	comprises  	 VBZ	O
the  	the  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
sequence  	sequence  	 NN	I-NP
of  	of  	 IN	I-NP
SEQ  	SEQ  	 NNP	I-NP
ID  	ID  	 NNP	I-NP
NO 	NO 	 NNP	O
:  	:  	 :	O
41.  	41.  	 CD	O
18 	18 	 CD	O
.  	.  	 .	O
A  	A  	 DT	O
vector  	vector  	 JJ	B-NP
comprising  	comprising  	 NN	I-NP
and  	and  	 CC	O
capable  	capable  	 JJ	O
of  	of  	 IN	O
expressing  	expressing  	 VBG	O
the  	the  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
of  	of  	 IN	O
any  	any  	 DT	O
one  	one  	 NN	O
of  	of  	 IN	O
claims  	claims  	 NNS	O
1 	1 	 CD	O
,  	,  	 ,	O
5 	5 	 CD	O
,  	,  	 ,	O
10 	10 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
14.  	14.  	 CD	O
19 	19 	 CD	O
.  	.  	 .	O
A  	A  	 DT	O
host  	host  	 NN	B-NP
cell  	cell  	 NN	I-NP
transformed  	transformed  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
vector  	vector  	 NN	B-NP
of  	of  	 IN	O
claim  	claim  	 NN	O
18.  	18.  	 CD	O
20 	20 	 CD	O
.  	.  	 .	O
A  	A  	 DT	O
method  	method  	 NN	O
of  	of  	 IN	O
producing  	producing  	 VBG	O
an  	an  	 DT	O
anti-Stx2  	anti-Stx2  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
comprising  	comprising  	 VBG	O
the  	the  	 DT	O
steps  	steps  	 NNS	O
of  	of  	 IN	O
culturing  	culturing  	 VBG	O
a  	a  	 DT	O
host  	host  	 NN	B-NP
cell  	cell  	 NN	I-NP
comprising  	comprising  	 VBG	O
the  	the  	 DT	O
nucleic  	nucleic  	 JJ	B-NP
acid  	acid  	 NN	I-NP
molecule  	molecule  	 NN	I-NP
according  	according  	 VBG	O
to  	to  	 TO	O
any  	any  	 DT	O
one  	one  	 NN	O
of  	of  	 IN	O
claims  	claims  	 NNS	O
1 	1 	 CD	O
,  	,  	 ,	O
5 	5 	 CD	O
,  	,  	 ,	O
10 	10 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
14 	14 	 CD	O
,  	,  	 ,	O
under  	under  	 IN	O
conditions  	conditions  	 NNS	O
suitable  	suitable  	 JJ	O
for  	for  	 IN	O
expression  	expression  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
antibody  	antibody  	 NN	B-NP
and  	and  	 CC	O
recovering  	recovering  	 VBG	O
the  	the  	 DT	O
antibody 	antibody 	 NN	B-NP
.  	.  	 .	O
